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Thesis Summary 
Buccal drug delivery combines the advantage of enhanced patient acceptance/ compliance of oral 
delivery, with overcoming drug degradation and poor absorption in the gastro intestinal tract (GIT), 
especially for large molecule therapeutics, such as insulin. Orally disintegrating tablets (ODTs) 
that dissolve rapidly in the mouth, are gaining widespread popularity, especially with extreme 
populations, including children and the elderly. This project unifies the advantages of buccal drug 
delivery with that of ODTs, with the view to developing a non-invasive delivery system for proteins 
like insulin.  
This work was carried out in three parallel streams: A Quality by Design (QbD) based 
characterisation of excipients to identify and predict multi-functional behaviours as binder/ 
disintegrant/ mucoadhesive agent in ODT formulations; the investigation of a cost effective and 
easily reproducible cell culture based in vitro method for assessment of buccal delivery; and protein 
characterisation followed by an in vitro investigation of the effect of basic and acidic amino acids 
on the solubility, permeability, mechanism and transport route of insulin through TR146 buccal 
cell culture layers as safe and effective alternative permeation enhancers for proteins. 
D-mannitol based tablets containing 7% low-substituted hydroxypropyl cellulose (LHPC) with 1.3 
% Polyox™ polymers compacted at 30 kN were able to maintain high mechanical properties with 
fast disaggregation of tablets and mucoadhesive properties. Addition of 1.2 to 1.5 mM Ca2+ to cell 
culture media was found to increase culture stratification, forming a tighter barrier to paracellular 
transport of macromolecules, to mimic in vivo barriers. Amino acids were able to significantly 
enhance insulin solubility in water, and exhibited a concentration-dependent enhancement of 
insulin permeability (over 400% enhancement) in vitro. Interestingly, results revealed that insulin 
was transported by an active transcellular process, probably provided by the presence of insulin 
receptors and amino acid nutrient transporters on the cell membrane.  
This result obtained for insulin is the first indication of a possible amino acid mediated transport 
of insulin via formation of insulin-amino acid neutral complexes by ion pairing.  
Keywords: Buccal drug delivery, insulin, amino acid, facilitated transport, ion pairs, permeability  
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1.1 Introduction 
Over the last few decades, tremendous progress has been made in the field of biotechnology, with 
the consequence of increased availability of large scale production volumes of therapeutic proteins 
and peptides. However, these macromolecules are still predominantly delivered via the parenteral 
route due to low bioavailability after oral administration. Limitations of parenteral drug delivery, 
including, requirement of daily injections, pain at injection site, complications such as injection 
accesses,  psychological trauma, cost, inconvenience and the risk of infection; compromise patient 
compliance and therefore therapeutic outcomes (Khafagy et al 2007). Despite the various advances 
and developments in drug delivery via new and novel routes of administration, the oral route of 
drug delivery still holds the highest levels of patient acceptance because of its lower cost, ease of 
administration and, therefore, patient compliance. However, setbacks of the oral route, including 
drug degradation in the gastro-intestinal tract (GIT) and first-pass metabolism in the liver leading 
to low bioavailability, has pushed research in the direction of delivery via other transmucosal routes 
such as rectal, vaginal, ocular, nasal, pulmonary and the buccal/ oral cavity (Patel et al 2011). 
Amongst the many advantages of these transmucosal routes of drug administration is the possibility 
for the drug to enter the systemic circulation by escaping first-pass metabolism and/ or pre-systemic 
degradation along the GIT. However, these transmucosal routes are not without their limitations. 
In addition to a small absorptive surface area, long term nasal drug delivery could trigger allergies 
(rhinorrhea, rhinitis), compromise nasal integrity and alter mucociliary activity (Ugwoke et al 
2005). The vaginal route exhibits poor and highly variable absorption, due to differences in age, 
and menstrual cycle changes, and poor patient compliance due to low dosage form retention and 
local irritation (Caon et al 2014). Although the transdermal route has advantages of a large surface 
area and ease of application, limitations such as local irritation and the visible nature of dosage 
forms (such as patches) may impede patient compliance. The pulmonary route is quite promising, 
with a very large absorptive surface comprising a monolayer of epithelial cells with high 
vascularisation, but high alveolar macrophages and metabolising enzymes reduce peptide 
absorption, in addition to pharmacokinetic differences existing between smokers and non-smokers, 
while long term use can cause irreversible damage to the lungs (Caon et al 2014). The ocular and 
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rectal routes are reserved for local delivery due to low patient acceptance and low treatment 
outcomes (Shojaei 1998). However, the robust mucosa and lymphatic system of the oral cavity, 
along with its high patient compliance, has driven drug delivery in the direction of the oral/ buccal 
cavity to deliver these highly GIT unstable drugs. Since this route retains the advantages of oral 
drug delivery while by-passing its shortcomings, this work will centre on peptide delivery via the 
mucosal membranes of the buccal region of the oral cavity. 
1.2 Overview of the oral cavity 
The lips, cheek, tongue, gingiva, hard palate, soft palate and floor of the mouth make up the oral 
cavity; most of which aid mastication and speaking, but the inner lining of the cheek (buccal) and 
sublingual (under tongue) mucosae are most absorptive (Patel et al 2011, Caon et al 2014). The 
oral cavity is covered by the oral mucosa, which is further divided into three types depending on 
their function (Figure 1.1).  
Figure 1.1  Schematic diagram highlighting the anatomical locations of the lining, masticatory and specialised 
mucosa that cover the oral cavity (Squier and Kremer 2000, Patel et al 2011) 
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The lining mucosa is 100 – 200 µm thick and comprises 60% of total oral surface area in adult 
humans and covers the buccal (cheek), sublingual (under the tongue/ floor of the mouth) and ventral 
portion of the tongue (Collins and Dawes 1987, Rossi et al 2005). This mucosa is not subject to 
high masticatory demands, but is flexible to allow for chewing, speaking and swallowing, and 
therefore has a non-keratinised epithelium and is more absorptive in nature (Squier and Kremer 
2000, Veuillez et al 2001). The masticatory mucosa (25%) covering the hard palate (roof of the 
mouth) and the gingiva (gums) are built to withstand stress and strain during eating, and thus, 
contain a superficial layer of thick keratinised cells similar to that found on the skin (without a 
stratum corneum). The specialised gustatory mucosa (15%) on the dorsal portion (surface) of the 
tongue contains both keratinised and non-keratinised cells and papillae (Patel et al 2011). The 
buccal mucosa in its complete definition refers to the lining of the cheeks, upper and lower lips 
(Rossi et al 2005). Unlike the intestinal and nasal epithelia, buccal epithelia lack tight junctions; 
cells are loosely linked together with the aid of gap junctions, desmosomes and hemidesmosomes 
(Rossi et al 2005).  
As a covering tissue, the buccal epithelium (Figure 1.2) is lined with 40-50 layers of stratified 
squamous epithelia, 500-600µm in thickness, that make up the top 1/4 to 1/3 of the mucosa, covered 
by a mucus layer (Shojaei 1998, Caon et al 2014).  
Figure 1.2 A schematic diagram of the human buccal epithelium highlighting possible barriers to drug delivery 
(Hao and Heng, 2003) 
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This epithelium protects the underlying tissues and organs from mechanical or chemical stress and 
prevents moisture loss due to a lipid barrier to permeability (Squier and Kremer 2000). A 
proteinaceous fibrous matrix called the basement membrane (1-2µm in thickness), from which 
cells migrate to the upper apical layers during differentiation/ maturation, separates the epithelium 
from the supporting connective tissue called the lamina propria, which is rich in blood vessels that 
drain into the jugular vein (Veuillez et al 2001, Hao and Heng 2003, Caon et al 2014).  
1.2.1 Physiological opportunities for drug delivery via the oral cavity 
The oral cavity provides various advantages that make it attractive for transmucosal delivery of 
drugs that cannot withstand the harsh environment of the GIT. This cavity is easily accessed, with 
a large surface area for absorption (100-200cm2), large expanse of smooth muscle and a relatively 
immobile mucosa when compared with that of the GIT (Khafagy et al 2007, Heinemann and 
Jacques 2009). There is direct access to the systemic circulation (leading to high bioavailability) 
due to its high vascularisation into the internal jugular vein, and by-pass of first-pass metabolism 
in the liver. There is also a substantial rate of blood flow through the oral cavity vasculature, which 
yields a somewhat constant and predictable drug concentration to the blood stream. Additionally, 
compared to the GIT, the oral cavity is free from transit time variability and has lower enzymatic 
activity (Khafagy et al., 2007). According to Patel et al (2011) enzymes found in the oral cavity 
include: aminopeptidases, esterases, dehydopeptidases and carboxypeptidases. Caon et al (2014) 
reported the absence of digestive enzymes such as pepsin, trypsin and chymotrypsin in the oral 
mucosa, thus the likelihood for peptide degradation as seen in the GI mucosa will be lower. Walker 
et al (2002) examined peptidase activity from buccal homogenates of the surface of the porcine 
oral mucosa, and reported only aminopeptidase N proteolytic activity. However, other groups have 
argued that this was only observed on the surface of porcine mucosa and more research should be 
structured and tailored towards various layers, as well as the human oral mucosa (Patel et al, 2011). 
Compared to the GIT (gastric pH 1-2 and intestinal pH 7-7.4), the oral cavity has a narrow pH 
range (6.6 – 7.4 depending on rested or stimulated states) maintained by saliva; saliva is also more 
mobile with less mucin/ enzymatic activity and practically no proteases (Patel et al 2011, Caon et 
Chapter One 
33 
 
al 2014). Also, the robust nature of the mucosa allows it to undergo mechanical, chemical and 
physical stresses, which allows room for incorporation of formulation additives.   
1.2.2 Physiological barriers to oral transmucosal drug delivery and possible 
solutions 
However, despite the various advantages the oral cavity possesses for transmucosal delivery of 
drugs, there are some physiological barriers to drug delivery that must be considered when 
administering drugs through this route. Table 1.1 highlights some advantages and disadvantages of 
buccal drug delivery, with possible strategies to overcome them, and considerations for these 
strategies. Insufficient membrane permeability poses the largest challenge to buccal drug delivery. 
The composition and thickness of the mucosal cells vary depending on the site in the oral cavity. 
For example, the gingival and palatal mucosae (which undergo mechanical stress during 
mastication) are keratinised, while the soft palate, buccal and sublingual mucosa are non-
keratinised. Thus, oral transmucosal drug delivery has been focused on these non-keratinised sites 
with more emphasis on the sublingual mucosa, which is even thinner than the buccal mucosa 
(Smart 1993, Patel et al 2011). Keratinised cells have been shown to be impermeable to water since 
they contain neutral lipids like ceramides and acyl ceramides, as opposed to non-keratinised 
epithelia which contain small amounts of ceramides along with neutral but polar lipids, such as 
cholesterol sulphate and glucosyl ceramides (Behra et al 2012). These differences in lipophilicity 
may play a role in the delivery of highly polar or highly lipophilic drugs.  It has been found that 
within the oral mucosa, the presence of organelles called membrane coating granules Q (MCGs) 
serve as a higher permeability barrier than keratinisation (see Figure 1.2). These organelles exist 
in the first 1/4 - 1/3 of the oral epithelium and occur in both keratinised and non-keratinised cells 
(Harris and Robinson 1992, Patel et al 2011). During cell differentiation, the MCGs fuse with 
superficial cells and extrude their lipid contents into the intercellular spaces, imparting a higher 
permeability barrier (Rossi et al 2005). It has been reported that cultured epithelium from which 
MCGs had been removed showed higher permeability for compounds that usually do not penetrate 
the oral epithelium; and this trend was observed for both keratinised and non- keratinised cells 
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(Hayward 1979, Salamat-Miller et al 2005, Patel et al 2011). Thus, it is possible that MCGs may 
play a higher role in permeability of the oral mucosa than keratinisation of cells. 
Table 1.1 Table highlighting pros and cons of buccal drug delivery and possible strategies to overcome these 
disadvantages, including considerations for each strategy (Salamat-Miller et al 2005, Khafagy et al 2007, Park et 
al 2011, Patel et al 2011, Caon et al 2014) 
Advantages Disadvantages Formulation 
strategy to 
overcome 
disadvantages 
Considerations 
Excellent 
accessibility with 
relatively immobile 
mucosa suitable for 
retentive DFs 
Insufficient 
membrane 
permeation 
facilitated by MCGs 
Absorption 
enhancers 
Increased transport of 
undesirable molecules 
present in the oral cavity. 
Irritant or bitter nature of 
enhancers may impede 
patient compliance. 
 
Substantial blood 
flow with direct 
access to the 
systemic 
circulation, by-pass 
of hepatic first-pass 
metabolism and low 
enzymatic activity. 
 
Enzymatic 
degradation within 
the buccal mucosa 
Enzyme inhibitors High toxicity during 
chronic administration; 
Non-specific and inhibits 
degradation of other 
proteins/peptides; changes 
metabolic pattern of GIT 
resulting in reduced 
digestion of food proteins. 
Presence of saliva, 
with a friendlier pH 
range, as a 
solubilising agent 
for drugs prior to 
permeation. 
Insufficient contact/ 
residence time at 
absorption site due 
to salivary 
scavenging, dose 
dilution and 
accidental 
swallowing. 
 
Mucoadhesive 
polymeric systems 
Natural mucus turnover in 
the buccal cavity may 
pose a drawback. 
Painless drug 
administration, easy 
dosage form 
withdrawal and 
control of direction 
of drug release. 
Direct contact of 
DFs with taste buds 
may reduce 
compliance with 
bitter or bad tasting 
formulations. 
 
Taste masking 
techniques. 
Availability of taste 
masking options. 
Short turn-over time 
of cells enabling the 
use of excipients 
that may mildly and 
reversibly damage 
the mucosa. 
Short turn-over time 
resulting in changes 
in permeability 
characteristics. 
  
DFs – Dosage forms, MCGs – Membrane coating granules 
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The presence of mucus in the oral cavity can serve as a further barrier to drug penetration. Mucus 
is made up primarily of water, but contains large molecules called mucins, which are made up of 
carbohydrates. At normal body pH, mucin molecules form a three-dimensional network which 
carries a negative charge (from residues of sulphate and sialic acid) and forms a strongly cohesive 
gelatinous layer that can bind to the epithelial surface and form a further barrier to drug penetration 
(Jiménez-Castellanos et al 1993, Rathbone et al 1994, Patel et al 2011). However, this property 
may be exploited to enhance buccal delivery using mucoadhesive polymers to prolong retention 
time of the drug/ dosage form in the buccal cavity (Khafagy et al 2007, Patel et al 2011). The 
physiological environment of the oral cavity is dictated by the pH, volume and composition of the 
saliva. Saliva has a resting pH of 6.6, and 7.4 upon stimulation; and 0.5 to 2 litres are produced 
daily (Salamat-Miller et al 2005). The saliva also acts as a dissolution medium for solid dosage 
forms to be disintegrated/ dissolved in the mouth. However, production of copious volumes of 
saliva due to the presence of dosage forms in the mouth may lead to accidental swallowing, 
resulting in dose dilution and diminished contact/ residence time of the dosage form with the buccal 
mucosa. Thus, transmucosal delivery of the drug cannot be ensured. The use of mucoadhesive 
retentive systems has been seen to overcome these setbacks (Khafagy et al 2007, Patel et al 2011, 
Behra et al 2012). 
The short turn-over time (estimated time required to replace all cells in the epithelium) of the oral 
cavity mucosa (3-8 days) as compared with the skin (about 30 days), may serve as a disadvantage, 
since the continuous changes in mucosal integrity may also lead to changes in permeability 
characteristics (Squier and Kremer 2000, Patel et al 2011). However, this short turn-over time 
enables the oral mucosa to tolerate drug excipients that cause mild/ reversible damage or irritation 
to the mucosa, and can therefore be exploited when modifying delivery systems (Khafagy et al 
2007, Caon et al 2014). The lower permeability of the buccal mucosa than the sublingual mucosa 
makes the former a preferred site for systemic delivery of drugs requiring prolonged/ controlled 
release, since there is no rapid onset of action; and its relatively immobile mucosa promotes the 
use of retentive systems (Dixit and Puthli 2009).   
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1.2.3 Routes of drug transport via the buccal mucosa 
Studies using small proteins and dextrans linked to tracers have revealed buccal drug absorption to 
occur mainly by passive diffusion (along a concentration gradient) via two main pathways (Figure 
1.3): the paracellular (intercellular spaces between cells) and the transcellular (intracellular across 
the cell membrane from one cell to another) routes (Rossi et al 2005, Sudhakar et al 2006). The 
paracellular route is more favoured for hydrophilic and small molecules ≤ 300 Da, but the increased 
lipophilicity of the buccal intercellular spaces following the extrusion of lipid components of the 
MCGs into the intercellular spaces of superficial cells further compromises paracellular 
permeation. However, drug transport can occur simultaneously via these two routes, with one route 
exhibiting predominant permeation (Rossi et al 2005, Patel et al 2011). The route and rate of drug 
permeation is dependent on the physicochemical properties such as lipophilicity and molecular 
weight of the permeant (Sudhakar et al 2006). The flux of permeant by passive diffusion through 
the epithelium traversing the paracellular route (Jp) under sink conditions may be represented as: 
𝐽𝑝 =  
𝐷𝑝𝜀
ℎ𝑝
𝐶𝑑 . . . .  . . . (Equation 1.1) 
where Dp is the diffusion coefficient of the permeant in the intercellular spaces, hp is the length of 
the paracellular path the permeant travels, ε is the area fraction of the paracellular route and Cd is 
the concentration in the donor compartment (Mashru et al 2005, Sudhakar et al 2006). 
Correspondingly, the flux of permeant by passive diffusion via the epithelium traversing the 
transcellular route (Jc) under sink conditions may be represented as: 
𝐽𝑐 =  
(1−𝜀)𝐷𝑐𝐾𝑐
ℎ𝑐
𝐶𝑑 . . . . . . . (Equation 1.2) 
where Dc is the diffusion coefficient of the permeant in the transcellular spaces, Kc is the partition 
coefficient between the aqueous phase and the lipophilic cell membrane and hc is the length of the 
transcellular path the permeant travels (Mashru et al 2005, Sudhakar et al 2006). In addition to 
passive diffusion, studies have revealed the presence of carrier-mediated transport across the buccal 
mucosa for nutrients and drugs. This transport may be active (requiring an energy input and can 
occur against a concentration gradient) or facilitated (not requiring a direct energy input, and cannot 
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occur against a concentration gradient). Evidence of active carrier mediated transport of 
monosachharides, amino acids and di-/ tri- peptides across the buccal mucosa have been presented 
by various studies, using nutrient transporters (Ho et al 1990, Rathbone et al 1994, Veuillez et al 
2001).   Utoguchi et al (1997) detected the presence of carrier-mediated transport for 
monocarboxylic acids across buccal epithelial cell layers in primary cell cultures of rabbit 
epithelium (Rossi et al 2005, Sudhakar et al 2006). Kurosaki et al (1998) suggested the presence 
of carrier mediated transport for D-glucose from perfusion cells attached to the dorsal side of the 
tongue of healthy volunteers. Permeation showed saturable kinetics that was absent from the buccal 
region of the oral cavity (Patel et al 2011). According to Sudhakar et al (2006) active carrier 
mediated transport is not likely to exist in the buccal mucosa. Figure 1.3 shows a schematic 
representation of the various routes of buccal drug transport. 
Figure 1.3 A schematic representation of the possible routes of drug transport across the buccal mucosa (Patel et 
al 2011). 
1.3 Considerations for therapeutic peptides and proteins 
Many protein and peptide drugs have found application in the management of chronic diseases, 
such as insulin for diabetes mellitus. However, these therapeutic peptides have been administered 
mainly via the parenteral route, due to instability and low bioavailability when administered orally 
for various reasons, including (Veuillez et al 2001, Torchilin and Lukyanov 2003, Wilcox 2005, 
Khafagy et al 2007, Caon et al 2014): 
- Fragility of structure: The ternary and quaternary structures of proteins can aggregate or 
degrade quite readily. 
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- Hydrophilic nature which decreases permeation through lipid bilayer of cells. For easy cell 
permeation, molecules should have a lipophilic nature, which allows for penetration of the 
cell lipid bilayer via the transcellular pathway. The normally hydrophilic nature of these 
large molecules results in reduced permeation into the blood stream. 
- High molecular weight. Small molecules that are hydrophilic in nature can be transported 
across cells by squeezing through the intercellular spaces between adjacent cells (the 
paracellular route). This is a limitation for proteins, which are large molecules.  
- Rapid elimination from the blood stream. This is usually due to renal filtration, uptake by 
the reticulo-endothelial system (RES) and enzymatic degradation. 
- Chemical and enzymatic degradation in the GIT: highly acidic conditions accelerate 
breakage of disulphide bonds; while the presence of enzymes causes total inactivation. 
1.3.1  Protein structure 
Protein structure is controlled by molecular weight, size, conformation, stereospecificity, 
immunogenicity and the availability of electrostatic charges (Veuillez et al 2001). Small molecules 
(< 75-100 Da) that are hydrophilic in nature can be transported across cells by squeezing through 
the intercellular spaces between adjacent cells (the paracellular route) (Siegel 1984). This is a 
limitation for proteins which are large molecules with sizes ranging from 600 to 100,000 Da. The 
ability of a permeant to diffuse across the buccal membrane is directly related to its molecular 
weight and size; with exponential decline in buccal absorption observed as molecular weight 
increased above 300 Da (Siegel et al 1981). Jacques and Buri (1998) reported that in vivo 
permeation studies in humans showed small peptides protirelin (MW: 365) and oxytocin (MW: 
1007) crossing the buccal mucosa while larger peptides buserelin (MW:1239) and calcitonin (MW: 
3500) did not cross the mucosa (Veuillez et al 2001). Thus for proteins larger than 500-1000 Da, 
addition of permeation enhancers would be necessary. 
Peptide drugs in solution may exist in different conformations exhibiting primary, secondary, 
tertiary or even quaternary structures depending on their size. Since drug permeation is 
stereospecific, it becomes a challenge to maintain favourable conformations for absorption and 
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pharmacodynamics during formulation, and in some cases, during sterilisation of proteins. Changes 
in the microenvironment of the protein due to temperature, pH, solvent, other solutes and protein 
crystallinity states can alter protein structure and conformation (Carino and Mathiowitz 1999).  
Ternary and quaternary structures of proteins are fragile and tend to aggregate, denature and 
degrade quite quickly. Use of inert polymers such as polyethylene glycols (PEGs) in formulations 
of peptide drugs have also been seen to reduce immunogenicity and enhance peptide resistance to 
proteolysis (Veuillez et al 2001).  
It has been found that the distribution of electrostatic charges along the amino acid chain of peptides 
and proteins may have a higher impact on buccal permeability than the partition coefficient of the 
molecule (Veuillez et al 2001). Ho et al (1990) investigated the effect of terminal protein charge 
on buccal permeation and reported that the presence of terminal charges on small peptide chains 
impeded buccal permeation, even though the overall partition coefficient on the molecule 
(calculated using octanol/ water) was high. Interestingly, Gandhi and Robinson (1991) reported 
that physiological membranes have isoelectric points (pH values where the mucosa has no net 
charge) ranging from 2.7 – 5.3, with that of the buccal mucosa found to be 2.7. Thus, at pH values 
below the isoelectric point (pI), buccal membranes possess a negative charge, while at physiologic 
pH (above the isoelectric point), the membrane has a positive charge. Membrane charges have been 
found to be due to dissociation of acidic and basic groups on membrane proteins, and the negative 
charge on the buccal mucosa at physiologic pH has been assigned to the presence of higher numbers 
of –COOH groups than –NH2 groups in the proteins along the transport pathway. Furthermore, this 
charge is suspected to accrue from the –COOH groups that make up the proteoglycans of 
glucoproteins, which are components of the MCGs that get extruded into the intercellular spaces 
of the buccal epithelium during differentiation (Gandhi and Robinson 1991). This charged effect 
of the buccal mucosa has been found to have a selective effect on the permeation of charged drugs 
such as peptides. Accordingly, Veuillez et al (2001) reported that the absorption of negatively 
charged insulin was found to be excluded from the paracellular pathway, while thyrotropin-
releasing hormone, a positively charged protein was transported via the paracellular pathway.  
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1.3.2  Physicochemical properties of proteins 
Physicochemical properties affecting protein transport include solubility, hydrophilicity, partition 
coefficient, aggregation, self-association and hydrogen bonding. The amphoteric nature of peptides 
makes their solubility profile complex, and highly dependent on solution pH and pKa of their 
ionisable side chains and end terminals. Thus, at the isoelectric point, most peptide drugs are poorly 
water soluble, with lipophilicity that gives high partition coefficient and subsequently higher 
mucosal permeability. As the pH moves away from the pI, aqueous solubility increases, with a 
decrease in permeation, since the degree of peptide ionisation is dependent on the drug’s pKa and 
the pH at the site of permeation. However, these solubility-partition relationships are not linear for 
peptide drugs, possibly due to the presence of multiple ionisable sites on the protein chains. Dowty 
et al (1992) showed that the permeability of thyrotropin-releasing hormone was independent on 
solution pH (Veuillez et al 2001).  Since a drug must first go into solution before it can be available 
to permeate the mucosa, solubility/ partition parameters for proteins are not very predictable, and 
a balance needs to be struck to obtain optimal results (Elshaer et al 2014).  
The propensity of peptides to self-aggregate interferes with their intrinsic characteristics, with the 
presence of ionic and phenolic additives increasing this ability (Bondos 2006). For example, the 
insulin monomer is the therapeutically relevant structure of the molecule, but the hexamer formed 
in the presence of ions like zinc, is the more stable form. Human insulin has been reported to self-
aggregate faster than bovine and porcine insulins (Banga and Chien 1988). Non-ionic surfactants 
such as PluronicF68 have shown potential as protein stabilisers (Veuillez et al 2001). Self-
association of peptides is linked to the formation of intermolecular hydrogen bonds and 
hydrophobic attractions, and this hydrogen bonding reduces the lipophilicity of peptides, and 
therefore, their ability to permeate the mucosa (Davis 1986). Although the addition of hydroxyl 
groups triggers hydrogen bonding in peptides, hydroxyl groups have also been shown to enhance 
protein lipophilicity, due to intramolecular hydrogen bonding leading, to cyclization (Veuillez et 
al 2001).  
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1.3.3  Enzymatic degradation and intracellular metabolism 
The efficacy of a buccally administered peptidic drug would depend on its ability to cross the 
membrane and enter the systemic circulation intact, without enzymatic degradation during 
transport. Although the buccal route has been found to have lower enzymatic activity than the GIT 
and other transmucosal routes (rectal, vaginal and nasal), proteolytic enzymes identified in the 
buccal mucosa using tissue homogenates or intact mucosal studies are highlighted in Table 1.2. 
The buccal mucosa is devoid of surface-bound peptidases, unlike that of the small intestines. 
Table 1.2 Table highlighting some enzymes identified in the buccal mucosa of various species and their peptide 
substrates (Veuillez et al 2001, Walker et al 2002) 
Enzyme Substrate Species Test system Reference 
Aminopeptidase Glutathione Human Buccal mucosa 
(in vivo) 
(Hunjan and 
Evered 1985) 
 
Leu-enkephalin Rabbit Tissue 
homogenate 
(Kashi and Lee 
1986) 
 
Carboxypeptidase(s) Thyrotropin 
releasing 
hormone 
 
Rabbit Excised intact 
mucosa 
(Dowty et al 
1992) 
Dipeptidyl 
carboxypeptidase 
Dipeptidyl peptidase 
 
Enkephalin 
analogues 
Rabbit Tissue 
homogenate 
(Kashi and Lee 
1986) 
Leucine 
aminopeptidase 
L-Leucine-b-
naphthylamide 
Rabbit, 
guinea pig 
Tissue 
homogenate 
(Zhou and Po 
1990) 
 
Serine protease  
(serine endopeptidase) 
Insulin Rabbit Tissue 
homogenate 
(Yamamoto et 
al 1990) 
 
Proinsulin Rabbit Tissue 
homogenate 
(Yamamoto et 
al 1990) 
 
Substance P Rabbit Tissue 
homogenates 
(Lee and 
Yamamoto 
1989) 
 
 
However, most of these studies were carried out using tissue homogenates and, thus, could not 
differentiate the location of enzymatic activity - whether cytosolic or within the membrane (Walker 
et al 2002). Insulin and proinsulin have been reported to be degraded by serine proteases but not 
affected by aminopeptidases (Yamamoto et al 1990, Veuillez et al 2002). Given that peptides are 
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believed to be transported across the buccal epithelium mainly via the paracellular route, the effect 
of cytosolic enzymes during drug transport would be expected to be negligible; peptide degradation 
would provide further insight to the actual route of drug transport present (Veuillez et al 2001).  
1.4 Formulation strategies for buccal delivery of GIT-sensitive agents 
Considering the vast advantages of drug delivery via the oral mucosa, coupled with an 
understanding of the characteristics of the mucosa, strategies are being investigated to overcome 
the short-comings of this route. Chemical modification of peptides by prodrug formation has been 
investigated to enhance lipophilicity and overcome enzymatic degradation during buccal transport; 
for example, the N-terminal of a dipeptide (Try-Leu) was acylated with myristic acid (Try-Leu-
Myr) and permeation through excised porcine buccal epithelium assessed. The acylated peptide 
was found to accumulate in the epithelium (80%), compared to its unmodified counterpart, which 
was found in the receiver chamber (53%), depicting high interaction of the prodrug with buccal 
mucosal proteins and/ or increased peptide stability within the mucosa (Veuillez et al 1999, Caon 
et al 2014). 
Bundgaard and Moss (1990) achieved improved results with acylation of the imidazoyl group of 
the histidine moiety of thyrotropin releasing hormone with chloroformates, leading to enhanced 
lipophilicity as well as enhanced permeation of buccal epithelia compared to the unmodified 
peptide (Caon et al 2014). pH variation and iontophoresis have also been employed as strategies. 
However, formulation strategies to enhance peptide drug permeation are discussed below and 
include the use of (Smart 1993, Khafagy et al 2007, Behra et al 2012, Caon et al 2014): 
- Absorption/ penetration enhancers to improve drug permeability across the mucosal cells. 
- Enzyme inhibitors to reduce the degradation of active ingredients due to enzymatic action. 
- Mucoadhesive polymeric systems to increase the contact time of active ingredient with the 
mucosal surface and prevent drug loss down the GIT. 
- Mucolytic agents to break-down mucin 
- Anti-aggregating agents to enhance peptide stability 
- Targeted (particulate carrier) delivery systems 
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1.4.1 Permeation enhancers 
Penetration enhancers increase the permeability of normally impermeable drug molecules like 
proteins and peptides through epithelia by increasing their paracellular (between cells) and/ or 
transcellular (through cells) transport (Mahato et al 2003). Mechanisms proposed for this increase 
in the small intestines include tight junction opening, protein leakage through membranes, decrease 
in mucus viscosity and changes to membrane fluidity (Mahato et al 2003, Khafagy et al 2007, 
Rajeswari 2011); while mechanisms in the buccal mucosa include extraction of intercellular lipids 
of the buccal epithelium, enhancing drug partitioning into the epithelial cells, interaction with 
buccal epithelial protein domains, enhancing muco-retention at buccal mucosal surface and 
possible reduction in mucus viscosity leading to enhanced peptide solubility  (Veuillez et al 2001, 
Nicolazzo et al 2005, Hassan et al 2010, Caon et al 2014). Examples of non-specific permeation 
enhancers include: bile salts, surfactants, fatty acids, salicylates, chelators, zonula occludens toxins 
and, more recently, polymers such as chitosan (Khafagy et al, 2007) (Table 1.3). Use of absorption 
enhancers has been extensively studied in the GIT, with increasing data available for their use in 
the oral cavity (Hoogstraate et al 1996a, Hoogstraate et al 1996b, Johnston et al 1998, Bird et al 
2001, Sohi et al 2010, Oh et al 2011). Lane et al (2005) reported improved paracellular absorption 
of insulin from rat intestines when mixed micellar systems containing bile salts and fatty acids as 
penetration enhancers were applied. Morishita et al (2000) also reported insulin pharmacological 
availability of 43.2% when emulsions containing eicosapentanoic acid (EPA) and docosahexaenoic 
acid (DHA) as permeation enhancers were administered to rat intestines in situ.  
Since absorption enhancers are site specific due to differences in enzymatic activity, lipid 
composition, cell morphology, and epithelial thickness at different mucosal sites, it becomes 
necessary that studies on these enhancers be carried out on the oral mucosa to determine their role 
in oral transmucosal absorption (Behra et al 2012). Hoogstraate et al (1996a) investigated the effect 
of concentration of bile salts (sodium glychodeoxycholate (SDGC), sodium taurodeoxycholate, 
sodium glycocholate and sodium taurocholate) on extent and route of permeation of fluorescein 
isothiocyanate labelled dextrans (FITC-dextran) (4, 10 and 20kDa) through excised porcine buccal 
mucosa. 
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Table 1.3 Classes and examples of absorption enhancers in common use and their proposed mechanisms of action 
(Bernkop-Schnürch and Kast 2001, Aungst 2012, Behra et al 2012, Caon et al 2014) 
Absorption 
enhancer 
Proposed mechanism of action Examples 
Bile salts Extraction of intercellular lipids, 
and in some cases intracellular 
lipids. Inhibition of buccal 
membrane peptidases. 
Sodium glycocholate, sodium 
deoxycholate, sodium taurocholate, 
sodium glycodeoxycholate, sodium 
taurodeoxycholate 
 
Chelators Binding to intercellular Ca2+ to 
alter tight junction integrity. 
Inhibition of membrane-bound 
aminopeptidases. 
 
Disodium EDTA, citric acid, sodium 
salicylate, methosy salicylates 
Surfactants Removal of superficial cell layers. 
Lipid extraction. Increased 
intercellular Ca2+leading to 
apoptosis 
Sodium lauryl sulphate, 
polyoxyethylene, polyoxyethylene-9-
laurylether, polyoxyethylene-20-cetyl 
ether, benzalkonium chloride, 23-
lauryl ether, cetylpyridinium chloride, 
cetyltrimethyl ammonium bromide, 
lysalbinic acid (natural non-ionic 
surfactant), sodium cholate (steroidal 
surfactant) 
 
Non-surfactants  Unsaturated cyclic urea 
 
Fatty acids Reduction in lipid packing in 
buccal epithelial cells. Possible 
increase in partitioning into buccal 
cells. 
Oleic acid, ecosapentaenoic acid, 
docosahexaenoic acid, capric acid, 
lauric acid, propylene glycol, cod 
liver oil methyl oleate, 
lysophosphatidylcholine, 
phosphatidylcholine 
 
Thiolated 
polymers 
Enhance residence time of 
permeant due to mucoretentive 
properties. Enzyme inhibition by 
modified chitosans. 
Chitosan-4-thiobutylamide, chitosan-
4-thiobutylamide/ GSH, chitosan-
cysteine, poly(acrylic acid)-
homocysteine, polycarbophil-
cysteine, polycarbophil-cysteine/ 
GSH, chitosan-4-thioethylamide/ 
GSH, chitosan-4-thioglycholic acid 
 
Amino acids Ion pairing and active transport 
through amino acid nutrient 
transporters. 
 
L-arginine, L-lysine 
Others  Aprotinin, azone, cyclodextrin 
(inclusion complexes), dextran 
sulphate, menthol, polysorbate 80, 
sulphoxides, various alkyl glycosides 
 
 
They reported that 10mM SDGC enhanced FITC-dextran 4kDa permeation only paracellularly, but 
at 100mM concentrations, transcellular permeation was simultaneously enhanced, up to 2000-fold 
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(Caon et al 2014).   However, once cell membranes are rendered permeable and intercellular 
junctions opened, absorption is then enhanced not just for the drug molecule of interest, but also 
for other undesirable molecules which may be present in the oral cavity (Khafagy et al, 2007). 
Furthermore, the loss of barrier function of the mucosa may imply mucosal damage. Although the 
fast recovery of the buccal mucosa compared to that of the skin may reduce this challenge, factors 
such as effect of concentration and type of enhancer on mucosal irritation, long term toxicity and 
enhanced permeability to oral pathogens must be investigated before progression to clinical studies 
(Caon et al 2014). 
1.4.1.1 Use of amino acids as permeation enhancers 
Modified amino acids have been studied as permeation enhancers for peptide drugs. Vávrová et al 
(2003) reported a 12.5% enhancement in theophylline permeation across skin segments of human 
cadaver in vitro in the presence of undecyl (C11H23) – substituted glycine based ceramide 
analogues. The mechanism of this transport was not elucidated. Sarpotdar et al (1988) invented 
and patented formulations containing L-amino acids in a non-polymeric matrix forming carrier 
produced from a metal salt (Na or K) of a fatty acid that enhanced transdermal permeation of 
levonorgestrel across hairless mouse skin; with  valine, cysteine, leucine, isoleucine, α-
aminobutyric acid, norvaline and norleucine being preferred candidates. The effect of pH on 
transport rate was investigated and found to be unpredictable. However, the presence of fatty acids 
which are known permeation enhancers in the formulation could obscure interpretation of the 
enhancement results observed. Leone-Bay et al (1995) investigated the benefit of N-acylated amino 
acids as permeation enhancers for the peptides, salmon calcitonin (MW: 3.5kDa) and α-interferon 
(MW: 20kDa) across the intestinal mucosa of rats and primates in vivo. They reported a significant 
enhancement in permeation of the small peptide, which correlated with partition coefficient (log 
P) values, but this was not seen for the larger more complex peptide. Acyclic amide amino acid 
derivatives (N-cyclohexanoylleucine) showed the highest activity, marked by decrease in serum 
calcium, in both rodents and primates (Aungst 2000).  The mechanism of permeation enhancement 
was not clarified, but was reported not to occur by intestinal enzyme inhibition or solubilisation of 
the lipid membranes, as revealed by the absence of histological damage to rat’s intestines post 
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mortem. Similar results were reported for low molecular weight unfractured heparin and human 
growth hormone (Leone-Bay et al 1998, Aungst 2000, Thanou et al 2001). Janůšová et al (2013) 
reported enhanced permeability in the presence of amino acid derivatives (proline attached to a 
hydrophobic chain via a biodegradable ester linkage). The proline derivative exhibited 40 times 
enhancement in theophylline permeation across porcine skin in vitro, with enhanced permeation 
and absence of toxicity also observed in vivo in rats. More recently, Elshaer et al (2014) 
investigated the ability of cationic amino acids (lysine and arginine) to enhance the permeability 
of anionic indomethacine across the Caco-2 intestinal cell monolayer in vitro. Significant 
permeation enhancement was observed in the presence of higher molar ratios of drug:amino acid 
(1:2 and 1:4 for arginine, and 1:2 for lysine). Proposed mechanisms of enhancement included 
formation of ion pairs between oppositely charges molecules via the counter ion mechanism, and 
the possible triggering of active transport via peptidyl and anionic transporters for amino acids as 
described by Bröer (2008). Evidence for this active transport was demonstrated by a decline in 
indomethacin transport at higher molar ratios (1:8 for arginine and 1:4 and 1:8 for lysine), probably 
due to transporter saturation. Interestingly, Okuda et al (2006) reported the cytoprotective abilities 
of taurine and L-glutamine by reversing the increase in intracellular Ca2+ leading to cytotoxicity 
caused by the permeation enhancer sodium laurate (Aungst 2012).  
1.4.2 Enzyme inhibitors 
Formulations for oral drug delivery, containing agents that inhibit the degrading enzymes present 
in the GIT have shown higher bioavailability. Enzyme inhibitors are usually employed in 
combination with penetration enhancers and/ or mucoadhesive agents. Their use becomes more 
important when drugs have to be delivered via the small intestines, where the concentrations of 
metabolising enzymes are high. Examples of inhibitors used for oral delivery of drugs include 
sodium glycocholate, camostat mesilate, bacitracin, soybean trypsin inhibitor and aprotinin.  
Yamamoto et al (1994) reported the ability for sodium glycocholate, camostat mesilate and 
bacitracin to improve the physiological availability of insulin from the large intestines; but they 
were ineffective as inhibitors in the small intestines. This could have been due to the high 
concentration of these enzymes in the small intestines (Khafagy et al, 2007). Although enzymatic 
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activity in the buccal cavity is relatively low as compared with the GIT, Table 1.2 highlights some 
enzymes found in the buccal mucosa. Chitosan and its derivatives have been recently investigated 
as multifunctional polymers delivering permeation enhancement, enzyme inhibition and 
mucoadhesive properties (Bernkop-Schnürch and Kast 2001, Şenel and Hıncal 2001, Rossi et al 
2005). 
1.4.3 Mucoadhesive polymeric systems 
Incorporation of polymers into dosage forms enables the adhesion of the dosage form/ drug to the 
mucin layer of epithelial or mucosal surfaces upon hydration (Behra et al, 2012). This phenomenon 
is known as mucoadhesion. Mucoadhesion prolongs the contact time of the drug at its 
administration site, to increase drug concentration gradient, reduce or prevent dilution/ degradation 
in the saliva and localise drug delivery (Khafagy et al, 2007). The mechanisms of mucoadhesion 
have been shown to be via hydrogen bond formation and other ionic interactions; according to Roy 
et al (2009b), these can either be chemical (by adsorption and electronic phenomena) and/ or 
physical (by wetting, diffusion and cohesion phenomena). Factors that affect mucoadhesion in the 
oral cavity can either be polymer-related (charge, flexibility, hydrogen bonding capacity, molecular 
weight, cross linking density, active polymer concentration and degree of hydration); or could be 
related to the internal environment (initial contact time, application strength, pH, mucin turnover 
and disease states) (Behra et al, 2012). Examples of mucoadhesive polymers for development of 
oral mucosal delivery systems are highlighted in Table 1.4 and include: cyanoacrylates, 
polyacrylates/ ployacrylic acid, sodium carboxy methyl cellulose, hyaluronic acid, hydroxypropyl 
cellulose, polycarbophil, polyethylene oxide, chitosan derivatives, gellan and cellulose derivatives 
(Khafagy et al, 2007; Roy et al, 2009; Behra et al, 2012). Morishita et al (2006) noted an insulin 
pharmacological activity of 9.5% from rat intestinal mucosa using hydrogel polymer-based 
microparticles, while a pharmacological activity of 14.9% was observed by Pan et al (2002) on 
administration of bioadhesive chitosan nanoparticles containing insulin, in vivo to rats. Hosny et al 
(2002) also formulated buccal adhesive tablets of insulin using Carbopol 934, hydroxyl propyl 
cellulose and various absorption enhancers; they reported a significant hypoglycaemic response 
without detectable fluctuations in blood glucose profile. 
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Table 1.4  Classes of polymers used to develop buccal mucoadhesive systems with examples (Khafagy et al 2007, 
Roy et al 2009b, Behra et al 2012) 
 
S/N Class of mucoadhesive 
polymer 
Examples 
1 Hydrophilic polymers Anionic polyelectrolytes e.g. polyacrylic acid, 
carboxymethyl cellulose 
Cationic polyelectrolytes e.g. chitosan and its 
derivatives 
Non-ionic polymers e.g poloxamer, hydroxypropyl 
methyl cellulose, methyl cellulose, poly vinyl alcohol, 
poly vinyl pyrrolidone 
Cellulose and its derivatives e.g. carboxymethyl 
cellulose 
 
2 Hydrogels Acrylates, polyacrylic acid and methyl cellulose 
 
3 Thiolated polymers Chitosan-immunothiolane, polyacrylic acid-cycteine, 
polyacylic acid-homocysteine, chitosanothioglycolic 
acid, chitosan-thioethylamide, alginate-
cysteine,polymethacrylic acid-cysteine, sodium 
carboxymethylcellulose-cycteine 
 
4 Lectin-based polymers Lectins extracted from legumes such as soyabeans, 
peanut, Lens culinarius 
 
1.5 Methods for assessing buccal drug transport 
During development of dosage forms for buccal drug delivery, drug transport across the mucosa 
and into the systemic circulation must be modelled both for new chemical entities and for existing 
drugs requiring a new route of delivery, in order to meet registration requirements by regulatory 
bodies. Approaches used to model drug transport across the buccal mucosa include in vivo methods 
in animals or healthy human volunteers, as well as in vitro methods using excised animal tissues 
and more recently cultured buccal cells.  
1.5.1 In vivo methods for assessing buccal drug permeation 
In vivo methods are modifications of the buccal absorption tests originally developed by Beckett 
and Triggs (1967). Here 25 mL of the test solution was swirled in the mouth of healthy human 
volunteers for 15 minutes, after which the solution was recovered, mouth rinsed, and the 
concentration of the analyte in both solutions quantified. The test assumed that the difference 
between initial and final analyte amount depicted the amount absorbed via the buccal cavity. 
However, accidental swallowing and saliva dilution was not taken into account; and there was no 
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method of confining the test solution to one particular area of the mouth (Shojaei 1998). 
Modifications of this test that accounted for possible saliva dilution and accidental swallowing by 
incorporating markers such as phenol red (Tucker 1988) and polyethylene glycol (Arbab and 
Turner 1971) in the test solution have since been developed, but the common setback of lack of 
test solution confinement had still not been overcome (Shojaei 1998, Şenel and Hıncal 2001, Patel 
et al 2012).  
Perfusion methods have been developed to localise drug absorption to specific areas of the buccal 
mucosa and prevent uncontrolled absorption from other regions of the oral cavity (Patel et al 2012); 
this involves the attachment of a perfusion system to the buccal cavity of dogs and pigs (Junginger 
et al 1999) and humans (Rathbone and Hadgraft 1991, Kurosaki et al 1997, Kurosaki et al 1998), 
circulating a test solution through this cavity, and withdrawing samples from both the perfusion 
chamber and the blood, to correlate the amount of drug lost from the sample to the amount absorbed 
in vivo. In a similar development, Adrian et al (2006) correlated the drug lost from the perfusion 
chamber to its appearance in saliva from the parotid gland, in place of plasma (Patel et al 2012). 
However, the cumbersome nature of this setup and the possibility of drug leakage from the 
perfusion system are amongst its many limitations (Gandhi and Robinson 1994, Li and Robinson 
2005, Patel et al 2012). 
1.5.2 In vitro methods for assessing buccal drug permeation 
1.5.2.1 Excised animal tissue  
Investigated in vitro methods involve the use of either excised animal buccal tissue or buccal cell 
cultures (Shojaei 1998, Şenel and Hıncal 2001), as it is almost impossible to obtain viable human 
buccal epithelium on a continual basis (Balimane et al 2000). The general protocol for the use of 
animal tissues involves the sacrifice of the animal just before experimentation and removal of the 
buccal mucosa with accompanying connective tissues, after which the buccal epithelium is excised 
using surgical scissors/ scalpel / dermatome and stored in appropriate buffers (Krebs buffer). 
Excised epithelium can then be mounted on perfusion/ diffusion chambers such as vertical Franz 
cells or horizontal Ussing chambers, and permeation experiments commenced (Shojaei 1998, Patel 
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et al 2012). Issues surrounding in vitro methods border around the viability and integrity of the 
excised tissue, and standardised methods to assess these are unavailable. Furthermore, difficulties 
in handling/ manipulation, intra- and inter-species variability, and the differences in buccal 
characteristics of the animal used, to that of humans, pose further challenges. Table 1.5 compares 
the dimensions and characteristics of available animal buccal tissues to that of humans, and their 
suitability for modelling buccal drug transport. Porcine buccal epithelium has been identified as 
being closest to that of man’s in terms of morphology, lipid composition and biochemistry (Lesch 
et al 1989, Davoudi et al 2012).  
1.5.2.2 Theory of cell culture (Mather and Roberts 1998, Butler 2003) 
Cell culture is a process where cells isolated from animal (or plant) sources are maintained in 
artificial environments enriched with nutrients and growth factors in an incubator maintained at 
37 ͦ C and 5% CO2 for 98% relative humidity. This enables individual cells to function as a whole 
unit, which can undergo replication by mitosis. Cells cultured in this way will continue to grow 
until limited by space or depletion of nutrients. Generally, cells are grown in culture to facilitate 
the study of metabolic/ biochemical processes, to investigate the effect of substances such as drugs, 
metabolites and hormones on cells, or to produce tissues with modified characteristics, such as 
producing skin grafts. The cells may be removed from the tissue directly and disaggregated by 
enzymatic or mechanical means to yield a primary culture; or the cells may be derived from a cell 
line or cell strain that has already been established (continuous cell line). Cells may then be cultured 
on solid/ semisolid supports (adherent cultures) or float in culture media (suspension cultures). 
Examples of solid supports used include cell culture flasks or microscope coverslips, while the 
membranes of transwell inserts are examples of semisolid supports. Culturing of blood cells is an 
example of suspension cultures. Primary cell cultures have been found to undergo a maximum of 
54 population doublings (passages) before they stop replicating and enter into a phase of 
senescence (cell ageing with deterioration of functions). This occurs due to the telomere shortening 
that occurs with each growth generation of somatic cells. 
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Table 1.5 Comparing the characteristics of available animal tissues used to model buccal drug delivery. Porcine 
buccal mucosa most closely resembles that of humans in thickness, morphology and biochemical composition. 
(Lesch et al 1989, Shojaei 1998, Patel et al 2012) 
Animal 
model 
Thickness 
(µm) 
Advantages Disadvantages 
Human 580 ± 90 Ideal Limited availability 
 
Rat,  
Hamster 
NA 
115.3 ± 11.5 
Small, size, easy handling, 
cheap 
 
Thick fully keratinised epithelium 
Rabbit 600 Non-keratinised epithelium 
similar to man 
Keratinised margin difficult to 
isolate from smaller non-
keratinised portions. 
 
Monkey 271 ± 50 Non-keratinised Difficult maintenance. Thin 
epithelium thus more permeable 
than humans. 
 
Dog 126 ± 20 Easy maintenance, less 
expensive than monkeys. 
Non-keratinised epithelium 
similar to human; easier to 
handle than pigs for in vivo 
studies. 
 
Epithelium thinner than humans, 
thus more permeable.  
Pig 772 ± 150 Non-keratinised epithelium. 
Closest animal to human in 
structure, composition, 
membrane morphology and 
permeability.  
 
Rapid growth makes it less 
suitable for in vivo studies. 
Small size.  
Cow >1000 Non-keratinised epithelium. 
Readily available and 
affordable. 
Very thick with large protrusions 
(striations), sectioning is difficult. 
Smooth areas limited. 
 
 
Thus when a threshold length is achieved, cells can no longer divide and, thus, undergo senescence. 
Originally, cells were maintained in media consisting of animal blood until culture media 
containing specific nutrients in known proportions were developed by Earle and Eagle - Eagle’s 
Minimum Essential Media (EMEM) being the first. EMEM had the advantage over animal 
products because it enabled the culture of reproducible batches, easy sterility and less chances of 
contamination. Viral vaccines, monoclonal antibodies and recombinant glycoproteins are examples 
of valuable products developed from cell culture.  
Cells derived from tissues require a surface to adhere to before growth can occur. Figure 1.4 shows 
the process of cell attachment to a surface (substratum). The process of cell attachment is mediated 
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by divalent cations (usually Ca2+) and proteins (cell surface glycoproteins, serum derived 
glycoproteins and conditioning factors secreted by cells) forming an adherent layer between the 
cells and the substratum.  
Figure 1.4 Mechanism of cell adhesion to a solid support. Proteins necessary for cell attachment and spreading: 
cell surface glycoproteins (v), (o) conditioning factors secreted by cells, ( )   serum-derived glycoproteins (Butler 
2003). 
Transformation of cells in vitro by inoculating with a virus leads to the formation of a continuous 
cell line which can replicate/ divide continuously; also known as immortalised cell lines.  
Differentiation, which is a process where cells develop different phenotypic characteristics slowly, 
can be stimulated in cell culture by changing the conditions and composition of the culture media.  
1.5.2.3  Buccal cell cultures 
Buccal epithelial cell culture models have been introduced to overcome the difficulties encountered 
with the use of excised animal tissues, and involve the harvesting and growth of cells of buccal 
origin under standard conditions of humidity, temperature, CO2 levels and high sterility 
(Hoogstraate and Boddé 1993). Tavakoli-Saberi and Audus (1989) successfully cultured buccal 
cells from the hamster’s cheek pouch, which formed non-keratinised epithelial cells with higher 
permeability (different from their original keratinised cells). Thus, this was thought to be a suitable 
model for predicting buccal drug transport (Patel et al 2012). The TR146 buccal cell line is a widely 
studied and well characterised cell culture model derived from a neck node metastasis of a buccal 
carcinoma removed from a 65 year old woman who had undergone radiotherapy (Rupniak et al 
1985, Jacobsen et al 1995, Jacobsen et al 1996, Nielsen et al 1999, Nielsen and Rassing 2000b, 
Nielsen and Rassing 2000a). When grown in culture for 30 days, TR146 cells produce a buccal 
epithelium similar to human buccal epithelium in morphology (stratified squamous epithelia), 
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biochemistry, enzymatic activity and differentiation patterns; and may serve as a model for buccal 
drug transport (Jacobsen et al 1995, Nielsen and Rassing 2000b, Patel et al 2012, Xue et al 2012). 
However, these cells have been reported to show higher permeability than human and porcine 
buccal mucosa to mannitol, nicotine, testosterone, dextrans and tritiated water, which may be due 
to their cancerous origins (Nielsen and Rassing 1999, Nielsen et al 1999, Nielsen and Rassing 
2000a, Nielsen and Rassing 2002). To improve on TR146 cell cultures, Selvaratnam et al (2001) 
developed a buccal cell culture derived from biopsies of healthy humans, which showed similar 
barrier properties to intact human buccal mucosa as well as similar morphology, lipid composition 
and the presence of membrane coating granules (Patel et al 2012). SkinEthic Laboratories (Nice, 
France) also developed a reconstituted human oral epithelium (RHOE), which is a commercially 
available tissue engineered oral mucosal model derived from TR146 cells cultured at the air-liquid 
interface on polycarbonate transwell inserts (http://www.episkin.com/HOE.asp). These have 
similar properties to that of TR146 cells in that they form a three dimensional, not fully 
differentiated, multi-layered buccal epithelium that is non-keratinised; similar in histology to that 
in humans (Moharamzadeh et al 2007). This tissue has been reported to express keratin 6 and 16, 
and involucrin differentiation markers, and has been employed to investigate candidal invasion in 
the oral cavity (Jayatilake et al 2005, Lu et al 2006). EpiOralTM is also commercially available from 
MatTek Corporation (Ashland, MA, USA) and is a three-dimensional reconstruct derived from 
normal human buccal epithelial cells; they form a multilayer stratified squamous epithelium, which 
is non-keratinised with similar growth and morphological characteristics as seen in vivo in humans 
(Moharamzadeh et al 2007). These cells have been reported to produce naturally occurring 
antimicrobial peptides, human beta defensins as well as cytokeratin K13 and K14. EpiOralTM has 
also been reported to show good in vitro - in vivo correlations for fentanyl transport and its 
bioavailability in humans (Agarwal et al 2005). Among the attractions to buccal cell cultures is 
the relative ease of handling, availability and the potential for mass testing.  
Table 1.6 compares the characteristics of excised animal tissues to that of cell cultures to model 
buccal drug transport.  
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Table 1.6 Comparing the use of excised animal tissues against buccal cell culture for modelling buccal drug 
delivery (Balimane et al 2000, Reichl et al 2004) 
Animal Tissues Cell Culture 
Low reproducibility due to inter - animal 
differences (e.g. damaged buccal mucosa in pigs 
due to chewing). 
 
High consistency and reproducibility when cells of 
a homogeneous population are used 
Isolation of buccal epithelium not straight 
forward. 
Initially time consuming requiring high sterility, 
but immortalised cell lines grow rapidly yielding 
high throughput. 
 
Difficulty in ensuring and maintaining viability 
and integrity of dissected tissue. 
 
Characterisation and control of number of cell 
layers and lipid composition required. 
High number of animals that need to be 
sacrificed to obtain sufficient tissues. 
Hard to obtain the same level of differentiation/ 
stratification observed in animal species. 
 
 As number of passage increases, cells may show 
different phenotypic characteristics than initial 
donor organism. 
 
 
1.6 Model Protein – Insulin 
The biologically active and circulating form of human insulin (Figure 1.5) is a 51 amino acid 
polypeptide comprising 2 amino acid chains joined by two di-sulfide linkages afforded by the 
amino acid, cysteine. 21 amino acids make up the A chain and 30 make up the B chain, with total 
molecular weight of 5800 Da. A di-sulphide  linkage also exists within the A chain (Sarmento et 
al 2006). Insulin is produced by the beta cells of the Islets of Langerhans in the pancreas and is the 
most important hormone in the regulation of glucose homeostasis in the body (Xu et al 2006). 
Insulin was isolated in 1922 from the bovine pancreas by Frederick Banting and Charles Best in 
John Macleod’s laboratory in Canada; Banting and Macleod later won a Nobel prize for this work 
(Khafagy et al 2007). The protein has since been administered subcutaneously, due to stability and 
bioavailability challenges associated with oral administration, for the management of insulin-
dependent diabetes in patients whose pancreas does not produce insulin (Type I), or those whose 
cells have developed low insulin sensitivity (Type II).  
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Figure 1.5 Primary structure of insulin showing A and B polypeptide chains, with inter- and intra-molecular di-
sulphide bridges (Snyder et al 2012) 
Diabetes is currently one of the most common metabolic disorders in the world, with global burden 
on a steady rise over that last three decades (Guariguata et al 2014). Insulin was the first therapeutic 
protein to be fully syntheisised, first to get its three-dimensional nomenclature elucidated, and the 
first protein to be produced by recombinant DNA technology and marketed  in large quantities; it 
is, therefore, one of the most studied therapeutic peptides in history (Heinemann 2008, Muheem et 
al 2014). Complications associated with insulin parenteral therapy have driven the on-going search 
for non-invasive methods for insulin delivery.  
1.6.1 Previous work done on oral transmucosal delivery of insulin 
Numerous data have been published on the oral delivery of insulin (along the entire GIT); however, 
although various reviews on insulin buccal delivery abound, actual research articles are few. 
Morishita et al (2001) reported the reduction in blood sugar in normal rats, after buccal 
administration of pluronic gels containing insulin with unsaturated fatty acids. Formulations 
containing oleic acid were found to exhibit the highest bioavailability of 15.9 ± 7.9 %. Yang et al 
(2002) also reported a 15.59% relative pharmacological bioavailability (relative to subcutaneously 
administered insulin solution), of insulin from phospholipid deformable vesicles delivered via the 
rabbit buccal mucosa. Aungst and Rogers (1988) had earlier compared the hypoglycaemic effects 
of insulin preparations containing absorption enhancers/ adjuvants administered transmucosally 
via the rectal, buccal and nasal routes in rabbits, to that of intramuscular (i.m.) insulin. The three 
routes investigated showed 30% of the hypoglycaemic effect from i.m. insulin, with sodium 
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salicylate and disodium ethylene diaminetetraacetic acid enhancing rectal insulin effect up to 40% 
of its i.m. counterpart. Aungst and Rogers (1989) reported similar findings when sodium lauryl 
sulphate was used as an absorption enhancer for buccal insulin delivery. Xu et al (2002) reported 
an Insulin Buccal Spray (IBS) comprising a combination of soybean lecithin and propandiol as 
absorption enhancers, to have improved significantly, the hypoglycaemic side effect of insulin in 
diabetic rats and rabbits. Modi (2002) patented mixed micellar formulations containing an alkyl 
sulphate for buccal insulin delivery while Modi et al (2010) patented a technology for 
administering insulin to the buccal mucosa via an atomiser, while restricting inhalation. A summary 
of the outcomes of studies employing bile salts and surfactants to enhance buccal insulin absorption 
is presented in Table 1.7 below.  
1.6.2 Non-invasive buccal insulin formulations on the market or under 
development 
A number of companies have oral (GIT) insulin preparations that are currently on the market or 
undergoing clinical development (Table 1.8). However, till date, only one marketed buccal 
formulation for insulin (OralynTM by Generex Biotechnology, Canada) has been approved and is 
in use in countries like Ecuador and India, while awaiting approval in others (Heinemann and 
Jacques 2009). OralynTM is a liquid preparation of regular recombinant human insulin administered 
just before meals, formulated with a propellant for aerosol administration via RapidmistTM patented 
technology which sprays the solution into the mouth towards the throat as micelles in a fine mist; 
and particle size of droplets (85% >10µm) are too large to enter deeply into the lungs (Heinemann 
and Jacques 2009, Bansal et al 2014, Verma et al 2014). 
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Table 1.7 Summary of insulin buccal transport studies employing bile salts and surfactants as permeation 
enhancers (Caon et al 2014); adapted 
Surfactant/  
Bile salt 
Test model Outcome Reference 
Laureth-9 Insulin solution 
administered to rats 
in vivo. 
Increase in 
hypoglycaemic response 
from 3.6% to 27.2% 
 
(Aungst and 
Rogers 1988) 
Laureth-9 (L9) 
polysorbate 20,  
PEG laurate, 
propylene 
glycolaurate, sorbitan 
laurate, glyceryl 
monolaurate, 
octoxynol-9, sodium 
dodecyl sulphate 
(SDS),  sodium 
glycocholate (SGC), 
sodium deoxycholate 
(SDC), sodium, 
laurate (SL), sodium 
lauryl sulphate (SLS)  
 
Insulin solutions 
administered in vivo 
in rats. 
Presence of bile salts 
(SGC, SDC) and 
surfactants (SL, SLS and 
L9)  showed maximum 
efficacy with >20% 
efficacy over i.m. insulin 
(Aungst and 
Rogers 1989) 
Sodium cholate (SC), 
sodium taurochlorate 
(STC) , 
lysophosphatidyl 
choline (LPC) 
Buccal insulin 
administered in 
anaesthetised dogs in 
vivo.  
Enhanced hypoglycaemic 
effect with glucose back 
permeation lowered by 
80% 5-8 hours after 
exposure to STC, but 
remained unchanged for 
SC. 
 
(Zhang et al 1994) 
Brij-35, STC.SLS, 
SDC 
Formulation 
solutions 
administered to 
rabbits in vivo 
Hypoglycaemic effect 
increased in the order 
SDC<SLC<STC<Brij-35 
 
(Oh and Ritschel 
1990) 
 
Octylglucoside and 
dodecylmaltoside 
Buccal 
administration of 
formulation solutions 
to rats in vivo 
Hypoglycaemic effect 
increased from 1% in the 
control to 20% and 30% 
respectively for 
octylglucoside and 
dodecylmaltoside 
 
(Aungst 1994) 
Soybean lecithin Application in rats 
and rabbits in vivo 
Significant blood glucose 
decrease by 60% and 
54% in rats and rabbits 
respectively. 
(Xu et al 2002) 
Lysalbinic acid In vitro permeation 
using excised 
hamster cheek pouch 
 
5-fold increase in buccal 
FITC-insulin permeation  
(Starokadomskyy 
and Dubey 2006) 
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Table 1.8 Oral insulin formulations in development; adapted from (Heinemann and Jacques 2009) 
Company Product Stage Dose 
(IU) 
Daily 
dose 
(IU) 
Functional 
bioavailabilit
y 
Mechanism 
Biocon, India IN-105, 
tablet, 
(NCE) 
 
Phase I 300-
500 
 
1200-
2000 
Low Active 
transport 
Diabetology, 
UK 
CapsulinTM 
Enteric-
coated 
capsule 
 
Phase I 
Phase IIa 
150 or 
300 
600-
1200 
Low Active 
transport 
Diasome, US HDV-1, 
Oral gel 
capsule 
 
Phase II 5 20 High Tight junction 
with hepatic 
targeting 
Emisphere, 
US 
Oral 
capsule 
 
Phase I, 
Phase IIa 
300 1200 Low Active 
transport 
Oramed, US Oral 
capsule 
Phase I 236 944 Low Active 
transport with 
possible 
hepatic 
targeting 
 
NCE- new chemical entity 
This insulin formulation is stable at room temperature for over 6 months, contains “a surfactant, a 
solubiliser, a micelle-creating agent, and emulsifying agents—all generally regarded as safe 
(GRAS)” and is presented in an asthma-type inhaler that releases 10 IU of insulin per puff; reported 
to rapidly penetrate the buccal mucosa and achieve fast absorption within 5-10 minutes in vivo 
(Heinemann and Jacques 2009, Bansal et al 2014). Advantages of OralynTM include patient 
acceptance of the inhaler-type device which is somewhat familiar and non-invasive. However 
several limitations exist including the training required to correctly operate the device to deliver 
insulin accurately; drug loss could occur due to non-compartmentalised delivery to the buccal 
region of the mouth, with some aerosol droplets travelling down the GIT with onward insulin 
inactivation. Furthermore, the specific formulation additives have not been disclosed, specific 
descriptions of mechanism and route of insulin transport have not been described for this system, 
and relative biopotency studies are still outstanding since 95% of the formulation is ingested by 
patients (Heinemann and Jacques 2009, Bansal et al 2014). 
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1.7 Orally Disintegrating Tablets (ODTs) 
Orally disintegrating tablets (ODTs) have been described as solid dosage forms that disintegrate 
and dissolve in the mouth (either on or beneath the tongue or in the buccal cavity) without water 
within 30 seconds (USP specification) or 3 minutes (BP specification) (Pfister and Ghosh 2005). 
ODTs are particularly useful to patients who have difficulty in swallowing (dysphagia) such as 
children and the elderly. Wagh et al (2011) reported that 30-40% of the elderly and 18-22% of 
persons in long-term care homes, as well as 35% of the general populace suffer from dysphagia. 
ODTs have advantages over chewable tablets in patients who have difficulty chewing or in children 
who have lost their milk teeth but are yet to grow their permanent teeth (Hirani et al 2009); also 
there would be no leaching out of unpleasant tasting drugs which occurs during chewing of taste-
masked chewable tablets (Alhusban et al 2010). ODTs are preferred to oral liquid dosage forms 
like suspensions and granules because they do not need a preparatory step before administration 
(AlHusban et al 2010). In disease conditions such as nausea and motion sickness, for psychiatric 
patients, patients on reduced fluid intake/ diet and even when there is no access to water such as 
when travelling, ODTs have proven to be a useful alternative to conventional solid dosage forms 
such as tablets/ capsules (Hirani et al 2009).  Some market surveys revealed that over 50% of the 
population would choose ODTs over other dosage forms; about 70% would request ODTs from 
their physicians, 70% would buy ODTs and over 80% would choose ODTs over conventional 
tablets/ capsules (Hirani et al 2009). Since ODTs disintegrate and dissolve rapidly in the mouth, 
which has a very high number of blood vessels (highly vascularised), the drug molecules can be 
rapidly absorbed from the pre-gastric area (the mouth, pharynx and oesophagus); though some 
absorption can still take place in the stomach and intestines.  Pre-gastric absorption has the benefit 
of rapid onset of drug action because the drug reaches the blood stream faster and does not depend 
on gastric emptying (Wagh et al 2011). This may result in higher bioavailability than conventional 
tablets, as ODTs evade hepatic first pass metabolism which is a major problem of the oral route of 
drug administration (Pfister & Ghosh 2005).  
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1.7.1 Characteristic Limitations/ Possible Solutions of ODTs  
Despite the numerous advantages of ODTs, a major limitation is the amount of drug the dosage 
form can contain. For ODTs produced by freeze-drying, drug content must be less than 60mg for 
soluble drugs and less than 100 mg for an insoluble drug (Pfister and Ghosh 2005). Directly 
compressed ODT have overcome this set-back (Al-Khattawi and Mohammed 2013). To ensure 
rapid disintegration, dissolution and drug release in the mouth, ODTs have to be porous enough to 
enhance wettability by saliva. However, the more porous a tablet, the less its mechanical strength 
and ability to withstand stress during manufacture, transportation and handling. Also, many ODTs 
are hygroscopic and can therefore not withstand humidity or elevated temperatures (Hirani et al, 
2009). Thus, some ODTs such as freeze- dried wafers have to be packed in specialised unit-dose 
blisters, which are only opened prior to administration. These, however, have higher cost 
implications (Pfister and Ghosh, 2005). Since ODTs disintegrate and dissolve in the mouth, the 
drug is released very near the taste buds. Thus, the taste of the drug is of paramount importance if 
compliance is expected. This is not a problem for drugs which are generally tasteless, but becomes 
a concern for drugs with bitter/unpleasant tastes. Taste masking is therefore an integral component 
of ODT manufacture and novel taste-masking methods are being investigated; however, whichever 
technique is employed for taste masking, it should not alter the characteristics of the ODT (Giri et 
al 2010). Shukla et al (2009) reported the development of pleasant tasting risperidone ODT 
fabricated using an ion-exchange resin that completely masked the bitter taste of risperidone. 
Saccharides and polyols are used extensively in lyophilised ODTs and this is a limitation for their 
long-term use in paediatric, diabetic or obese patients or those on multiple-dose regimens because 
of the narrow daily limit for these substances (Al-Khattawi and Mohammed 2014). In an attempt 
to overcome this drawback, AlHusban et al (2010) formulated freeze-dried ODTs with a novel 
amino acid (proline/serine) combination in place of saccharides and reported improved formulation 
characteristics. However, polyols such as mannitol with zero calorie content and good mouth-feel 
have been utilised (Al-Khattawi and Mohammed 2013). Rapid disintegration limits the use of 
ODTs for controlled-release of drugs except when formulated with “slow-dissolving, 
microparticulate-coated drugs” that disperse on disintegration and are swallowed (Pfister & Ghosh 
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2005). Fini et al (2008) however reported the successful production of fast-dispersible, slow-
release ibuprofen ODTs prepared by wet granulation method using lecithin and coating agents. 
Cilurzo (2005) investigated the feasibility of preparing fast dissolving tablets containing 
microparticles with mucoadhesive properties to enhance residence time of the dosage form on the 
sublingual mucosa. A formulation containing 70% piroxicam and 30% Eudragit®L100 sodium salt 
was found to impart mucoadhesive properties and enhanced apparent drug solubility while 
incorporating the lowest concentration of polymer. 
1.7.2 ODT formulation 
Properties of ODTs depend on the technology used in their manufacture. Techniques/ technologies 
employed in production of ODTs can be grouped as: heat-based technologies (such as mass 
extrusion, melt granulation, flash heating, phase transition, tablet moulding, sintering, sublimation, 
and wet granulation processes); and non-heat-based technologies such as freeze-drying, direct 
compression/ spray drying processes and effervescent disintegration systems (Goel et al 2008, 
Hirani et al 2009, Giri et al 2010, Wagh et al 2011). Of the various technologies for producing 
ODTs, studies have shown that lyophilisation seems to be the most successful because it provides 
highly porous tablets, resulting in rapid disintegration and ease of swallowing; however high 
friability is a concern with lyophilised tablets (AlHusban et al, 2010). Direct compression is gaining 
grounds as a simple, cost effective method not requiring the use of moisture or heat that produces 
ODTs with good mechanical properties (Al-Khattawi et al 2014). Gosai et al (2008) formulated 
ondansetron ODTs by direct compression using super disintegrants. The ODTs were found to 
disintegrate in the mouth within 3-5 seconds, and showed higher dissolution/ release rates than 
both the pure drug and the conventional tablets available in the market. 
1.8 Research aims and objectives 
Unfortunately, the use of peptides for chronic illnesses requires one or more injections per day on 
patients and this comes with inherent setbacks such as pain, psychological and physiological stress, 
risk of infection, and depositions at the site of administration; which all lead to poor patient 
compliance and probably therapeutic failure. Also, although parenteral routes result in delivery of 
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adequate doses to the bloodstream, some common problems with the administration of a protein 
like insulin include hyperinsulinaemia in the peripheral systems, entrance of insulin into arterial 
wall lipids, increase in smooth muscle cell growth; all leading to angiopathy at micro and macro 
levels (Khafagy et al 2007). Thus, with advancements in mass protein and peptide production via 
recombinant technologies, research has been directed towards novel, non-invasive methods to 
deliver these agents. Although these alternative routes have so far not recorded overwhelming 
successes in terms of improved or comparable bioavailability and efficacy, scientists are still 
working towards non-invasive delivery, because of the promise of an improved quality of life for 
the patients (Caon et al 2014). 
The advantages of buccal drug delivery, as discussed above, and the high acceptability of ODTs 
necessitate further studies into the applicability of this dosage form to deliver large molecule 
therapeutics such as peptides and proteins like insulin, which cannot withstand the harsh 
environment of the GIT. However, there are various gaps in currently available knowledge. No 
literature exists that explores the buccal delivery of proteins formulated as an ODT.  The 
unavailability of standardised, cost effective methods for in vitro modelling of buccal transport is 
still a concern. Most of the published literatures report the use of amino acid derivatives as 
permeation enhancers with little or no elucidation of mechanisms of such enhancement; few studies 
employed unmodified amino acids. However till date, no evidence exists on the use of amino acids 
as permeation enhancers across the buccal cavity, or for the peptide insulin. Thus, it becomes 
pertinent that a multivariate study employing strategies that overcome the physiological barriers of 
peptide drug delivery via the buccal cavity be carried out, to investigate increases in bioavailability, 
if any, of peptide drugs administered via this route. The objectives of this work therefore include:  
- To systematically investigate the tabletting properties of novel multifunctional excipients 
and their applicability in ODT manufacture by direct compression method. 
- To employ quality by design (QbD) principles in the fabrication of ODTs exhibiting 
mucoadhesive properties which still meet ODT criteria of good mechanical strength and 
fast disintegration. 
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- To investigate the development of a robust and cost effective cell culture based method for 
in vitro assessment of buccal drug transport exhibiting characteristics similar to that 
expected in vivo. 
- To characterise and quantify the model protein, insulin and determine the effect of ODT 
manufacturing process parameters on protein stability and secondary structure. 
- To model insulin transport across the buccal mucosa in vitro in order to identify preferred 
candidates, as well as elucidate exact routes and mechanisms of insulin transport in the 
presence of amino acids as permeation enhancers. 
- To formulate and characterise insulin ODTs containing amino acids and mucoadhesive 
agents. 
Research Hypothesis 
The overall hypothesis of this work was built on the premise that the absorption of large molecules 
like proteins and peptides which are degraded in the harsh environment of the GIT can be 
significantly increased via buccal transmucosal delivery, when formulated as ODTs including 
penetration enhancers and mucoadhesive agents.  
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2.1 Introduction 
Cellulose is the most abundant and renewable naturally occurring polymer or raw material 
presently available (Roy et al 2009a). It is a component of the cell wall of green plants, some algae 
and bacteria amongst others. Cellulose consists of repeating linear chains of anhydrous D-glucose 
molecules linked by β(1→4)-glycosidic linkages (Figure 2.1). The abundance and easy 
accessibility of cellulose has driven its application in various industries such as food, 
pharmaceutical and textile (Roy et al 2009a). However, comparing the current applications of 
cellulose to its high abundance, it is an under-utilised natural resource.  
The multiple hydroxyl groups in the cellulose polymer backbone enable hydrogen bond formation 
(Figure 2.2 and Figure 2.3) between hydroxyl hydrogen and the oxygen atom in the glucose ring. 
This inter- and/ or intra-molecular hydrogen bonding imparts high crystallinity and a very rigid 
structure on cellulose (Sharma et al., 2009). Therefore, pure cellulose is insoluble in water and 
most organic solvents and has limited applications, especially in the pharmaceutical industry. 
Structural modifications of the cellulose backbone have provided polymers with better 
characteristics for diverse applications. Cellulosic polymers such as microcrystalline cellulose 
(MCC) and low substituted hydroxypropyl cellulose (LHPC) have been employed in the 
development of compressed ODTs, with tablets exhibiting high hardness and fast disintegration 
(Al-Khattawi and Mohammed 2013). Cellulosic polymers offer the advantage of their natural 
origin, biodegradability and accessibility. A major setback to the use of cellulosics in compressed 
ODT formulation is the poor mouth-feel or grittiness due to large particle size (Al-Khattawi and 
Mohammed 2013). Thus research has been geared into improving the physical characteristics of 
these excipients. 
Figure 2.1 Molecular structure of cellulose showing repeating anhydrous glucose molecules linked by β(1,4)-
glycosidic linkages (Roy et al 2009a) 
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Figure 2.2 Intra-molecular hydrogen bonding in cellulose (Roy et al 2009a) 
  
Figure 2.3 Inter-molecular hydrogen bonding in cellulose (Roy et al 2009a) 
One of such efforts was reported by Ishikawa et al (2001) where new grades of MCC (PH-M series) 
were reported, which were spherical with smaller particle size, to reduce the gritty mouth-feel of 
the original excipient.  
To continue the investigation of cellulosics, a new grade of hydroxypropyl cellulose with small 
particle size was investigated. This grade of HPC had been reported by the manufacturers to impart 
desirable tablet characteristics to ODT formulations. HPC is a non-ionic ether of cellulose which 
is obtained when some or all the hydroxyl groups of the glucose units on the cellulose backbone 
have been hydroxypropylated to -CH2CH(OH)CH3 groups using propylene oxide (Sharma et al 
2009). HPC possesses advantageous features such as biocompatibility, biodegradation, 
hydrophilicity/ water solubility and phase transition behaviors that change depending on polymer 
concentration (Gong et al 2011). According to the number of substituted hydroxyl groups on the 
cellulose backbone, various HPCs can be obtained differing in their degree of substitution (DS). 
The maximum DS obtainable is 3, since only 3 hydroxyl groups exist per anhydrous glucose unit 
of cellulose. A second important parameter for HPC is the moles of substitution (MS), which 
represents the total number of moles of propylene oxide molecules that have reacted per glucose 
moiety (Samuels 1969). MS may be greater than 3 because the –OH groups of the hydroxypropoxy 
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substituents are available for further etherification to incorporate more propylene oxide groups 
during the preparation of HPC (Sharma et al 2009). For HPC to be soluble in water, it must have 
an MS of at least 4, because of the high crystallinity of cellulose (Gong et al 2011). An idealised 
structure of HPC is shown in Figure 2.4 indicating that the propylene oxide moieties can either 
react with the hydroxyl group of the anhydrous glucose moiety, or the hydroxyl group on the 
previously attached hydroxypropyl substituent (Werbowyj and Gray 1980). 
 
Figure 2.4 Idealised structure of hydroxypropyl cellulose portraying hydroxypropylation occurring either on the 
hydroxyl group of glucose, or on previously hydroxypropylated side chains (Werbowyj and Gray 1980)   
 
The specific application of HPC in pharmaceutical dosage formulation depends on different 
variables, especially its structural features, which can be defined by its DS. DS of HPC determines 
its behavior in the presence of water; thus, HPCs with medium or high DS which are 
characteristically soluble in water, are applied as thickeners and in the formulation of matrix 
tablets; while those with low DS reported not to dissolve, but swell in the presence of water, are 
applied as disintegrants during formulation of conventional tablets (Alvarez-Lorenzo et al 2000). 
HPC has been reported to exhibit properties as a binder, disintegrant, and/or mucoadhesive agent 
for drug delivery systems (Machida 1974, Sakagami et al 2001, Francis et al 2003). Studies 
employing low-substituted hydroxypropyl cellulose (LHPC) have used it as a co-excipient in 
conventional or orodispersible tablet formulations. Little or no data exists for the use of HPC or 
LHPC as the main excipient for ODT studies. Alvarez-Lorenzo et al (2001) studied the 
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characteristic effect of 5 varieties of LHPC on the behaviors of conventional tablets prepared by 
direct compression. Thus it is important to investigate and highlight the roles these polymers play 
in ODT formulation development.  
Orally disintegrating tablets (ODTs) have gained popularity and are useful for drug delivery to 
paediatric and geriatric populations (Wagh et al 2011). These tablets are required to disintegrate in 
the mouth in less than 30 seconds (USP requirement), without the need to drink water (Pfister and 
Ghosh 2005). One of the constraints of ODT usage is the small quantity of drug it can accommodate 
(Aurora and Pathak 2005). Thus, to maximise drug loading without producing very large tablets, 
it is necessary to employ excipients with multi-functionalities. Scant data is available on the use of 
HPCs on their own as binders and/or disintegrants for formulation of ODTs. The availability and 
incorporation of multi-functional excipients into oral tablets is becoming more popular due to the 
potential for reduced excipient load, increased dose capacity, smaller tablet size enhancing patient 
compliance and suitability for ODT manufacture by direct compression, without the need for 
granulation (Al-Khattawi et al 2014).  
The objective of this study was to investigate the tableting properties of a novel grade of HPC, 
which was claimed by the manufacturers to be applicable as a binder/ disintegrant in ODT 
formulation (to substantiate or refute their claims) and compare with a low substitution HPC 
(LHPC), with the overall aim of obtaining an optimised ODT formulation by direct compression. 
2.2 Materials and methods 
2.2.1 Materials 
Hydroxypropyl cellulose (HPC-SSL-SFP) was a gift from Nisso Soda Co. Ltd (Japan). Low-
substituted hydroxypropyl cellulose (L-HPC, NBD-022) was a gift from Shin-Etsu Chemical Co 
(Tokyo, Japan), while magnesium stearate and D-mannitol were purchased from Sigma-Aldrich 
(Pool, UK).  
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2.2.2  Methods 
2.2.2.1 Bulk/ pre-formulation characteristics of powders 
Pre-formulation characterisation was carried out on HPC and low substituted HPC (LHPC) to serve 
as a basis for comparing behaviours when tablets were formulated. 
2.2.2.1.1 Particle size analysis (Diffractometry) 
Approximately 2 g of the dry powders was spread on a VIBRI/L feeder tray, and dispersed through 
a RODOS disperser attached to a Sympatec HELOS/BR particle size analyser (Clausthat-
Zellerfeld, Germany) at trigger condition of 2% Copt for 10 sec using compressed air at 3 bar 
pressure. As a beam of monochromatic light passed through the chamber, the powder particles 
diffracted the light at certain angles depending on their particle size through lens range of 0-175µm 
and results were produced as a volume distribution. Triplicate measurements were made and the 
accompanying software calculated the 10% (D10), median (D50%), 90% (D90) particle sizes, as 
well as the volume mean diameter (VMD) of particles (n=3). 
2.2.2.1.2 Angle of repose (ө) 
The angle of repose has been described as ‘an engineering property of granular materials’ and is 
‘the maximum angle of a stable slope with the horizontal determined by friction, cohesion and the 
shape of the particle’ (Deshpande and Yadav 2009). The fixed height cone method (Fahmy and 
Kassem 2008) was adapted for this test. A funnel was attached to a retort stand at a specific height 
and the powders were poured freely through the funnel until a conical heap was achieved. The 
height (h) and diameter (d) of the heap were measured. The angle of repose ѳ, which is the internal 
angle between the horizontal surface and the powder surface, was then calculated from the 
equation: 
Tan  ѳ =
2h
d
  . . . . . . .  (Equation 2.1) 
The test was performed in triplicate (n=3) for each sample and the mean angle recorded in degrees. 
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2.2.2.1.3 Bulk and tapped density 
A specific weight (20 g) of the sample was poured into a 100 mL measuring cylinder attached to a 
Sortax tap density tester USP I apparatus (Allschwil, Switzerland). The initial volume (volume at 
zero tap or bulk volume) was recorded. The machine was set to vibrate and the volumes at 50, 
100,150, 200 and 250 taps were obtained and recorded. This was repeated for all the samples. The 
tapped and bulk densities, Hausners ratio and Carrs’ index were calculated for the samples using 
the equations below: 
𝑇𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑜𝑤𝑑𝑒𝑟
𝐹𝑖𝑛𝑎𝑙 𝑝𝑜𝑤𝑑𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒
  . . . . . (Equation 2.2) 
𝐵𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑝𝑜𝑤𝑑𝑒𝑟
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑝𝑜𝑤𝑑𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑎𝑡 𝑧𝑒𝑟𝑜 𝑡𝑎𝑝)
  . . . (Equation 2.3) 
𝐻𝑎𝑢𝑠𝑛𝑒𝑟′𝑠 𝑟𝑎𝑡𝑖𝑜 =
𝑇𝑎𝑝 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝐵𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
  . . . . . (Equation 2.4) 
𝐶𝑎𝑟𝑟′𝑠𝑖𝑛𝑑𝑒𝑥 =
𝑇𝑎𝑝 𝑑𝑒𝑛𝑠𝑖𝑡𝑦−𝐵𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑇𝑎𝑝 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
 𝑥
100
1
  . . . . (Equation 2.5) 
2.2.2.1.4 True density and porosity of powders 
A multipycnometer from Quantachrome Instruments (Syosset, USA) utilising helium gas was used 
to measure the true density of the powders at ambient temperature. Tablet true volume 
measurement was based on Archimedes principle of fluid displacement since helium gas can 
penetrate tiny pores of up to 1 angstrom (10-10 m) in diameter.  Weighed samples (0.9-1.1 g) were 
employed. The true density of the sample was automatically calculated by the accompanying 
software using equation 2.6 below. The bulk volume of the powder was further measured by 
pouring the weighed sample into a 1mL volumetric cylinder. The tests were performed in triplicates 
for each of the samples. The porosity of the powders was calculated from equation 2.7: 
𝑉𝑡 = 𝑉𝑐 −  𝑉𝑟 (
𝑃1
𝑃2
− 1) . . . . . . . (Equation 2.6) 
𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 (𝜀) = 1 −
𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑡𝑟𝑢𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
  .. .  . . (Equation 2.7) 
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Where Vt, Vc and Vr are the sample true volume, sample cell volume and known reference 
volume respectively. P1 and P2 represent the atmospheric pressure and air pressure change during 
determination. The true and bulk densities of the tablet can then be calculated from Vt and bulk 
volume. 
𝑇𝑟𝑢𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =  
𝑃𝑜𝑤𝑑𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡
𝑃𝑜𝑤𝑑𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑉𝑡)
 . . . . . (Equation 2.8) 
𝐵𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =  
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑜𝑤𝑑𝑒𝑟
𝑏𝑢𝑙𝑘 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑝𝑜𝑤𝑑𝑒𝑟
 . . . . . (Equation 2.9) 
2.2.2.1.5  Powder moisture content  
The moisture content of the powders was determined by the ‘loss on drying method’ using a 
thermobalance (Sartorius, Surrey, UK). Samples of <200 mg were loaded unto the balance and the 
initial weight recorded. After heating at a constant rate, the final weight was recorded. Moisture 
content was then calculated as the percentage weight loss from the sample using equation 2.10.  
𝑀𝑜𝑖𝑠𝑡𝑢𝑟𝑒 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 =
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡−𝑓𝑖𝑛𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
 𝑥
100
1
  . . . (Equation 2.10) 
The samples were tested in triplicates and reported as mean ± standard deviation.  
2.2.2.1.6 Scanning electron microscopy (SEM) 
For powders, approximately 1mg samples were lightly sprinkled on the carbon surfaces of 
universal specimen stubs taped with double-sided adhesive strip, while tablets were dissected with 
a blade and a thin section was added to the specimen stub. Samples were then double coated with 
a thin layer of gold under low vacuum for about 3 minutes in the presence of Argon gas using a 
sputter coater, Polaron SC500 (Polaron Equipment Ltd, Watford, UK) at 20 mA. The particle 
surface morphology was captured using a Cambridge Stereo Scan (S90) Electron Microscope to 
produce micrographs including acceleration voltage and magnification. 
2.2.2.1.7 Fourier transform infrared (FTIR) spectroscopy   
FTIR spectroscopy was carried out on the powders using a Nicolet IS5 FTIR spectrometer 
equipped with an iD5 attenuated total reflectance (ATR) diamond from Thermo Fisher 
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(Massachusetts, USA). A small mass of dry powder was lightly spread on the lens and after 
measurements the accompanying software identified the available peaks.  
2.2.2.1.8 X-ray diffractometry (XRD) 
To investigate the absence or presence of crystallinity in the polymers, x-ray diffraction using a D2 
Phaser from Bruker (Massachussetts, USA) was carried out on the polymer powders. The angular 
range (2ө) varied from 4 – 50° with increment steps of 0.02° and measured at 0.25 seconds/ step. 
Diffractive patterns were generated as counts per step and thereafter analysed using Eva 18.0.0.0 
software (Bruker, AXS). Runs were carried out in triplicate and representative results reported.  
2.2.2.2 Tablet preparation and characterisation 
500 mg tablets consisting of 100% polymer were compacted using a manual bench-top hydraulic 
tablet press from Specac Ltd (Slough, UK) equipped with 13mm flat-faced dies. The punches were 
externally lubricated with a suspension of magnesium stearate in acetone (5% w/v) and powders 
were manually filled into dies. Tablets were punched at a pressure range of 5-30 kN and 5sec dwell 
time. Six batches of 500 mg placebo tablets were prepared. The tablets were individually weighed 
from mixes that contained 0.5% magnesium stearate as lubricant, D-mannitol as filler and 0-10% 
polymer (HPC or LHPC) as binder/ disintegrant. The composition of the batches is shown in Table 
2.1. 
Table 2.1 Composition of placebo tablets 
Formulation D-Mannitol (%) Polymer (%) Magnesium stearate (%) 
F0 (control) 99.5 0.0 0.5 
 
F1 98.5 1.0 0.5 
 
F2 96.5 3.0 0.5 
 
F3 94.5 5.0 0.5 
 
F4 92.5 7.0 0.5 
 
F5 89.5 10.0 0.5 
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2.2.2.2.1 Tabletting behaviour of pure polymer tablets 
In order to examine powder densification mechanisms and obtain mean yield pressure (Py) values, 
out-of-die Heckel’s profiles were generated for the pure polymer tablets. This analysis involves 
compaction of the tablets at different pressures and measuring the porosity after tablet ejection. Py 
can be obtained from the reciprocal of the slope (K) of the linear portion of the Heckel plot (–Ln 
porosity vs compaction pressure), which is represented by equation 2.11 (Paronen 1986): 
𝐿𝑛 (
1
1−𝐷
) = 𝐾𝑃 + 𝐴  . . . . . . . (Equation 2.11) 
where D = relative density (apparent tablet density/ effective particle density) of powder bed during 
compression, P = applied pressure, K = constant which reciprocal gives the material’s mean yield 
pressure that shows the ability of a material to undergo deformation under pressure; and the 
intercept, A, sheds light on the movement of particles at the initial compaction stage. 
FTIR spectroscopy, SEM and XRD (described above) were also carried out on the pure polymers 
compacted at pressures of 5, 10 and 30 kN, to attempt an elucidation of the bonding processes that 
occur during their compaction. 
2.2.2.2.1 Tablet hardness 
The hardness (crushing strength) of the tablets was measured using a 4M hardness tester from 
Schleuniger (Thun, Switzerland). Tensile strength, ơ was calculated from equation 2.12: 
𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ (Ơ) =
2 𝑥 𝐻𝑎𝑟𝑑𝑛𝑒𝑠𝑠
𝜋𝑑h
   . . . . . (Equation 2.12) 
Where d and h represent the diameter and thickness of the tablet, measured using a digital Vernier 
calliper. 
2.2.2.2.2 Tablet porosity 
The apparent density of the tablets was measured using the helium pycnometry method described 
above (section 2.2.2.1.4). Bulk volume, calculated from tablet diameter (d) and thickness (h) using 
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equation 2.13, was used to compute bulk density (equation 2.14) while porosity was calculated 
using equation 2.7 above. 
𝐵𝑢𝑙𝑘 𝑣𝑜𝑙𝑢𝑚𝑒 =  𝜋 (
𝑑
2
)
2
ℎ  . . . . .  (Equation 2.13) 
𝑇𝑎𝑏𝑙𝑒𝑡 𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑡𝑎𝑏𝑙𝑒𝑡
𝑏𝑢𝑙𝑘 𝑣𝑜𝑙𝑢𝑚𝑒
  . . . . (Equation 2.14) 
2.2.2.2.3 Tablet friability 
The ability of the tablets to withstand mechanical stress, known as friability was measured using a 
rotating drum friabilator from J. Engelsmann AG (Ludwigshafen, Germany). 6 tablets were utilised 
at 25 rpm for 100 revolutions or 4 minutes.  Tablets were carefully de-dusted before and after the 
test, and friability expressed as the percentage loss in weight. 
𝐹𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡−𝑓𝑖𝑛𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
 𝑥
100
1
  . . . . (Equation 2.15) 
2.2.2.2.4 Tablet disintegration time 
The time taken for the tablet to disintegrate and completely pass through the mesh of a 
disintegration basket was determined according to the official USP monograph 701, on a ZT3 USP 
II disintegration test apparatus (Erweka, Heusenstamm-Germany). A tablet was placed in the 
disintegration basket and covered with a disk. The basket was then raised and lowered at a constant 
frequency of 30 cycles/ min in the disintegration medium (800 mL distilled water) maintained at 
37°C. Measurements were carried out on tablets individually to improve operator accuracy and 
precision.   
2.2.2.2.5 Formulation optimisation 
The formulation which showed the best overall tablet characteristics, of low friability and 
disintegration time, but high hardness and porosity, was optimised by compacting at various 
pressures and tablet characterisation repeated as above. 
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2.2.2.6 Statistical analysis 
All data generated in triplicates were presented as mean ± standard deviation (SD), where n=3.  
The data was then analysed for statistical significance using one-way analysis of variance 
(ANOVA) and Tukey-Kramar multiple comparison  post-test from Graphpad Prism® version 5.04 
(Graphpad Software, San Diego, CA, USA). The level of significance was quoted as p<0.05 
(probability values of 95%). 
2.3 Results and discussion 
2.3.1 Pre-formulation characterisation 
2.3.1.1 Effect of morphology on power characteristics 
Table 2.2 and Figure 2.5 present the particle sizes of the polymers using laser diffractometry. The 
results showed HPC as a much finer powder than LHPC. These results were consistent with that 
from SEM studies displaying HPC particles (Figure 2.6) as smaller than that of LHPC (Figure 2.7). 
The morphology of HPC particles was somewhat spherical, non- elongated, with an irregular 
surface; while that of LHPC particles was fibrous, needle-shaped/ elongated with an irregular 
surface. Picker-Freyer and Durig (2007) reported that for fine particle grades of HPC, the 
morphology of the smaller particle size grades was spherical, while those with larger particle size 
showed more elongated structures. The irregular surface of the particles would be expected to lend 
to higher interactions and hardness on compaction (Korhonen et al 2002). Particle size becomes 
important because it may control many properties such as flowability, agglomeration and 
dissolution of powders (Sinko 2011). Small particle size is advantageous because it increases the 
particle surface area and thus decreases dissolution time, but particles smaller than a critical 
dimension (approximately 20 µm) tend to agglomerate and thus impede tablet dissolution (Sinko 
2011). 
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Table 2.2 Particle size analysis of powders using difractometry (n=3). HPC exhibited significantly smaller particle 
size than LHPC 
 
Property HPC L-HPC 
D10 (µm) 2.57 ± 0.05 16.15 ± 0.13 
 
D50 (µm) 15.08 ± 0.21 42.30 ± 0.22 
 
D90 (µm) 39.21 ± 1.52 85.51 ± 2.09 
 
VMD (µm) 19.12 ±0.44 47.02 ± 0.82 
 
 
On the other hand, particles with large sizes tend to exhibit good flow characteristics (Sinko 2011). 
Flowability of powders is important because small particle sizes can result in poor die fill and 
inconsistent content uniformity, which in turn can cause entrapment of air within the tablet upon 
compaction, resulting in lamination and capping (Al-Khattawi et al 2014). 
 
 
 
 
Figure 2.5 Representative graph showing particle size distribution of HPC powder by laser diffractometry using 
a Sympatec HELOS/BR particle size analyzer (n=3) 
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Figure 2.6 SEM of HPC powder at 50 µm magnification showing somewhat spherical particles with irregular 
surface 
 
Table 2.3 is a summary of the pre-formulation characteristics of the powders. According to the 
USP 29, the angle of repose (AOR) is a characteristic related to the inter-particulate friction or 
resistance to movement between particles. The lower the AOR, the better would be the flowability 
of the powder.  HPC showed a high angle of repose indicative of very poor flow (Table 2.4). This 
was expected considering its small powder particle size.  According to Elshaer et al (2013) AOR 
values above 40° describe powders that possess very poor flowability. Based on this classification, 
HPC can be said to have poor flowablity and L-HPC passable flowability. This can be explained 
based on the smaller mean particle diameter of HPC (<20µm).   
 
Figure 2.7 SEM of LHPC powder at 50 µm magnification showing somewhat elongated particles with irregular 
surface 
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Table 2.3 Summary of pre-formulation characteristics of HPC and LHPC powders (n=3) 
Parameters HPC LHPC 
Angle of repose (°)  40.68 ± 0.57 34.42 ± 1.13 
Bulk Density (g/cm3) 0.341 ± 0.01 0.330 ± 0.01 
Tap Density (g/cm3) 0.408 ± 0.01 0.445 ± 0.02 
Hausner’s ratio 1.197 ± 0.01 1.349 ± 0.05 
Carr’s Index (%) 16.48 ± 0.88 25.82 ± 2.50 
True Density (g/cm3) 1.46 ± 0.02 1.90 ± 0.03 
Porosity 0.84 ± 0.01 0.86 ± 0.01 
Moisture content (%) 9.91 ± 0.94 12.08 ± 1.92 
 
Hancock et al (2001) reported low particle size grades of HPC to exhibit very poor flow properties. 
The Carr’s index gives a representation of changes that occur in the packing arrangement of a 
powder when it is tapped and this can then be extrapolated to the effect expected during movement, 
shipping and handling (Nerurkar et al 2005). However, using the Carr’s indices, LHPC would be 
classified as having poor flow and HPC as having fair flow. This was an unexpected result and 
may be explained by the fact that Carr’s index is based on bulk density measurements.  
Table 2.4 AOR and Carr's index as indicators of powder flowability (Aulton, 2002, adapted) 
S/N Type of Flow AOR (°) Carr’s index (%) 
1 Excellent <20 5-15 
2 Good 20-30 12-16 
3 Fair to passable 30-34 18-21 
4 Poor 34-40 23-35 
5 Very poor >40 33-38 
6 Extremely poor - >40 
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According to Sinko (2011), the bulk density of a powder is not a fixed value, but is dependent on 
various factors including: particle size and size distribution, particle shape, true density, the ability 
of the particles to adhere to one another and the method of measurement. Nerurkar et al (2005) 
reported similar results for bulk density and Carr’s index measurements for a small particle size 
grade of HPC. 
The true density of a powder usually depicts the powder’s basic chemical properties, such as unit 
cell dimensions, molecular weight and molecular formula (Hancock et al 2003). As explained 
above, the bulk density, unlike the true density, is not constant and changes depending on different 
factors. Although there is no direct correlation between the bulk density of a powder and its 
flowability, this density becomes important in determining the fill of tablet powders from hoppers 
and into dies, as well as the size of tablets to be used for a powder of a certain mass, to ensure a 
reproducible and constant content (Sinko 2011). The true density of LHPC was significantly higher 
than that of HPC (Table 2.3), which could be explained based on the lower degree of hydroxypropyl 
substitution in LHPC. Thus, although the chemical compounds present are similar, their 
compositions differ. Alvarez-Lorenzo et al (2000) reported that LHPC powders with lower degrees 
of hydroxyl substitution had higher true densities than those with higher degrees of substitution. 
However, the two powders showed bulk and tapped densities with no significant differences 
between them.  
Tablet porosity is a derived value and gives an indication of the solid fraction available for bonding 
in the tablet. Porosity has been shown to affect various properties of tablets including hardness/ 
tensile-strength, friability, disintegration time and dissolution characteristics (Bredenberg et al 
2003). As with the bulk density measurements, porosities of LHPC and HPC powders (Table 2.3) 
were in the same range, with no significant difference between them. 
2.3.1.2 Effect of degree of substitution on powder properties  
FTIR spectra (Figure 2.8) were obtained to identify the peaks corresponding to functional groups 
present in the polymers. HPC and LHPC spectra exhibited absorption peaks that are characteristic 
for the cellulose backbone; (-OH 3418 cm-1, -CH- 2873 cm-1,  -COC- 1049 cm-1, β-linkage 839 cm-
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1) for HPC and (-OH 3333 cm-1, -CH- 2879 cm-1,  -COC- 1020 cm-1, β-linkage 897 cm-1) for LHPC. 
The broad -OH absorption peak observed at 3418 cm-1 in the HPC spectrum shifted downwards to 
3333 cm-1 and was larger in the LHPC spectrum. This confirms that the –OH groups in LHPC are 
not completely substituted and there is higher inter-molecular and intra-molecular hydrogen 
bonding available in LHPC (Wang et al 2003). The replacement of the hydroxyl groups of cellulose 
with ether linkages that occurs in HPC, reduces the intra-molecular hydrogen bonding. Shifting of 
IR peaks from lower to higher intensities are associated with destruction of intermolecular 
hydrogen bonds; as seen in HPC (Yamada et al 1999). C-H stretching vibrations from 2969 to 2873 
cm-1 were observed in HPC and were consistent with results obtained by Kim and Park (2011). This 
C-H vibration of HPC characteristically shows a shoulder at 2969 cm-1 which is assigned to the 
CH stretching of the methyl group indicative of the hydroxypropyl groups (Sharma et al 2009). 
This shoulder was not noticed in the spectra for LHPC as hydroxypropyl substitution is low in 
LHPC. Alvarez-Lorenzo et al (2000) reported that lower degrees of substitution in LHPC impart 
higher crystallinity to the polymer structure.  
 
Figure 2.8 FTIR spectra for HPC and LHPC powders showing higher molecular hydrogen bonding in LHPC 
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The actual degree of substitution of HPC and LHPC can be determined by gas chromatography or 
NMR (Alvarez-Lorenzo et al 2000). Alvarez-Lorenzo et al (2000) also reported that crystallinity 
indices of different varieties of LHPC decreased with increasing hydroxypropyl content. Therefore, 
the degree of crystallinity in LHPC would be expected to be higher than that of HPC. 
The x-ray diffraction patterns for the powders are depicted in Figure 2.9 . Amorphous humps were 
obtained for both HPC and LHPC. The absence of crystalline peaks in the diffraction patterns of 
the polymers showed that they existed in the amorphous state (Yang et al 2004, Cilurzo et al 2005). 
Yamada et al (1999) reported similar findings for x-ray diffraction of HPC powders. However, the 
larger amorphous humps found in the HPC patterns than that in LHPC is consistent with the higher 
amorphous character of HPC, revealed by FTIR results.  
 
 
Figure 2.9 X-ray diffraction patterns for HPC and LHPC powders showing amorphous humps. The larger size of 
the amorphous humps in HPC than LHPC correlates with the lower degree of substitution and therefore higher 
crystallinity of LHPC. 
LHPC 
HPC 
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2.3.2  Compaction characteristics of polymers 
2.3.2.1 Compaction mechanisms  
When pressure is applied to a powder mass during compaction, different processes come into play 
(Alderborn and Nystrom 1995): First, the particles of the powder rearrange themselves in the die 
to produce a closer packing structure until a certain pressure, where friction between particles 
prevents any further movement of particles. Thus, to continue the compaction process, plastic 
deformation of the particles may ensue, leading to volume reduction, which is irreversible after the 
pressure is removed. Some particles undergo elastic recovery, which occurs when the particles 
initially deform with increased pressure, leading to volume reduction, but upon removal of the 
pressure, the particles rebound, leading to increase in volume. Elastic recovery is associated with 
capping at higher pressures, resulting in tablets with low tensile strength or hardness (Alderborn 
and Nystrom 1995). Some other materials undergo fragmentation, which is the breakdown of 
particles into smaller fragments under pressure. As the compaction process continues, these smaller 
fragments may undergo further deformation. Thus, a single particle may undergo one or more of 
these processes before a compaction cycle is completed. Plastically deforming particles result in 
higher volume reduction and increased inter-particulate bonding, and thus may produce harder 
tablets (Alderborn and Nystrom 1995). Since pharmaceutical powders undergo compaction by one 
or more of these mechanisms, adequate powder characterisation is important. 
Figure 2.10 shows the Heckel’s plots for HPC and LHPC. The mean yield pressure, Py gives an 
indication of the plastic deformation of a substance under pressure (Odeku et al 2005). The lower 
the Py value, the higher the plastic deformation of the material upon compaction, and vice versa. 
The yield pressure has been reported to be affected by various factors, including particle fracture, 
particle and die wall friction, inter-particulate rearrangement, plastic or elastic deformation, and 
inter-particulate friction (that is the prevention of increased closeness of particle surfaces due to 
inter-particulate bonding) (Eriksson and Alderborn 1995). 
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Figure 2.10 Out-of-die Heckel's plots for HPC and LHPC pure compacts (n=3). Higher volume reduction and 
thus lower porosity was observed for HPC, although both powders exhibited similar mean yield pressure values. 
 
Py value calculated as the reciprocal of the gradient of the linear portion of the Heckel’s plot was 
found to be 666.67 MPa-1 for both HPC and LHPC. This yield pressure value indicates that some 
plastic deformation occurs during compaction of the two polymers, since the out-of-die method of 
porosity measurement was employed (Al-Khattawi et al 2014). HPC and LHPC have been reported 
as plastically deforming materials by some authors (Khossravi and Morehead 1997, Picker-Freyer 
and Dürig 2007); however, Sonnergaard (1999) stated that the Heckel’s plot yield pressure value 
alone cannot totally describe the compaction behaviour of powders. Moreover, Hiestand (1997) 
argued that materials do not undergo plastic deformation or fracture exclusively, but that the higher 
the plastic deformation, the less the tendency for fracture/ fragmentation and vice versa. Thus, both 
events may occur during a single compaction process.  
The yield pressure value obtained for HPC was expected to be lower than that obtained for LHPC, 
because crystalline portions of materials deform by fragmentation while amorphous portions 
deform plastically (Suzuki and Nakagami 1999). Thus, HPC with a more amorphous nature (as 
confirmed from FTIR and XRD results) would be expected to yield a lower mean yield pressure. 
Suzuki and Nakagami (1999) reported an increase in the mean yield pressure and tablet hardness 
of MCC as degree of crystallinity increased. The opposite trend was seen here, as both polymers 
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showed equal yield pressures, but HPC tablets showed higher hardness at similar compaction 
forces than LHPC (Table 2.5).  
Table 2.5 Characteristics of pure HPC and LHPC tablets compacted at various pressures (n=3) 
 
Compaction 
pressure 
(MPa)  
Hardness (N) Disintegration time (s) Porosity  
HPC LHPC HPC LHPC HPC LHPC 
38.00 340.27 ± 
19.04  
122.90 ± 
41.00 
>1800.00 30.00 ±  
4.00 
0.20 ± 0.02 0.35 ± 0.02  
75.00 >520.00 240.57 ± 
15.17 
>1800.00 130.30 ± 
7.51 
0.20 ± 0.04 0.34 ± 0.01 
113.00 >520.00 374.37 ± 
11.77 
>1800.00 212.20 ± 
2.11 
0.18 ± 0.0 0.2846 ± 
0.01 
151.00 >520.00 484.60 ± 
5.46 
>1800.00 332.40 ± 
2.75 
0.17 ± 0.01 0.27 ± 0.01 
188.00 >520.00 488.43 ± 
6.25  
>1800.00 338.20 ± 
19.56 
0.16 ± 0.02 0.25 ± 0.04 
226.00 >520.00 >520.00 >1800.00 366.80 ± 
5.70 
0.16 ± 0.04 0.24 ± 0.02 
 
An interesting observation was made upon compaction of the pure HPC tablets. First, a change in 
colour of the tablets from white to cream occurred at compaction pressures from 10-30 kN (75-226 
MPa). Also on visual observation of tablets within this pressure range, two distinct layers could be 
noticed (Figure 2.11) and the tablets appeared to have melted and solidified. Hardness of tablets 
within this pressure range could not be verified because the hardness recorded was >520N which 
is the maximum hardness the instrument can record. For LHPC tablets, no colour change was 
observed and although the tablet hardness was very high (122->520 N), only the tablets compacted 
at 30 kN recorded hardness values >520N (Table 2.5). HPC compacts did not disintegrate even 
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after 30 minutes at all compaction pressures tested, and this was expected considering the high 
hardness recorded. However, despite the high hardness of LHPC compacts, disintegration time at 
maximum pressure was less than 6 minutes, and disintegration time increased with increasing 
compaction pressure (Table 2.5). This difference in disintegration characteristics between HPC and 
LHPC, despite the high hardness, can be attributed to the behaviour of the polymers in the presence 
of water. HPC is more soluble in water and, therefore, dissolves on contact with water, thus 
dissolution occurs by tablet erosion and is slower (Alvarez-Lorenzo et al 2000); while insoluble 
LHPC swells on contact with water. This swelling action disrupts the tablet, leading to faster 
disintegration (Shirai et al 1993, Fukami et al 2006). 
 
Figure 2.11. (A) Photograph of HPC tablet compacted at 5, 10 and 30 kN (left to right); highlighting the 
appearance of distinct layers (B) 
The extremely high tablet hardness exhibited by LHPC tablets at 30 kN may be substantiated by 
x-ray diffraction patterns for these tablets. Figure 2.12 shows the XRD patterns for pure LHPC 
tablets compacted at 5, 10 and 30 kN respectively. The appearance of small crystalline peaks can 
be seen as compaction pressure increased to 10 and 30 kN, respectively. This introduction of 
crystallinity to LHPC upon compaction, would lead to more ordered arrangement of the LHPC 
molecules, and thus impart higher hardness to the compacts. Ek et al (1995) reported an increase 
in crystallinity of MCC with increasing compaction pressure, up to 125 MN/m2 after which 
crystallinity decreased. This increase was said to be due to alteration of stressed structures in the 
polymer particles, resulting in a more ordered form as compression increased. This is also in line 
with reports by Suzuki & Nakagami (1999) who investigated the effect of degree of crystallinity 
on the compaction properties of MCC. They reported a decrease in tablet hardness (and energy 
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required for crushing tablets) with a decrease in MCC crystallinity.  Gracias & Somorjai (1998) 
also reported an increase in hardness of polymers as crystallinity increased.  
 
Figure 2.12 X-ray diffraction patterns highlighting the appearance of small crystalline peaks (highlighted in 
circles) in LHPC compacted at 10 and 30 kN, and the absence of such peaks in the patterns at 5 kN pressures and 
the polymer powder 
 
The above crystallinity trend was not observed in compacts of pure HPC compacted at equal 
pressures (Figure 2.13). This could be because HPC was more amorphous than LHPC, and might 
therefore require much higher pressures to impart any measureable crystallinity to the polymer 
molecules (Al-Khattawi et al 2014). It was, therefore, important to attempt an elucidation of the 
mechanism of the hard compact formation observed with the HPC compacts.  Various hypotheses 
have been given for high tablet strength upon compaction, and they are discussed as possibilities 
below: Hydrogen bonding has been shown to contribute to tablet hardness due to the presence of 
OH groups in the HPC structure. But, hydrogen bonding has been reported to provide a lower 
contribution to tablet hardness than other bonding mechanisms (Alderborn and Nystrom 1995, 
Hiestand 1997). However, careful observation of the FTIR spectra for HPC and LHPC compacts 
at different compaction pressures (Figure 2.14) showed identical peaks as those observed in the 
powders. 
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Figure 2.13 Xray diffraction patterns showing the absence of crystalline peaks in HPC powder and pure tablet 
compacted at 5, 10 and 30 kN respectively. No difference in diffraction patterns was observed with increasing 
compaction pressures. 
 
Peak location and intensity was not observed to vary with compaction pressure for both polymers. 
Thus, the increase in compact hardness for two polymers may not be attributable to increased 
hydrogen bonding. Smaller particle size results in higher surface area which lends to higher inter-
particle attraction (Adolfsson et al 1998). Small particle size of plastically deforming materials also 
promote volume reduction during compaction, resulting in closer packing of particles in the 
compact (Korhonen et al 2002). Comparing LHPC to HPC, the smaller particle size and lower 
porosity of HPC particles than LHPC, as seen from laser diffractometry (Table 2.2) and SEM 
results (Figure 2.6 and Figure 2.7), would produce a higher surface area for interaction and, 
therefore, higher binding and consequently harder compacts for HPC. Also, the Heckel’s plot for 
the polymers shows a higher volume reduction (lower porosity) of HPC than LHPC, on compaction 
(Figure 2.10). 
Solid bridge formation has been reported for coarse, plastically deforming materials that melt 
upon compaction (Hiestand 1997). Alderborn & Nystrom (1995) reported that formation of solid 
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bridges occurs as a result of crystallisation, sintering, binder hardening, melting and chemical 
reactions. 
 
Figure 2.14 Comparing FTIR spectra of HPC powder with HPC tablets at different compression forces revealed 
no difference in -OH stretching bands or other peaks. 
 
 
 
Figure 2.15 Comparing FTIR spectra of LHPC powder with LHPC tablets at different compression forces 
revealed no difference in –OH stretching bands or other peaks 
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Nystrom et al (1993) investigated the bonding mechanisms that come into play when powders are 
compacted into tablets. They reported the formation of solid bridges for highly plastically 
deforming particles, which could confer high compact strengths on the tablets. However, solid 
bridges were observed with coarse materials such as sodium chloride. The HPC compacts, when 
viewed with the naked eyes, appeared to have melted during compaction (Figure 2.11). Figure 2.16 
shows SEM micrographs (all at 50 µm magnification) of the pure HPC and LHPC polymers 
compacted at 5, 10 and 30 kN respectively. At 5 kN pressure, HPC was somewhat compacted into 
sheets, with a general loss of its individual particle morphology, while the LHPC tablets retained 
some of the elongated structures, as seen from the SEM of its powder. With increasing compaction 
pressure, the pores in the tablets were observed to decrease, and this is consistent with the 
compressibility results for both powders (Figure 2.17) where porosity decreased with increasing 
compression force. However, there was greater decrease in the observed pores for HPC compacts 
than LHPC. Interestingly, with increasing compaction force, the HPC particles appeared to have 
coalesced to form a cohesive layer, which appeared larger than that observed at lower pressure; 
while the micrograph of LHPC remained fairly constant. This observation might be indicative of 
some fusion and/or bonding between HPC particles, which might be indicative of solid bridge 
formation, and give an insight into the high hardness of these HPC compacts. 
2.3.2.2 Compressibility, compactability & tabletability 
Compressibility shows the ability of a material to undergo volume reduction when pressure is 
applied to it (He et al 2007). This is determined from a plot of porosity against compaction pressure. 
Compactability reflects the material’s ability to form compacts of reasonable strength upon 
densification, and is determined from a plot of tensile strength against porosity (Tye et al 2005). 
While tabletability demonstrates how effective the applied pressure is at increasing the strength of 
the compacted tablet (Tye et al 2005). Tabletability can be represented by plotting the tensile 
strength against compaction pressure. 
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Figure 2.16 SEM of HPC (A,C,E) and LHPC (B,D,F) tablets compacted at 5, 10 and 30 kN respectively, showing 
consolidation of HPC particles with increasing compaction pressures; particles of LHPC remained fairly constant 
as compaction pressure increase. 
Figure 2.17 shows the compressibility profile for HPC and LHPC at dwell time of 5 secs.  There 
was generally a decrease in porosity with increase in compaction pressure, resulting in higher solid 
fraction for both powders.  However, the compressibility and solid fraction of LHPC was lower 
than that of HPC, as would have been expected considering the smaller particle size of HPC. LHPC 
has been reported to impart high porosity to tablets (Watanabe et al 1995). Materials with high 
plastic flow and solid fraction have been reported to exhibit higher surface areas for bonding 
between particles (Tye et al 2005). Since the more porous a tablet, the easier and faster its 
disintegration, it is important to determine the compressibility of a tablet upon densification. 
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Figure 2.17 Compressibility profiles showing the variation in tablet porosity with increasing compaction 
pressures. The lower porosity values displayed by HPC depict higher compressibility than LHPC (n=3). 
Unfortunately, because tablet hardness could not be estimated, compactability and tabletability 
profiles were not generated for the polymers. Nevertheless, the high hardness values of 340 and 
122 kN recorded at compression force of 5 kN indicates that HPC and LHPC, respectively, showed 
high tabletability even at low compression pressures. Picker-Freyer and Durig (2007) had earlier 
reported that low particle sized HPC powders (D50 about 66µm) formed very hard tablets (about 
200N) at significantly lower compression forces, when compared to other powders and even HPC 
powders with larger particle size.  
2.3.3 Placebo tablet characterisation 
To assess the application of the characterised polymers in ODT formulations, placebo tablets 
containing mannitol as filler, magnesium stearate as lubricant and either HPC or LHPC 
(concentrations 0 - 10%) were compacted at 10 kN and characterised. For a tablet to be useful as 
an ODT, it should show considerable hardness, fast disintegration time (<1 minute) and low 
friability to be able to withstand stress during packing and shipping (Alhusban et al 2010). 
2.3.3.1 Tablet hardness 
Figure 2.18 compares the hardness of mannitol tablets containing either HPC or LHPC (0 -10%) 
as binder. As was expected, there was a general increase in tablet hardness with increasing HPC 
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concentration, depicting the binding property of HPC. Contrary to what would have been expected 
following the high hardness values recorded for the HPC compacts (>520N), the hardness of the 
mannitol formulations incorporating HPC was not very high (<60N at 10% HPC concentration). 
Elshaer et al (2015) highlighted the unavailability of simple relationships to predict tablet 
characteristics of binary mixtures from the behaviours of their pure polymer compacts. Maggi 
(2002) reported higher hardness for compacted pure polymer tablets when compared to formulation 
tablets compacted at the same compaction pressures due to the influence of other additives/ 
excipients in the system. This suggests that the incorporation of mannitol (with low tabletability) 
had a significantly large influence on the cohesiveness of HPC (Al-Khattawi et al 2014).  But the 
prepared tablets exhibited sufficient hardness for practical use. HPC has been reported to act as a 
binder in concentration ranges from 2-8% w/w, in combination with other excipients (Picker-
Freyer and Dürig 2007).  
 
Figure 2.18 Hardness of tablets containing HPC or LHPC as binder (n=3). Dotted line depicts minimum desirable 
hardness. 
 
There was also generally an increase in hardness of tablets with increasing LHPC concentration. 
However, a decline in hardness was observed when LHPC concentration increased from 7% to 
10%. Watanabe et al (1995) had reported a similar decline in crushing strength of tablets 
comprising LHPC and other excipients, when LHPC concentration was increased from 10% to 
30%; though reasons for this anomaly were not presented. When compared to HPC tablets, LHPC 
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tablets exhibited significantly higher hardness at the same polymer concentrations.  The appearance 
of crystallinity peaks in LHPC tablets compacted at 10 kN (Figure 2.12), may account for the 
higher hardness of LHPC placebo tablets compared to that of HPC. Wantanabe et al (1995) also 
reported lower hardness for tablets comprising crystalline cellulose and LHPC with smaller particle 
size, than systems containing larger particle sizes. 
2.3.3.2 Tablet disintegration time 
The higher tablet disintegration times observed with increasing concentrations of HPC (Figure 
2.19) infer that HPC may not have disintegrant properties as reported previously (Machida 1974, 
Francis et al 2003). The tablets comprising HPC were visually observed to disintegrate by erosion. 
Fast disintegration is a requirement, especially for ODTs which must disintegrate in the mouth in 
<30 seconds (USP standard) or <3 minutes (BP standard).  However, tablets containing LHPC 
maintained a relatively fast disintegration time (all <60s) irrespective of polymer concentration. 
LHPC tablets were visually observed to disintegrate by flaking off.  
 
Figure 2.19 Disintegration time of tablets containing HPC or LHPC as binder (n=3). Dotted line depicts 
maximum acceptable disintegration time acceptable according to BP standards. 
 
The much faster disintegration of LHPC tablets than those of HPC can occur for various reasons. 
Differences in disintegration behaviours of similar substances has been attributed to factors such 
as level of cross-linkage, degree of substitution and particle size of disintegrants (Fukami et al 
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2006). Firstly, LHPC tablets showed significantly higher porosities than those from HPC (Table 
2.5). Thus, the availability of more pores within the tablet makes water penetration easier, thereby 
facilitating disintegration. Watanabe et al (1995) ascribed the fast disintegration of tablets 
containing LHPC to its ability to form relatively porous tablets, and therefore promote capillary 
action via these hydrophilic pores. Secondly, as confirmed by FTIR results, some of the molecular 
hydrogen bonding present in cellulose had been destroyed by hydroxypropylation in HPC; thus, 
HPC is more amorphous and dissolves in the presence of water. This dissolution causes the tablet 
to disintegrate slowly by erosion (this disintegration mechanism was noticeable upon visual 
observation), thereby prolonging disintegration time. On the other hand, LHPC  with lower degree 
of substitution, retains some of the crystalline nature of cellulose and is thus insoluble in water 
(Gómez-Carracedo et al 2003).  LHPC has been reported to swell in the presence of water and not 
dissolve (Shirai et al 1993, Fukami et al 2006) which causes the tablet to disintegrate. Alvarez-
Lorenzo et al (2000)  characterised different LHPCs with varying degrees of hydroxyl substitution, 
and reported an increase in disintegration time with increasing degrees of substitution. 
2.3.3.3 Tablet friability 
The friability of the placebo tablets also decreased with increasing HPC concentration (Figure 
2.20), but even at the highest concentration tested (10%), friability did not meet the BP standard of 
<1%. Increasing the proportion of HPC as binder in the formulations to yield better friability results 
would be expected to further compromise tablet disintegration time. Furthermore, at about 20% 
concentration, HPC has been reported to act as a matrix forming polymer (Picker-Freyer and Dürig 
2007). LHPC tablets exhibited similar friability to HPC tablets, with friability still significantly 
above the specification for tablets. Both polymers, however, greatly reduced the friability of 
mannitol tablets (>12% when compacted without a binder). The high friability recorded even at 
10% polymer concentration may be attributed to the fragmenting nature of mannitol tablets, which 
causes the tablet to lose its cohesion and, thus, exhibit lower hardness and higher friability (Al-
Khattawi and Mohammed 2013). However, to utilise LHPC for ODT formulations, methods to 
decrease tablet friability would be necessary. 
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Figure 2.20 Friability of tablets containing HPC or LHPC as binder. Dotted line depicts maximum acceptable 
friability. Missing points show tablets that failed the friability test (broken tablets) 
 
2.3.4  Formulation optimisation  
Considering the tablet characteristics discussed above, the LHPC formulation containing 7% 
LHPC showed the best overall tablet properties with high hardness and fast disintegration time 
(Figure 2.18 and Figure 2.19). This formulation was chosen for optimisation to decrease friability 
which was >2%, and incorporation of other excipients. These tablets were compacted at various 
pressures (5, 10, 15, 20, 25 and 30 kN) to attempt a reduction in tablet friability upon higher 
compaction. Results showed a linear increase in hardness as compaction pressure increased, but no 
significant change in disintegration time was observed, due to the behaviour of LHPC in water 
(Figure 2.21). Tablet friability was observed to decrease, alongside porosity with increasing 
compression pressure (Figure 2.22). However, there was an increase in both friability and porosity 
of the tablets at maximum compaction pressure tested; highlighting the direct relationship between 
tablet friability and porosity. Although the lowest friability was achieved at 25 kN pressure, this 
value (1.52%) was still higher than the acceptable limit for tablet friability. Additional steps will 
be required to further improve the friability of the formulation. 
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Figure 2.21 Plot showing the effect of increasing compaction pressure on hardness and disintegration time of 
formulation containing 7% LHPC (n=3). Despite the higher hardness observed with increasing compaction 
pressures, tablet disintegration time remained significantly constant. 
 
 
 
Figure 2.22 Plot showing the effect of increasing compaction pressure on friability and porosity of formulation 
containing 7% LHPC 
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2.4 Conclusion 
During the development of successful ODT formulations, it becomes important to systematically 
investigate the role each excipient plays individually in the ODT, to locate multi-functional 
excipients and use this information to design intelligent dosage forms with favourable attributes 
built into them. The degree of substitution (DS) in HPC and LHPC polymers played a key role in 
their behaviour as binders and/ or disintegrants. The lower DS in LHPC made it more crystalline 
yielding higher hardness, practically insoluble in water, with high disintegrant properties. 
However, the higher DS of HPC made it more amorphous (as confirmed from XRD and FTIR 
results) exhibiting lower hardness and high water solubility, which diminished its ability to act as 
a disintegrant. HPC and LHPC exhibited an interesting characteristic of forming pure compacts 
with extremely high hardness at elevated compaction pressures (>520N). However, this high 
hardness of pure polymer compacts could not be translated to ODTs containing polymers and D-
mannitol only, with HPC ODTs  exhibiting hardness of <60N even at 10% polymer concentration; 
thus highlighting the detrimental effect of low tabletability grades of mannitol on ODT 
characteristics. However, the results obtained suggest that this grade of HPC may not be suitable 
for use by itself in ODT formulations. ODTs require fast disintegration in the mouth, sufficient 
friability to withstand mechanical stress, and the use of multi-functional excipients to allow for 
higher drug loading without compromising tablet size. LHPC on the other hand showed good 
hardness and disintegration time acceptable for ODT formulation. With formulation optimisation 
to reduce tablet friability, LHPC may be useful as a single multifunctional excipient in the 
formulation of ODTs.  
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3.1 Introduction 
Critical qualities or attributes of a successful ODT include sufficient hardness to impart low 
friability and withstand mechanical stress encountered during packaging and transport, and optimal 
porosity to enable imbibing of water into the ODT, thereby facilitating fast disintegration. 
However, these attributes have opposing effects. For instance, increased hardness tends to lower 
porosity and thus elongate disintegration time. The formulation scientist is thus faced with the 
dilemma of optimising ODT formulations in combinations that provide the best qualities. If all 
factors affecting the critical ODT qualities are to be investigated one after the other, a huge amount 
of resources (time, man power and money) would be required. Thus, the Quality by Design (QbD) 
theme incorporating Design of Experiments (DoE) has become popular in the pharmaceutical 
terrain. QbD is based on the philosophy that quality should be designed into a product before 
manufacture, and not just tested after manufacture (ICH 2009). QbD has been defined by the 
International Conference on Harmonisation (ICH Q8) as “a systematic approach to development 
that begins with predefined objectives and emphasizes product and process understanding  and 
process control, based on sound science and quality risk management” (ICH 2009). QbD 
incorporates a step-by-step mechanistic process that identifies product features and pre-empts 
potential sources of inconsistency in order to apply robust manufacturing procedures to generate a 
reliable product over time, with quality strategically built into it (Lionberger et al 2008). QbD 
usually begins with setting the quality targeted product profile (QTPP) which outlines prerequisites 
for product quality, efficacy and safety, while incorporating elements such as dosage form/ strength 
and administration route (Lawrence 2008, Lionberger et al 2008). From here, critical process 
parameters (CPPs) that are vital to the manufacturing process are identified and ranked in order of 
importance based on their influence on critical quality attributes (CQAs) of products. Assessment 
of potential risks is completed by measuring the intended QTPP against the CPP and their effect 
on CQAs. These can then be included in a design of experiments (DoE) study.  
DoE enables one to design a set of experiments that can simultaneously assess the contributions of 
various factors or variables (CPP) on responses or outcomes (CQA). Because these experiments 
Chapter Three 
100 
 
are run in combinations, less time and resources are required (Anderson and Whitcomb 1974). 
Factors may be described as tools used to control or manipulate a system, while responses provide 
information about the characteristics and state of the system (Eriksson 2008). Factors are variables 
that, when changed, cause changes in the responses and thus the system. Three major experimental 
objectives can be achieved using an experimental design and they include: screening – this 
highlights the effects that many factors have on the system, to identify the important/ dominating 
factors; optimisation – this provides information on the optimal factor combinations to produce 
expected responses; and robustness testing – to confirm the vigorousness/ strength of the model/ 
system (Eriksson 2008).  
Polyethylene oxide (PEO), popularly known as Polyox™, is a trademark of the DOW company. 
Polyox™ are non-ionic, water-soluble resins exhibiting high swelling and thermoplastic capacity 
with molecular formula (-OCH2CH2)n, where n represents the average number of oxyethylene 
moieties per polymer chain (Tadokoro et al 1964). Polyox has been found to exhibit stability, non-
toxicity, good flow properties, high compressibility enabling direct compression, good 
mucoadhesive properties and faster hydration (Dimitrov and Lambov 1999). Thus, polyox has been 
applied as a mucoadhesive agent, binder, coating and viscosity imparting agent with 
pharmaceutical applications such as hot-melt extrusion, immediate and delayed/sustained-release 
formulations (Maximilien 2013).  
One of the challenges of conventional ODTs is the short residence time in the mouth due to saliva 
scavenging and accidental swallowing. To improve this short-coming, the addition of multi-
functional excipients with mucoadhesive properties was proposed. Cilurzo et al (2005) had 
investigated the feasibility of producing fast-dissolving mucoadhesive microparticulate systems to 
prolong residence time of disintegrated formulations on the sublingual mucosa. Eudragit sodium 
salts were used as mucoadhesive polymers. They reported an optimal formulation with good drug 
release and mucoadhesion, which was dependent on drug loading.  
The aim of this work was, therefore, to apply QbD principles in a DoE to determine the effects of 
significant factors (polyox viscosity, polyox concentration and compaction pressure) on ODT 
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characteristics (responses) in order to produce ODTs with good mechanical properties and fast 
disintegration that promote mucoadhesion of the dosage form upon disintegration/ disaggregation 
in the buccal cavity. The objectives of this initial DoE were two-fold. Firstly, to identify the 
influence of variations and interactions of the chosen factors on the responses highlighted; and 
secondly, to optimise the system to determine the optimal factor combinations that would yield 
desired or targeted responses.  
3.2 Materials and methods 
3.2.1 Materials 
Sentry Polyox® (polyethylene oxide) WSR N10 (MW 100,000 Da), 1105 (MW 900kDa), N-60K 
(MW 2000 kDa) and Coagulant (MW 5000 kDa) were a gift from Colorcon (Kent, UK). L-HPC 
grade NBD-022 was a gift from Shin-Etsu (Tokyo, Japan). D-Mannitol, magnesium stearate and 
Krebs buffer were purchased from Sigma Aldrich Chemicals (Poole, UK). All materials were of 
pharmaceutical grade and used as received. 
3.2.2  Methods 
3.2.2.1 Pre-formulation characterisation of polymers 
The various viscosity grades of polyox were characterised according to flow properties, true, bulk 
and tapped densities; porosity and moisture content as described below: 
3.2.2.1.1 Angle of repose (ө) 
The angle of repose has been described as ‘an engineering property of granular materials’ and is 
‘the maximum angle of a stable slope with the horizontal determined by friction, cohesion and the 
shape of the particle’ (Deshpande and Yadav 2009). The fixed height cone method (Fahmy and 
Kassem 2008) was adapted for this test. A funnel was attached to a retort stand at a specific height 
and the powders were poured freely through the funnel until a conical heap was achieved. The 
height (h) and diameter (d) of the heap were measured. The angle of repose ѳ, which is the internal 
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angle between the horizontal surface and the powder surface, was then calculated from the 
equation: 
Tan  ѳ =
2h
d
  . . . . . . .  (Equation 3.1) 
The test was performed in triplicate for each sample and the mean angle recorded in degrees. 
3.2.2.1.2 Bulk and tapped density 
A specific weight (20g) of the sample was poured into a 100mL measuring cylinder attached to a 
Sortax tap density tester USP I apparatus (Allschwil, Switzerland). The initial volume (volume at 
zero tap or bulk volume) was recorded. The machine was set to vibrate and the volumes at 50, 
100,150, 200 and 250 taps were obtained and recorded. This was repeated for all the samples. The 
tapped and bulk densities, Hausner ratio and Carr’s index were calculated for the samples using 
the equations below: 
𝑇𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑝𝑜𝑤𝑑𝑒𝑟
𝑓𝑖𝑛𝑎𝑙 𝑝𝑜𝑤𝑑𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒
  . . . . . (Equation 3.2) 
𝑃𝑜𝑤𝑑𝑒𝑟 𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑝𝑜𝑤𝑑𝑒𝑟
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑝𝑜𝑤𝑑𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒
  . . . . (Equation 3.3) 
𝐻𝑎𝑢𝑠𝑛𝑒𝑟′𝑠 𝑟𝑎𝑡𝑖𝑜 =
𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
  . . . . . (Equation 3.4) 
𝐶𝑎𝑟𝑟′𝑠𝑖𝑛𝑑𝑒𝑥 =
𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦−𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
 𝑥
100
1
  . . . (Equation 3.5) 
3.2.2.1.3 True density and porosity 
A multipycnometer from Quantachrome Instruments (Syosset, USA) utilising helium gas was used 
to measure the true density of the powders at ambient temperature. Powder true volume 
measurement was based on Archimedes principle of fluid displacement. Helium gas can penetrate 
tiny pores of up to 1 angstrom (10-10 m) in diameter.  Weighed samples (0.9-1.1g) were employed. 
The true density of the sample was automatically calculated by the software using equation 3.6 
below. The bulk volume of the powder was further measured by pouring the weighed sample into 
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a 1mL volumetric cylinder. The tests were performed in triplicates for each of the samples. The 
porosity of the powders was calculated from the equation 3.7: 
𝑉𝑡 = 𝑉𝑐 −  𝑉𝑟 (
𝑃1
𝑃2
− 1) . . . . . . . (Equation 3.6) 
𝑃𝑜𝑟𝑜𝑠𝑖𝑡𝑦 (𝜀) = 1 −
𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑡𝑟𝑢𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
  .. .  . . (Equation 3.7) 
Where Vt, Vc and Vr are the sample true volume, sample cell volume and known reference 
volume respectively. P1 and P2 represent the atmospheric pressure and air pressure change during 
determination. The true and bulk densities of the tablet can then be calculated from Vt and bulk 
volume. 
𝑇𝑟𝑢𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =  
𝑃𝑜𝑤𝑑𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡
𝑃𝑜𝑤𝑑𝑒𝑟 𝑣𝑜𝑙𝑢𝑚𝑒 (𝑉𝑡)
 . . . . . (Equation 3.8) 
𝐵𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =  
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑜𝑤𝑑𝑒𝑟
𝑏𝑢𝑙𝑘 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑝𝑜𝑤𝑑𝑒𝑟
 . . . . . (Equation 3.9) 
3.2.2.1.4  Powder moisture content  
The moisture content of the powders was determined by the ‘loss on drying method’ using a 
thermobalance (Sartorius, Surrey UK). Samples of <200mg were evenly loaded unto the balance 
and the initial weight recorded. After heating at a constant rate, the final weight was recorded. 
Moisture content was then calculated as the percentage weight loss from the sample using the 
equation:  
𝑀𝑜𝑖𝑠𝑡𝑢𝑟𝑒 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 =
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡−𝑓𝑖𝑛𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
 𝑥
100
1
  . . . (Equation 3.10) 
Three samples were tested in triplicates and reported as mean ± standard deviation.  
3.2.2.2 Elements of quality by design (QbD) 
Information from preliminary studies and literature reviews was used to identify QTPP and CQA, 
which were then assessed against each other using ICH Q9 risk assessment guidelines, information 
from previous developmental work and current knowledge to ascertain the level of risk (ICH 2009). 
Each outcome was assigned a ranking of low, medium or high depicting the magnitude of influence 
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the QTPP had on the CQA. All QTPP with medium or high ranking were then inserted into the 
DoE as CPP representing fundamentally independent factors (ICH 2009).  
3.2.2.2.1 Design of experiments (DoE) 
The experimental design for incorporation of polyox into the selected formulation (F4 containing 
7% LHPC from chapter 2) was carried out using the MODDE 8.0.2 software (Umetrics Inc., USA). 
A central composite face-centred (CCF) design comprising 17 experiments with 3 replicated centre 
points was selected by the software to investigate the influence of variations in three independent 
variables (factors) on the dependent variables (responses). The total number of experiments was 
computed from the equation: 
2k + 2k + 3, where k = number of factors (variables)  . . (Equation 3.11) 
The factors investigated were polyox polymer viscosity (X1), polymer concentration (X2) and 
compaction pressure (X3); and the critical responses investigated were tablet disintegration time 
(Y1), tablet friability (Y2), tablet hardness (Y3) and tablet porosity (Y4). The levels of the 
investigated factors are summarised in Table 3.1 and these levels were chosen based on literature 
and preliminary experiments. The design of experiments with run order developed by MODDE 
software is shown in the appendix. Each experiment was carried out in triplicate according to their 
run order, and the means of the responses incorporated into the software. The resultant data was fit 
using partial least squares (PLS) model and the relationship between factors and responses studied 
and interpreted using response surface and contour plots generated by the software.  
3.2.2.2.2 Regression model verification & interpretation 
A statistical model comprising both interactive and polynomial terms was used to evaluate the 
responses and is depicted in the regression model equation below (Montgomery 2004, Eriksson 
2008).  
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Table 3.1 List of independent variables (factors/ CPP) with their feasible investigational ranges that were 
employed in the optimisation DoE 
Process parameter  Level 
 
 
 High level Medium level Low level 
 
Polymer viscosity (cP) 5,500 -7,500a (1) 8,800 – 17,600b (0) 12 -50b (-1) 
 
Polymer concentration (%) 2.5 1.5 0.5 
 
Compaction pressure 
(tons) 
3.0 2.0 1.0 
 
a = 1% solution, b = 5% solution. The number between brackets was used to represent the viscosity levels in the DoE 
with 1 as the highest and -1 as the lowest. 
 
 
𝒀𝒊 =  𝜷𝟎 +  𝜷𝟏𝑿𝟏 + 𝜷𝟐𝑿𝟐 +  𝜷𝟑𝑿𝟑 +  𝜷𝟏𝟐𝑿𝟏𝑿𝟐 + 𝜷𝟏𝟐𝑿𝟏𝑿𝟐 +  𝜷𝟏𝟑𝑿𝟏𝑿𝟑 +   𝜷𝟐𝟑𝑿𝟑 +
  𝜷𝟏𝟏𝑿𝟏
 𝟐 +  𝜷𝟐𝟐𝑿𝟐
 𝟐 + 𝜷𝟑𝟑𝑿𝟑
 𝟐 +  𝜷𝟏𝟐𝟑𝑿𝟏 𝑿𝟐𝑿𝟑 .  . . (Equation 3.12) 
where Yi is the modelled response, β0 is the arithmetic mean response of the runs; β1, β2 and β3 are 
the estimated coefficients for the factors X1, X2 and X3 respectively. The main effects (X1, X2 and 
X3) represent the mean results when one factor at a time is changed from its low to its high value, 
and other factors are kept at their centre points; the interactive terms (X1X2, X1X3, X2X3 and 
X1X2X3) represent the mean effect when factors are varied simultaneously, while the polynomial 
terms (X12, X22 and X32) were included to investigate non-linear correlations in the model (Gohel 
et al 2004, Alhusban et al 2011). For each of the regression coefficients (e.g., B1) accompanying 
X1, the value was scaled and centred which allows for its interpretation. Therefore, if Y1 is the 
disintegration time, the constant β0 is the estimated disintegration at the design centre point when 
the other factors have their values as zero. In order to compare responses with different ranges, the 
values of the coefficients were divided by the standard deviation of the individual responses for 
normalisation (by the MODDE software). 
Results obtained from the DoE were fit using partial least squares (PLS) model and the model 
verified using PLS parameters including the distance to model, summary fit, lack of fit, analysis of 
variance (ANOVA), and predicted versus observed plots generated by the MODDE software. 
During model verification, outliers and insignificant terms that did not affect the model were 
eliminated, since the presence of insignificant terms in a model may reduce the model’s prediction 
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power (Eriksson 2008). After model verification was complete, evaluation and prediction tools 
(main effect, interaction, contour and/ or response surface model plots) were employed to identify 
the effect of individual or interactive CPP on CQA, and the results utilised for further optimisation 
and prediction of design space. 
3.2.2.3  Tablet preparation & characterisation 
500 mg tablets consisting of 7% LHPC as binder/ disintegrant, 0.5% magnesium stearate as 
lubricant, D-mannitol as filler, varying polymer viscosity, concentration and compaction pressure 
with 30 second dwell time were compacted using a manual bench-top hydraulic tablet press from 
Specac Ltd (Slough, UK) equipped with 13mm flat-faced dies. Tablets were prepared according to 
the run order generated by MODDE software; and then characterised for disintegration/ 
disaggregation time, friability, hardness and porosity.  
3.2.2.3.1 Tablet disintegration time 
The disintegration/ disaggregation time was determined according to the USP, on a ZT3 USP II 
disintegration test apparatus (Erweka, Heusenstamm-Germany), and for these experiments was 
taken as the time for the tablet to disaggregate into a slurry still held together by the mucoadhesive 
polymer. Measurements were made at 37°C and 30 cycles/ min.  
3.2.2.3.2 Tablet friability 
The ability of the tablets to withstand mechanical stress, known as friability was measured using a 
rotating drum friabilator (J. Engelsmann AG, Ludwigshafen, Germany). 6 tablets were utilised at 
25 rpm for 100 revolutions or 4minutes.  Tablets were carefully dusted before and after the test, 
and friability expressed as the percentage loss in weight. 
𝐹𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡−𝑓𝑖𝑛𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
 𝑥
100
1
  . . . . (Equation 3.13) 
3.2.2.3.3 Tablet hardness 
The hardness (crushing strength) of the tablets was measured using a 4M hardness tester 
(Schleuniger, Thun-Switzerland). Tensile strength, ơ was calculated from the equation: 
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𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ (Ơ) =
2 𝑥 𝐻𝑎𝑟𝑑𝑛𝑒𝑠𝑠
𝜋𝑑h
   . . . . . (Equation 3.14) 
Where d=tablet diameter and h=tablet thickness; measured using a digital Vernier calliper. 
3.2.2.3.4  Tablet porosity 
The apparent/true density of the tablets was measured using the helium pycnometer described 
above (section 3.2.2.1.3). 500mg tablets were used in place of powder. Tablet bulk volume was 
calculated from the volume of a cylinder by measuring tablet diameter (d) and thickness (h) using 
a digital Vernier calliper (equation 3.15) and was used to compute tablet bulk density. Tablet 
porosity was calculated by substituting with the relevant equations below: 
𝐵𝑢𝑙𝑘 𝑣𝑜𝑙𝑢𝑚𝑒 =  𝜋 (
𝑑
2
)
2
ℎ  . . . . . . (Equation 3.15) 
𝑇𝑎𝑏𝑙𝑒𝑡 𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑡𝑎𝑏𝑙𝑒𝑡
𝑏𝑢𝑙𝑘 𝑣𝑜𝑙𝑢𝑚𝑒
  . . . . . (Equation 3.16) 
𝑇𝑎𝑏𝑙𝑒𝑡 𝑡𝑟𝑢𝑒 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑡𝑎𝑏𝑙𝑒𝑡
𝑡𝑟𝑢𝑒 𝑣𝑜𝑙𝑢𝑚𝑒
  . . . . . (Equation 3.17) 
3.2.2.3.5 Mucoadhesive efficiency 
Optimal formulations obtained from the results of the DoE were carried forward to test their 
mucoadhesive efficiency and was adapted from Cappello et al (2006). Porcine buccal mucosa was 
obtained from freshly killed pigs (abattoir in Wolverhampton, UK).The buccal epithelium was 
separated from the connective tissues using surgical scissors and a scalpel and immediately stored 
at -80 ͦ C until required. Porcine buccal mucosa defrosted in Krebs buffer at room temperature and 
was fixed on a stainless steel surface of a MicroTest 5848 mechanical tester (Instron, 
Buckinghamshire, UK) and hydrated with deionised water. Test tablets were fixed using double 
adhesive tape to the probe of the mechanical tester and probe moved at a constant speed until 
contact was made with the mucosa and a force of 1.6 N exerted for 60 seconds; the probe was 
thereafter withdrawn at a constant speed. The accompanying software plotted a graph of 
compressive load against compressive extension. Mucoadhesive efficiency was determined from 
equation 3.18 below: 
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𝑀𝑢𝑐𝑜𝑎𝑑ℎ𝑒𝑠𝑖𝑣𝑒 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝐴𝑈𝐶𝑜𝑢𝑡𝑝𝑢𝑡 (𝑒𝑥𝑡𝑒𝑛𝑠𝑖𝑜𝑛)
𝐴𝑈𝐶𝑖𝑛𝑝𝑢𝑡 (𝑐𝑜𝑚𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛) 
 . . . (Equation 3.18)  
where AUCinput and AUCoutput represent the calculated area under the curve during contact (load) 
and withdrawal (extension) of tablet respectively. 
3.2.2.4 Statistical analysis 
All data generated in triplicates were presented as mean ± standard deviation (SD), where n=3.  
The data was then analysed for statistical significance using one-way analysis of variance 
(ANOVA) and Tukey-Kramar multiple comparison  post-test from Graphpad Prism® version 5.04 
(Graphpad Software, San Diego, CA, USA). The level of significance was quoted as p<0.05 
(probability values of 95%). 
3.3 Results and discussion 
3.3.1 Bulk characteristics of polyox 
Preformulation characteristics of the polymers are highlighted in Table 3.2. The three powders 
showed similar results with no significant difference for all parameters measured except the true 
density. The powders were characterised by good flow properties based on angle of repose, 
Hausner’s ratios and Carr’s index (2.3.1.1, page 75). Shah & Bhandary (2010) reported that various 
grades of polyox exhibited similar flow properties and are generally free-flowing. There was no 
significant difference between the true densities of the medium and high viscosity grades of the 
polymers, but a significant difference was seen between true densities of the low and medium, as 
well as the low and high polymer grades (Tukey-Kramar post-test). This difference in true density 
may be related to the molecular weight of the polymers, as polymer viscosity increases with 
increasing molecular weight (Shah and Bhandary 2010); and the lower the true density of a powder, 
the higher the possibility of the presence of enclosed voids (Nerurkar et al 2005). 
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Table 3.2 Preformulation characterisation of different viscosity grades of polyox polymers. No significant 
difference was observed for all characteristics tested, except that of true density. 
PARAMETERS LOW MEDIUM HIGH 
Angle of repose (°) 23.90 ± 2.87 22.81 ± 2.70 25.48 ± 0.33 
Bulk density (g/cm3) 0.47 ± 0.03 0.45 ± 0.05 0.42 ± 0.01 
Tapped density (g/cm3) 0.59 ± 0.05 0.52 ± 0.01 0.54 ± 0.01 
Hausner's ratio 1.26 ± 0.03 1.16 ± 0.11 1.28 ± 0.02 
Carr's index (%) 20.37 ± 1.97 12.90 ± 8.98 21.68 ± 1.10 
True density (g/cm3) 1.51 ± 0.02 1.44 ± 0.01 1.42 ± 0.01 
Porosity 0.73 ± 0.01 0.74 ± 0.01 0.72 ± 0.01 
Moisture Content (%) 8.36 ± 1.16 7.96 ± 1.37 9.45 ± 0.92 
3.3.2 Elements of quality by design (QbD) 
The aim of this work was to develop a new dosage form with robust mechanical strength and 
optimal disintegration time, imbibing a mucoadhesive polymer which could retain the formulation 
in the mouth and enhance epigastric absorption. Using QbD, a study to determine the effects of 
viscosity grade and concentration of polyethylene oxide (as model excipient) and compaction 
pressure (factors) on ODT characteristics (responses) was run. QTPP were selected based on the 
targeted properties from which CQAs were determined, as depicted in Table 3.3, while CQAs were 
based on compendia regulations and preliminary studies.  
Table 3.3 QTPP and CQAs of the final ODTs used for risk assessment 
Quality Attribute Targeted outcome CQA Comments 
 
Disintegration time Conforms with BP 
specification of < 3 
minutes (BP 2012) 
 
Yes Successful ODTs include sufficient 
hardness to impart low friability and 
withstand mechanical stress 
encountered during packaging and 
transport. Optimal porosity is targeted 
to enable imbibing of water into the 
ODT, thereby facilitating fast 
disintegration time in seconds (Al-
Khattawi et al 2014).  
Tablet friability <1% Yes 
 
Tablet Hardness ≥60N Yes 
 
Tablet porosity >0.2 Yes 
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Results of risk assessment to determine the risk score of each process parameter on each of the 
assigned CQA are shown in Table 3.4. Those with risk ranking of medium or high were used as 
factors/ responses in the DoE.  
Table 3.4 Risk assessment of the process parameters against the CQAs including justification for assigning these 
risk values. 
Process 
parameter 
Critical Quality Attributes 
 Disintegration 
time 
Friability Tablet 
porosity 
 
Hardness Justification 
Polymer 
viscosity 
High Low Low  Medium High polymer viscosity 
will increase the 
viscosity of the 
disintegration medium 
thereby adversely 
affecting disintegration 
time (Efentakis and 
Vlachou 2000). 
 
Polymer 
concentration 
High  High  Low High At higher polymer 
concentrations, more 
molecules interact to 
form a strong matrix 
that impedes entrance of 
water and disintegration 
time, while enhancing 
hardness and reducing 
friability due to its 
binding capacity 
(Nerurkar et al 2005). 
 
Compaction 
pressure 
High Medium High High High compaction 
pressures should 
increase compactability, 
increase hardness, 
decrease porosity and 
possibly decrease 
friability, thereby 
hindering tablet 
disintegration (Al-
Khattawi et al 2014). 
 
 
The present work was aimed at determining the influence of three independent variables (factors): 
polymer viscosity (X1), polymer concentration (X2) and compaction pressure (X3) on the 
characteristics (responses) of tablets prepared by direct compression. The investigated responses 
included tablet disintegration time (Y1), tablet friability (Y2), tablet porosity (Y3) and tablet 
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hardness (Y4). A CCF design with highest efficiency factor was selected by the software and 
resulting data was fitted using a partial least squares (PLS) model. PLS was chosen as the fitting 
method instead of multiple linear regression (MLR) because PLS is utilised when more than 3 
responses are investigated. PLS takes into cognisance, the covariance of the various responses, and 
the influence/ relationship the various responses have on each other. MLR on the other hand, 
generates separate regression models for each response (Eriksson 2008). 
3.3.2.1 Model verification 
3.3.2.1.1 PLS model summary fit plot 
In order to obtain a good model, the presence of outliers in the data set must first be identified and 
excluded. Also, the presence of insignificant factor terms in the model can reduce the model’s 
prediction power (Q2). Therefore, it is important to identify insignificant terms and delete them 
from the model, thereby improving the model’s usability (Eriksson 2008). However, this exclusion 
should be undertaken carefully, ensuring that only model factor terms that are insignificant to all 
responses are excluded. Based on the foregoing, three experiments detected as outliers, which did 
not compromise the model, were excluded. The ‘distance to model’ plot is shown in Figure 3.1, 
highlighting the excluded data sets. Also, being a quadratic model, all quadratic terms were initially 
included in the model. The terms which were found to be insignificant to all the responses, and did 
not interfere with the model hierarchy, were excluded from the model. The resulting regression 
equation is shown in equation 3.19: 
𝒚 =  𝜷𝟎 + 𝜷𝟏𝑿𝟏 + 𝜷𝟐𝑿𝟐 +  𝜷𝟑𝑿𝟑 +  𝜷𝟏𝟑𝑿𝟏𝑿𝟑 +  𝜷𝟐𝟑𝑿𝟑 +  𝜷𝟐𝟐𝑿𝟐
 𝟐 . (Equation 3.19) 
Data generated from the experimental design is highlighted in the appendix. The PLS summary fit 
plot of the design is shown in Figure 3.2. Four important parameters can be highlighted from this 
plot, analyses of which give the goodness or strength of the model. The R2 is the correlation 
coefficient and gives an idea of the “goodness of fit” of the model, i.e. the extent to which the 
model fits the data generated. R2 gives the per cent of variation in a response that is explained by 
Chapter Three 
112 
 
the model. An R2 value of 1 depicts a perfect fit (minimal residuals (noise), observed points/ means 
equals predicted means). 
 
. 
 
 
 
 
 
 
An R2 value of 0.75 gives a rough but stable and useful relationship (Eriksson 2008). However, R2 
is not the only parameter required to confirm the goodness of a model. The Q2 value gives the 
percent of variation in the responses that is predicted by the model. A large Q2 value is useful; 
however, it is more important that the R2 and Q2 values are not far apart from each other. A low Q2 
value may be obtained when there are insignificant terms in the model, removal of which would 
enhance the model’s predictive power. 
The model validity bar gives an indication of the validity of the model. When this bar is below 
0.25, there is a lack of fit, i.e. the model error is significantly larger than the pure error. A model 
validity of unity implies a perfect model. The fourth important parameter is the model 
reproducibility bar. This bar reveals the variation in the response carried out under identical 
situations, compared to the total variation of the response; and this is mostly at the centre points. 
A reproducibility bar of unity depicts a pure error of zero, thus under the same conditions, the 
results for the responses were always the same. 
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Figure 3.1 Distance to model plot showing the closeness of the various experimental runs to the model.  Identified 
outliers (highlighted with the blue shapes), that did not affect the model detrimentally, were excluded. 
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From Figure 3.2 it can be seen that the model showed good R2, Q2, model validity and 
reproducibility values. Because the Q2 values for each of the responses is not too far from the 
corresponding R2 values for the actual data (less noise), the amount of the data that can be predicted 
by the model is high.  
 
Figure 3.2 Partial least squares (PLS) fit summary plot for all responses. R2 represents the extent to which 
observed data fits the model, Q2 depicts the per cent of actual data that can be predicted by the model, model 
validity of >0.25 shows the model has no lack of fit. 
For example, for the response tablet hardness (Y3) with R2 and Q2 values of 0.92 and 0.64 
respectively, 92% was actual data while 8% can be attributed to noise; and from the 92% of actual 
data, 64% of that data is predicted by the model, and vice versa (Eriksson 2008). Generally, for the 
actual data obtained for all the responses, over 60% of the data was predictive. The lowest 
predictive ability was seen with the disintegration time response. This may be due to the fact that 
the test is subjective and depends on the visual evaluation of the test endpoint by the experimenter; 
unlike the other tests which are more instrument-dependent. Thus, any inefficiency in evaluating 
disintegration time to the tune of a few seconds can produce errors in the model (Alhusban et al 
2011). 
Figure 3.3 shows the lack of fit plots for the various responses. For a model to show no lack of fit, 
the first bar (the model error) must be smaller than or equal to the third bar (the pure error adjusted 
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for uncertainties). The middle bar is the standard deviation of the pure error (the standard deviation 
of the responses at the centre points). From this figure, it can be seen that all the responses showed 
no lack of fit, and, thus, the absence of significant model error. The lack of fit plot is an expatiation 
of the information obtained from the model validity bar in the summary fit plot (Figure 3.2) 
(Eriksson 2008). 
 
Figure 3.3 The lack of fit plots for all responses. As long as the 1st bar is smaller than or equal to the 3rd bar, the 
model shows no lack of fit. 
3.3.2.1.2  Analysis of variance (ANOVA) 
The analysis of variance (ANOVA) plot compares the standard deviations of the regression line 
(the model) to the standard deviation of the residuals (the noise). These are depicted as the first and 
third bars, respectively, in Figure 3.4. As long as the first bar is larger than the third bar (the 
standard deviation of the noise at its upper confidence level), then the model is good. From Figure 
3.4, it can be seen that all the models were good. Summary of ANOVA results showing model 
significance (p<0.05) for all assessed factors are shown in Table 3.5, depicting minimal model 
error. 
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3.3.2.1.3  Observed vs predicted plot 
This important plot displays the relationship between the observed responses of the model and the 
responses predicted by the model. For good models, the points should fall around a 45 degree 
regression line and the correlation coefficient should be as close to unity as possible (Eriksson 
2008). 
 
Figure 3.4 ANOVA plots comparing the standard deviations of the model (1st bar) to that of the noise (2nd bar), 
for all responses. When the first bar is larger than the third bar, the model is good 
 
Generally, regression coefficients above 0.75 are acceptable within the limits of experimental error 
(Eriksson 2008). From Figure 3.5, which depicts this plot for our model, all the responses had R2 
values greater than 0.9, except for disintegration time with a slightly lower value of 0.82. A possible 
explanation for this has been given above. However, these values are still representative of a good 
model.  
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Table 3.5 Summary of results obtained from ANOVA of four responses to test model validity. P is the probability 
and R2 is the regression coefficient. 
CQA P value R2 
Disintegration time 
Regression 
Lack of fit 
 
0.02 
0.13 
 
 
0.82 
Friability 
Regression 
Lack of fit 
 
0.00 
0.34 
 
 
0.92 
Hardness 
Regression 
Lack of fit 
 
0.00 
0.62 
 
 
0.92 
Porosity 
Regression 
Lack of fit 
 
0.00 
0.65 
 
 
0.91 
 
 
Figure 3.5 The observed vs predicted plots for all responses showing the closeness of the data predicted by the 
model to the actual data observed. The closer the R2 value is to 1, the better the model. 
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3.3.2.2 Effect of factor variation on responses 
The disintegration time of the tablets varied from 51.0 to 223.33 secs, friability from 2.02 to 2.92 
%, hardness from 48.04 to 154.1 N, and porosity from 0.201 to 0.337 (data in the appendix) 
indicating that these responses were strongly dependent on the factors varied (Alhusban et al 2011). 
Three parameters will be employed to discuss the effect of changes in the various factors on the 
responses and they include: 
 The model equation/ ANOVA coefficients list with significance level: The ANOVA 
coefficients list gives the magnitude and direction of the effect a factor has on a response. 
It also highlights the significance of such effects. Generally, at 95% confidence limit, all p 
values <0.05 are considered significant. Table 3.6 shows the effect of the various factors 
on the observed responses and their significance at 95% confidence interval (ANOVA 
p<0.05).  
 The main effects plots to explain linear models: This plot depicts the change in a 
response, when one factor is increased from its low to high value while keeping other 
factors at their middle (or centre) values. With response surface modelling (RSM) 
objective is chosen, the three centre points (the black dots in Figure 3.6) must be within or 
close to the confidence interval, for the effect to be valid. From our model, because the 
dots are within, or in a few cases close to, the confidence intervals, these effects are valid. 
Also because a PLS fitting model was used, the main effect of one factor can be generated 
without interference from the other factors (Eriksson 2008).  The quantitative effects of 
the various factors on the responses are summarised in Table 3.6. These effects are 
discussed in detail in later sections of this work. 
 The response surface model (RSM) and interactive plots to interpret interaction or 
quadratic models where available. These plots highlight the interactions between two 
factors and how they affect a particular response, while keeping other factors at their 
middle levels. 
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Table 3.6 Quantitative factor effects on the responses and their corresponding p values. A (+) sign indicates a 
direct proportionality while a (-) sign indicates a reverse proportionality. 
Term Disintegration 
time 
 
 
Friability 
 
 
 
Hardness 
 
 
 
Porosity 
 
 
 Effect P 
value 
Effect P 
value 
Effect P 
value 
Effect P 
value 
X1 58.70 0.02 0.03 0.85 4.99 0.56 0.02 0.10 
 
X2 47.11 0.028 0.41 0.02 -20.02 0.04 0.02 0.11 
 
X3 -48.24 0.04 -1.14 0.00 71.79 0.00 -0.04 0.00 
 
X22 34.23 0.32 0.41 0.15 -14.82 0.34 -0.02 0.46 
 
X1X3 -30.67 0.15 -0.15 0.34 6.72 0.46 -0.01 0.24 
 
X2X3 -29.85 0.16 -0.49 0.01 7.92 0.39 0.06 0.00 
 
3.3.2.2.1 Regression models for all CQA 
The data was fitted using quadratic models containing 6 model terms (constant, concentration, 
viscosity, compaction pressure, concentration*concentration, viscosity*pressure and 
concentration*pressure) to yield the following model equations: 
𝑌1 = 92.39 + 30.09𝑋1 + 19.75𝑋2 − 20.60𝑋3 . . . . (Equation 3.20) 
𝑌2 = 1.38 + 0.18𝑋2 − 0.45𝑋3 − 0.17𝑋2𝑋3 . . . . (Equation 3.21) 
𝑌3 = 110.53 − 8.78𝑋2 + 28.16𝑋3 . . . . . (Equation 3.22) 
𝑌4 = 0.28 − 0.017𝑋3 + 0.02𝑋2𝑋3 . . . . . (Equation 3.23) 
where Y1 is the disintegration time, Y2 is tablet friability, Y3 is tablet hardness and Y4 is tablet 
porosity. X1 is polyox polymer viscosity grade, X2 is polyox concentration, and X3 represents 
compaction pressure.  
3.3.2.2.2 Effect on disintegration time (Y1) 
Tablet disintegration time response was significantly affected by the linear models of polymer 
viscosity, polymer concentration and compaction pressure (Equation 3.20 and Figure 3.6, Figure 
3.7 & Figure 3.8). An increase in polymer viscosity or polymer concentration increased 
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disintegration time significantly, while an increase in compaction pressure resulted in a decrease 
in disintegration time; as shown by the positive and/ or negative signs in the model equation (3.20) 
above. The largest effect coefficient (+30.09) was seen for polymer viscosity and this suggests that 
polymer viscosity had a larger effect on disintegration time than polymer concentration and 
compaction pressure. The increase in disintegration time upon increasing viscosity of polymer was 
expected, since viscosity of polyox is directly proportional to its molecular weight (Royce 1993). 
The more viscous the polymer in solution, the harder it is for water to diffuse into and wet the 
tablet, thereby slowing down the disintegration process (Alhusban et al 2011). Higher molecular 
weight matrix forming polymers with longer polymer chains exhibit increased chain entanglement, 
which is synonymous with extended release formulations, thereby inhibiting matrix erosion and 
tablet disintegration (Royce 1993, Lee et al 1999, Efentakis and Vlachou 2000, Streubel et al 
2003).  
 
Figure 3.6 Main effects plot highlighting the effect on tablet disintegration time when polymer viscosity is 
increased from its low to high value and other factors maintained at their middle values. The three centre points 
(black dots) within the white area indicate validity of the effect, as they fall within the confidence limits of ± 95%. 
 
Physical observation of the disintegration of tablets containing higher viscosity polyox showed the 
formation of a sticky gel-like mass that did not disintegrate within a couple of minutes. A similar 
observation was reported by Nerurkar et al. (2005) and Khan et al. (2007). The main effect of 
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polymer concentration on disintegration time (Figure 3.7) varied depending on concentration used. 
Disintegration time was found to incline slightly from 0.5 to 1.5% polymer concentration, after 
which there was a steeper increase between 1.6-2.5%. This implies that disintegration time is more 
significantly affected at higher polymer concentrations. This can be explained because at low 
polymer concentrations, there are less molecules of polyox interacting to form the gelatinous 
matrix that interacts to impede disintegration time via formation of a discontinuous gel layer; the 
reverse occurred at higher polymer concentrations (Sung et al 1996, Nerurkar et al 2005). Similar 
results have been reported by Al-Khattawi et al (2014).  
 
Figure 3.7  Main effect plot highlighting the effect on tablet disintegration time when polymer concentration was 
increased from its low to high value and other factors maintained at their middle values. The three centre points 
(black dots) within the white area indicate validity of the effect, as they fall within the confidence limits of ± 95%. 
 
 
The main effect of compaction pressure on disintegration time (Figure 3.8) showed that this 
response decreased linearly as compaction pressure increased. This was contradictory to our 
expectations as increasing compaction pressure would generally increase tablet hardness and 
thereby extend disintegration time (Al-Khattawi et al 2014). This effect has been observed in 
materials that show elastic recovery upon compression, where increase in compaction pressure 
increases the elastic energy of the system, leading to recovery of tablet shape, low hardness and 
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low disintegration time, especially at high compaction pressures (Yoshinari et al 2003, 
Kleinebudde 2004). Accordingly, Picker (2004) and Yang (1996) reported polyox polymers as 
exhibiting elastic recovery or viscoelastic properties with increasing compaction pressures.  
 
Figure 3.8  Main effects plot highlighting the change in disintegration time as a function of compaction pressure 
variations while other factors remained constant at their middle values. The three centre points (black dots) within 
the white area indicate validity of the effect, as they fall within the confidence limits of ± 95%. 
 
 
3.3.2.2.3 Effect on tablet friability (Y2) 
Tablet friability was only significantly influenced by the linear models of polymer concentration 
and compaction pressure, as well as the interactive model of both factors (Equation 3.21). The 
effect coefficient for compaction pressure (-0.45) was much higher than that for polymer 
concentration (+0.18), implying that compaction pressure plays the highest role in tablet friability. 
This was further seen in the negative effect coefficient of the interactive term (-0.17), which implies 
that the detrimental effect of polymer concentration on friability is minimised when combined with 
increasing compaction pressure. Pinto (2004) reported that tablets containing polyox as a binder/ 
matrix forming agent showed a decrease in friability on increasing the compaction pressure. This 
observation can be explained by the fact that higher forces lead to increased binding capacity. Also, 
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previous work in the literature showed no significant difference in tablet friability (Al-Khattawi et 
al 2014) or a decrease in friability (Shahi et al 2013) with increasing polyox concentration. Figure 
3.9 is a plot of the interactive effect of polymer concentration and compaction pressure on tablet 
friability. From this plot, it can be seen that at low pressures and high polymer concentrations there 
was high friability. However, as we navigate to a higher compaction pressure, an interactive 
relationship can be seen where low friability values are recorded at high compaction pressures and 
high polymer concentrations. The elastic recovery property of polyox can account for this 
interaction effect, as explained above. 
 
Figure 3.9 Interaction plot highlighting strong interaction effect of polymer concentration and compaction 
pressure on tablet friability. Two lines that cross each other depict a strong interactive effect. 
 
3.3.2.2.4 Effect on tablet hardness (Y3) and porosity (Y4) 
The regression model equation for tablet hardness (Equation 3.22) showed that the only factors 
that significantly affected tablet hardness were the linear model terms of polymer concentration 
and compaction pressure; with compaction pressure contributing the major impact. Tablet porosity 
was only influenced by the linear model of compaction pressure and the interaction model of 
polymer concentration and compaction pressure (Equation 3.23). As expected, compaction 
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pressure was directly proportional to hardness and inversely proportional to porosity as seen in 
their main effect plots (Figure 3.10). This was expected since high compaction pressures bring 
particles into closer proximity which yields lower porosity and, therefore, higher solid fraction. 
Thus providing more contact points for inter-particle bonding, leading to higher cohesiveness and 
hardness of the tablet (Bi et al 1996, Tye et al 2005).  
 
Figure 3.10 Main effect plot highlighting the effect on tablet hardness and porosity when compaction pressure is 
increased from its low to high value and other factors maintained at their middle values. The three centre points 
(black dots) within/ close to the white area indicate validity of the effect as they fall within the confidence limits 
of ± 95%. 
 
 
Interestingly, there was an insignificant decrease in tablet hardness with increase in polymer 
concentration from 0.5-1.5% (Figure 3.11). Similar results have been reported (Al-Khattawi et al 
2014) using low viscosity grades of polyox. However, tablet hardness was observed to decrease 
markedly above 1.5% polymer concentration. This was a totally unexpected trend because one 
would expect that increase in binder concentration would increase the cohesiveness of the powder 
mix, and therefore result in higher hardness. However, an examination of the response surface 
model (RSM) plot of polymer concentration and compaction pressure on porosity (Figure 3.12) 
reveals a decrease in tablet porosity with increasing compaction pressures (at low polymer 
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concentrations); however, at higher concentrations, tablet porosity was seen to increase. Thus, the 
elastic recovery of polyox increased with increasing polymer concentration and this effect 
supersedes the effect of increasing compaction pressure, thereby resulting in increased tablet 
porosity and subsequently decreased hardness. Bi et al (1999) reported lower tablet tensile strength 
and increased porosity with increase in polymer concentration. In our model, polymer viscosity did 
not significantly affect tablet hardness.  
 
Figure 3.11 Main effect plot highlighting the effect on tablet hardness when polymer concentration is increased 
from its low to high value and other factors maintained at their middle values. The three centre points (black 
dots) within the white area indicate validity of the effect, as they fall within the confidence limits of ± 95%. 
 
 
L’hote-Gaston et al (2009) reported a small increase in tablet hardness/ breaking force, with 
increasing polyox viscosity. On the other hand, Nokhodchi et al (1995) reported a decrease in 
tensile strength/ hardness of HPMC tablets with increasing polymer viscosity grades. However, a 
slight increase in porosity was observed on increasing polymer viscosity. This increase in porosity 
may be explained by the densification behaviour of the polymers upon compression. Polymers with 
lower viscosities and molecular weights have been reported to deform easily to fill the voids in the 
dies, during tablet compaction. Nokhodchi et al (1996) reported a linear increase in porosity of 
HPMC tablets with increasing polymer viscosity grades. However, in our model, the increase in 
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porosity seen with increasing polymer viscosity was regarded as insignificant by ANOVA (Table 
3.5). 
 
 
Figure 3.12 Response surface plot showing the effect on tablet porosity, of varying polymer concentration and 
compaction pressure, with polymer viscosity held at its mid position. An increase in tablet porosity at high 
compaction pressures and high polymer concentrations reveal the elastic recovery at high pressures, of polyox 
polymers 
 
3.3.2.3  Prediction of design space/ formulation optimisation 
Low polymer viscosity and concentration combined with high compaction pressures were 
identified as necessary CPPs for formulating desirable ODTs containing polyox. Figure 3.13 
represents the sweet spot plot highlighting combinations of factors that would yield ODTs with 
disintegration times <180 secs, tablet hardness >60 kN and possible friability <1%. From here, it 
can be seen that low to medium viscosity polyox grades should be used at about 1.5% concentration 
and compacted at pressures between 2.6 – 3.0 tons to achieve ODTs with desirable characteristics. 
Based on this information, the MODDE software optimiser was used to set specific parameters 
(CPP levels) to yield ODT characteristics that would maximise tablet hardness, while minimising 
tablet disintegration time and friability. Tablet porosity was allowed to run free. ODTs were then 
formulated using these parameters for the various grades of polyox polymer viscosities tested. 
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Figure 3.13 Sweet plot depicting polymer viscosity and compaction pressure ranges for obtaining optimal ODT 
characteristics when polymer concentration is set at its mid value (1.5%).  
 
From experimental results highlighted in Table 3.7, tablets produced with the various viscosity 
grades of polyox were able to disintegrate/ disaggregate in < 60s, except those containing the 
highest viscosity grade of polyox. Hardness was > 110N for all tablets including the control, and 
tablet friability was much lower than for previous formulations (1.08 – 1.14%). Thus, using any 
combination of chosen factors designed by the MODDE optimiser, ODTs with optimal 
characteristics could be produced, although strategies to decrease friability would still need to be 
employed, as suggested by Al-Khattawi et al (2014).  
3.3.3 Mucoadhesive efficiency 
The ability of the ODT formulations to adhere to the surface of excised porcine buccal mucosa was 
assessed to determine the mucoadhesive efficiencies of the polymers. Results of the mucoadhesive 
efficiencies obtained for the optimised formulations are shown in Figure 3.14 while a typical 
compressive load vs compressive extension graph produced by the software is depicted in Figure 
3.15. From Figure 3.14, only ODTs containing the polymer with the highest viscosity (Polyox 
coagulant) showed any significant enhancement in mucoadhesive efficiency, compared to 
formulations with other polyox polymers and the control which contained only LHPC.  
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Table 3.7. Table highlighting CPP levels chosen by the MODDE optimiser to yield ODTs with favourable 
characteristics, and results obtained after testing the ODTs (n=3). ODTs prepared without polyox were used as 
control. 
 
FACTORS (CPP) RESPONSES (CQA) 
Polymer 
viscosity 
grade 
Polymer 
concentration 
(%) 
Compaction 
Pressure 
(tons) 
 
Disintegration 
time (s) 
Hardness (N) Friability 
(%) 
Porosity 
Polyox 
N10 
 
1.39 2.99 37.00  ± 5.57 125.03 ± 5.56 1.12 0.43 ± 0.06 
 
Polyox 
1105 
 
1.36 2.99 49.67 ± 2.52 121.87 ± 5.41 1.08 0.43 ± 0.03 
 
Polyox 
N60K 
 
1.32 2.99 51.00 ± 3.00 129.63 ± 0.60 1.13 0.47 ± 0.04 
 
Polyox 
Coagulant 
 
1.32 2.99 65.67 ± 1.53 119.93 ± 7.16 1.14 0.42 ± 0.03 
 
Control - 2.99 27.67 ± 3.05 118.70 ± 5.06 1.12 0.42 ± 0.02 
 
 
Mucoadhesion has been reported to be directly proportional to polymer viscosity/ molecular chain 
length from molecular weights above 100,000 Da, for polyox polymers (Boddupalli 2010, Manly 
2012). Shah et al (2014) reported that polyox polymers with molecular chain lengths 4,000,000 
and above, showed the highest mucoadhesive potential. Mucoadhesion is affected by various 
properties of polymers, including molecular weight/ viscosity, flexibility, cross-linking density, 
hydrogen bonding capacity, hydration, charge and concentration (Boddupalli 2010). Considering 
that the concentration of the polymers in the formulations were almost constant, the similarities in 
mucoadhesive efficiencies of the low to medium viscosity polyox polymers may be related to the 
lower ability of these polymers to interact with water to form the interlinking chains with mucus 
(Cilurzo et al 2005). Conversely, Di Colo et al (2001) reported the mucoadhesive potential of low 
molecular weight polyox polymers to be higher than that of higher molecular weight polyox.  
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Figure 3.14 Results showing mucoadhesive efficiencies of ODTs containing various viscosity grades of polyox 
using CPPs designed by the MODDE software optimiser (n=2). Tablets containing only LHPC without polyox 
used as control. Only polyox coagulant tablets showed a significant increase above the control. 
 
 
 
 
 
 
Figure 3.15. Typical plot of compressive load against compressive extension highlighting the energy input into the 
system and the resulting work of adhesion  
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3.4 Conclusion 
Quality by design (QbD) incorporating design of experiments (DoE) proved an effective tool for 
designing quality into ODTs to yield optimal tablet characteristics. Furthermore, an understanding 
of the interactive and polynomial relationships generated by the model, brought to light the effect 
of the elastic recovery exhibited by polyox on the tablet characteristics of ODTs. From our model, 
tablet disintegration time was found to be directly proportional to polymer viscosity and 
concentration, but inversely related to compaction pressure. This effect of compaction pressure on 
disintegration time was unexpected but was found to be due to the elastic recovery of polyox that 
occurs at high compaction pressures and polymer concentrations, resulting in increased tablet 
porosity. Tablet friability decreased with lower polymer concentrations and higher compaction 
pressures. Tablet hardness was inversely related to polymer concentration and directly related to 
compaction pressure; while tablet porosity was found to decrease with increasing compaction 
pressures.  These factors were successfully combined to intentionally produce ODTs with optimal 
characteristics and mucoadhesive properties that would enhance residence time of the ODT in the 
mouth, prevent saliva scavenging/ unintentional swallowing, and therefore enhance therapeutic 
outcomes.
Chapter Four 
130 
 
 
 
Chapter 4 
A systematic investigation of the role 
of extracellular calcium ion in 
promoting stratification of buccal cell 
cultures 
 
 
 
 
 
 
Publications relating to chapter 4 
Iyire, A.; Russel, C.; Bailey, C.; Mohammed, A. (2014) Investigating buccal cell cultures to 
enhance in vitro assessment of transmucosal drug delivery. UKICRS Newsletter pp 38-40. 
http://www.ukicrs.org/uploads/1/2/1/5/12158556/ukicrs_2014.pdf 
Chapter Four 
131 
 
4.1 Introduction 
On delivery of a solid dosage form into the buccal cavity, the drug must diffuse out of the dosage 
form rapidly, dissolve in the saliva, partition into the lining of the epithelium, then across the whole 
epithelium, and thereafter diffuse into the systemic circulation via the internal jugular vein 
(Mathias and Hussain 2010). Because the buccal route is used mainly as an alternative non-invasive 
route to maximise the advantages of oral delivery while minimising its challenges, the formulation 
scientist must ensure that pharmacokinetic and pharmacodynamic parameters are similar between 
the two routes of administration. During formulation of potential buccal dosage forms, drug 
permeation via the buccal cavity has to be modelled. One area of continuous concern is the 
availability of effective in vitro methods to assess buccal drug delivery which are reproducible and 
representative of the in vivo environment (Shojaei 1998, Şenel and Hıncal 2001). 
Ideally in vivo methods, if properly developed, would give the best representation of the fate of 
delivery systems upon buccal administration. In vivo methods available are modifications of the 
buccal absorption tests originally developed by Beckett and Triggs (1967). This test had limitations 
of accidental swallowing and saliva dilution that were not accounted for; and there was no method 
of confining the test solution to one particular area of the mouth (Shojaei 1998). Modifications of 
this method which accounted for possible saliva dilution and accidental swallowing have since 
been developed, but the common setback of lack of test solution confinement had still not been 
overcome (Shojaei 1998, Şenel and Hıncal 2001). Other in vivo methods include the attachment of 
a perfusion system to the buccal cavity of dogs and pigs, circulating a test solution through this 
cavity, and withdrawing samples from both the perfusion chamber and the blood, to correlate the 
amount of drug lost from the sample to the amount absorbed in vivo (Junginger et al 1999). Thus, 
in vivo methods for modelling buccal delivery are cumbersome and non-standardised. However, 
the use of mucoadhesive polymers to localise test systems to one site in the oral cavity would 
greatly improve the applicability of these tests (Sudhakar et al 2006). 
Available in vitro methods involve the use of either excised animal buccal tissue or buccal cell 
cultures (Shojaei 1998, Şenel and Hıncal 2001); as it is almost impossible to obtain viable human 
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buccal epithelium on a continual basis (Balimane et al 2000). Here, excised animal buccal 
epithelium is mounted on perfusion/ diffusion chambers such as Franz cells, and permeation 
experiments carried out (Shojaei 1998). Table 1.5 (section 1.5.2, page 51) compares the dimensions 
and characteristics of available animal buccal tissues to that of humans. Porcine buccal epithelium 
has been identified as being closest to man’s in terms of morphology, composition and 
biochemistry (Lesch et al 1989, Davoudi et al 2012). In order to overcome the disadvantages 
associated with the use of animal tissues, buccal cell cultures have been investigated as a high 
throughput method of buccal transport assessment.  
Table 1.6 (section 1.5.2, page 54) compares the use of animal tissues and buccal cell cultures for 
modelling buccal delivery. 
At present, commercially available buccal cell culture models include the TR146 cell line, 
reconstituted human oral epithelium (RHOE) and Epioral tissues. TR146 is a continuous cell line 
derived from a neck node metastasis of a buccal squamous cell carcinoma in a 67 year old woman 
who had undergone radiotherapy prior to incision (Rupniak et al 1985, Moharamzadeh et al 2007). 
They are reported to form a non-keratinised epithelium, 7-10 cell layers thick, with organelles 
identified as membrane coating granules (MCGs) and they cost approximately £800 including 
freight. RHOE are modified cells derived from the TR146 cell line and grown at the air-liquid 
interface on polycarbonate membranes in media supplemented with insulin, hydrocortisone and 
calcium chloride (Moharamzadeh et al 2007). These were reported to form epithelia devoid of the 
stratum corneum, similar to oral epithelia and cost approximately £200 for 12 tissues (4 replicate 
experiments). Epioral tissues are the most developed buccal models currently available. They are 
normal human derived epithelial cells grown in serum-free media (Moharamzadeh et al 2007). 
They form highly differentiated cells (8-12 layers thick) expressing normal keratins and naturally 
occurring antimicrobial peptides found in human tissues. These cost approximately £800 without 
shipping for 24 tissues (8 replicate experiments). However, the buccal stratification observed in 
humans (40-50 cell layers) has not been achieved by any presently available cell culture model 
(Shojaei 1998). 
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Calcium is a divalent, stable cationic component of bones and teeth that is never found unbound in 
nature. It is required for an extensive range of cellular processes in the body including enzymatic 
activities, cell attachment/ adhesion, cell-cell signalling, cell motility and morphology, cell 
differentiation and even electrochemical responses by the more specialised neural and muscle cells 
(Coppolino et al 1997, Jeyaraju et al 2009). In the cell, calcium is primarily stored in the 
endoplasmic reticulum and plays a role in signalling attachment events from inside the endoplasmic 
reticulum. Calcium has been implicated in many events that affect the shape or morphology, 
movement and three-dimensional structure of cells. It also modulates the functions of groups of 
adhesion molecules including cadherins, selectins and integrins, which are involved in regulation 
of homologous/ heterologous cell-cell and cell-matrix interactions. Desmosomes are molecular 
complexes that connect epithelial cells to one another and they attach the cytoskeleton of the keratin 
intermediate filament to the cell surface (Kelly 1966). These desmosomes comprise various 
proteins collectively called desmosomal proteins that include members of the cadherins 
superfamily, which are dependent on Ca2+ to function (Presland and Dale 2000). Thus, desmosome 
formation and assembly in cultured epithelial cells have been reported to occur rapidly in the 
presence of high extracellular calcium (Trinkaus-Randall and Gipson 1984, Watt et al 1984, Garrod 
and Chidgey 2008). The mechanism of this rapid assembly has been linked to the regulation of 
desmosomal cadherin by calcium and the specific phosphorylation and de-phosphorylation of 
desmosomal proteins. Watt et al (1984) reported that extracellular calcium concentrations up to 2.0 
mM resulted in rapid cell adhesion and stratification, with the absence of stratification observed 
below 1.0 mM.  
The objective of this work was, therefore, to test the hypothesis that increasing extracellular Ca2+ 
concentration in the specialised culture media for TR146 buccal cell line would enhance 
stratification of the TR146 buccal cell model; thereafter translating to significant changes in 
membrane permeability in vitro, with the larger aim of achieving higher in vitro - in vivo 
correlations during buccal drug delivery assessment. 
Chapter Four 
134 
 
4.2 Materials and methods 
4.2.1 Materials 
Atenolol, recombinant human insulin, propranolol, hydrated calcium chloride, 
methylthiazolydiphenyl-tetrazolium bromide (MTT) and fluorescein isothiocyanate (FITC)-
labelled dextran 4kDa and trifluoroacetic acid (TFA) were purchased from Sigma Aldrich, UK. 
Fetal bovine serum (FBS), 1% penicillin-streptomycin, 2 mM glutamine and gentamycin were 
purchased from Bio Sera, UK. Hank’s balanced salt solution (HBSS) and Ham’s F-12 nutrient mix 
were purchased from Invitrogen UK. Trypsin-EDTA and Fungizone (amphotericin B) were 
purchased from Gibco Lab, UK. 4′,6′-diamidino-2-phenylinodole (DAPI) in Vectashield® was 
purchased from Vector Laboratories, UK. Trypan blue, acetonitrile, absolute ethanol and 
hydrochloric acid were purchased from Thermo Fisher Scientific, UK. Cell culture plates, 
microscope coverslips Biofreeze® were purchased from VWR, UK; while transwell inserts with 
plates were purchased from Appletonwoods, UK. All water used was double-distilled and 
autoclaved. 
4.2.2 Methods 
4.2.2.1 TR146 Cell culture procedure 
Growing TR146 cells purchased at passage 4+ from Public Health England, were maintained 
(according to suppliers instructions) on 75 cm3 T-flasks in Hams-F12 media fortified with 10% 
FBS, 2mM glutamine, and antibiotics; incubated at 37  ͦC and 98% relative humidity provided by 
5% CO2/ 95% air. Media change occurred every 2-3 days, cells were sub-cultured at 80 - 90% 
confluence using 0.1% trypsin/EDTA solution in HBSS and passages 10 - 27 were used for 
experiments. 
4.2.2.2 Passaging of cells  
At 80 – 90% confluence, the media was decanted and cells washed twice with HBSS, to remove 
any dead or non-adherent cells. 5 mL of 0.1% trypsin-EDTA solution in HBSS was then added and 
flasks shaken at 450 rpm and 37 ͦ C for 10 minutes, in an orbital plate shaker. Flasks were examined 
Chapter Four 
135 
 
under light microscopy to ensure that disaggregation had occurred. Care was taken not to leave 
trypsin solution on for longer than 15 mins to prevent irreversible cell damage. 5 mL of culture 
media was added to quench trypsin reaction and cell density was measured by haemocytometry 
(section 4.2.2.5). Cells were then seeded unto continuation flasks, microscope coverslips, well 
plates or transwells respectively, at the required density. 
4.2.2.3 Cell storage and revival 
After trypsinising (as described earlier), cell suspensions were centrifuged at 1000 rpm for 5 
minutes, the supernatant decanted and withdrawn fully using a pipette. Cells were then resuspended 
in sufficient volume of cryoprotectant - Biofreeze® to produce 106 – 107 cells/mL, and 1 mL each 
of the resulting cell suspension was transferred into cryovials. After labelling, cryovials were 
placed in a polystyrene box kept at -20 ͦ C for 1 hour which ensures a constant cooling rate of 1 ͦ C/ 
min, then retained overnight at -80 ͦ C. The following day, the cryovials were transferred to liquid 
nitrogen for long-term storage. To ensure cell viability, one cryovial of cells was revived one month 
later. To revive cells, cryovials containing frozen cells were removed from liquid nitrogen and 
thawed in the incubator at 37 ͦ C, after which contents were immediately emptied into a 25cm3 T-
flask containing 6mL cell culture media. Flasks were incubated at 37 ͦ C and, at confluence, 
passaged into 75 cm3 T-flasks, and then used as required.  
4.2.2.4 Seeding of cells 
Microscope coverslips were place in absolute ethanol for 2 minutes, and then transferred singly 
into the wells of a 12 well plate, and left partially open in the laminar flow hood to dry for two 
minutes. 1 mL of 0.02% collagen solution in deionised and autoclaved water was added to each 
well and left partially open in the hood to facilitate collagen coating of coverslips. After 3 hours, 
collagen solution was removed and wells rinsed twice with 1mL HBSS (to remove residual acetic 
acid used to solubilise collagen). Upon drying, enough cell suspension to give the required seeding 
density was added to the wells using an automatic pipette. Seeding density for all supports was 
maintained at approximately 24,000 cells/ cm2. Seeding volumes were maintained according to 
manufacturer recommendations, and are listed in Table 4.1. 
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Table 4.1 Characteristics of solid supports for cell culture: dimensions and media volumes used 
 
Support Diameter 
(mm2) 
Surface 
area (cm2) 
Total media 
volume 
(mL) 
Apical 
media 
volume 
(mL) 
Basolateral 
media 
volume 
(mL) 
T 25 flask - 25.00 7.00 - - 
 
T 75 flask - 75.00 25.00 - - 
 
6 well plate 34.80 9.50 2.50 - - 
 
12 well plate 22.10 3.80 1.00 - - 
 
96 well plate 4.26 0.14 0.31 - - 
 
6 well transwell 24.00 4.67 4.10 1.50 2.60 
 
12 well transwell 12.00/’; 1.12 2.00 0.50 1.50 
 
 
4.2.2.5 Cell quantification (haemocytometry) 
To calculate cell density, 20 µL each of trypan blue solution and post-trypsinised cell suspension 
were added to an Eppendorf tube and mixed together. The resulting suspension was placed under 
a microscope slide cover slip on a haemocytometer, and the number of live cells (cells not stained 
blue) per square was counted using a TMS-F inverted microscope (Nikon, Japan). Cell density 
which is the number of live cells per mL of cell suspension was calculated using equation 4.1 
below. Subsequently, cell seeding density was achieved by diluting the required number of cells in 
sufficient culture media.  
Cell Density =
Total number of live cells in squares
(Number of squares (4))
 x dilution factor x  1000 (Equation 4.1) 
4.2.2.6 Effect of extracellular calcium on cell viability, proliferation and 
stratification 
4.2.2.6.1 Preparation of calcium solutions 
A 20% w/v stock solution of anhydrous calcium chloride in deionised water was prepared and 
autoclaved. Sufficient volumes were added to prepare 50 mL of calcified media per concentration 
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needed, and is shown in Table 4.2. For all experiments, normal media (approx. 0.3 mM Ca) was 
used as a negative control. 
Table 4.2 Volumes of calcium chloride solution required to prepare 50 mL of calcium fortified media 
S.N. Ca2+ concentration (mM) Volume of calcium stock added (µL) 
 
1 0.6 11.0 
 
2 0.9 22.0 
 
3 1.2 33.0 
 
4 1.5 44.0 
 
5 1.8 55.0 
 
6 2.1 66.0 
 
8 4.2 132.0 
 
9 8.4 164.0 
 
10 16.8 528.0 
 
11 33.6 1056.0 
 
4.2.2.6.2 Qualitative analysis 
4.2.2.6.2.1 Light microscopy 
All cells grown on T-flasks, well plates, microscope coverslips or polyester transwell inserts were 
viewed using a TMS-F inverted light microscope (Nikon, Japan) at 10x or 40x magnification. 
4.2.2.6.2.2 Confocal Laser Scanning Microscopy (CLSM) 
Cells grown on microscope coverslips or transwell inserts were rinsed twice with HBSS, and then 
fixed with 4% paraformaldehyde (PFA) in PBS for 10 minutes. Thereafter, cells were rinsed four 
times with PBS. For microscope coverslips, a drop of DAPI (4′,6′-diamidino-2-phenylinodole) in 
vectashield® was placed on a microscope slide and the coverslip placed on the drop, such that the 
surface with cells contacted the mounting medium, and allowed to air-dry for 10 mins. Transwells 
were placed on microscope slides and the membrane carefully cut out using a scalpel. Two drops 
of DAPI in vectashield® were used to mount the specimen, which was immediately covered with 
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a microscope coverslip and allowed to air-dry for 10 minutes. All prepared samples were then 
viewed using a Leica confocal microscope (Wetzlar, Germany) at 10x (dry) and/ or 40x (oil) 
magnifications.  
4.2.2.6.3 Quantitative analysis 
4.2.2.6.3.1 Cell proliferation using haemocytometry 
Cells were seeded unto 25 cm2 T-flasks in increasing Ca2+ concentrations (control, 1.2, 1.5 & 1.8 
mM Ca). Cells were trysinised daily and live cells counted by haemocytometry (see section 4.2.2.5 
above). 
4.2.2.6.3.2 Cell proliferation/ viability by MTT assay 
The MTT assay was used to assess proliferation and viability of cells in the presence of increasing 
Ca2+ concentrations over a 7-day period. Cells were seeded equally into 96 well plates at 10,000 
cells/well (n=8) in increasing Ca2+ concentrations (control, 1.2, 1.5, 1.8, 2.1, & 2.4 mM Ca). For 
one set of experiments, cells were continuously exposed to calcium fortified media while the 
second set of cells had an intermittent calcium exposure lasting 24 hours, alternating with normal 
(control) media for 24 hours, throughout the duration of the test. For the MTT assay, 20 µL MTT 
solution (5 mg/mL in HBSS) was added to each well containing 200 µL culture media (wells 
containing media with no cells serving as blank) and the plate incubated for 4 hours at 37 ͦ C and 
5% CO2 in air. After 4 hours, wells were emptied and MTT solution was replaced with 100 µL 
DMSO, then shaken for 15 minutes in an orbital plate shaker at 100 rpm. Finally, the formazan 
absorbance was read on a Multiskan® spectrum plate reader (Thermo Scientific, UK) at 490 nm. 
Blank readings were subtracted from the well readings to determine the final absorbance of the 
cells. The relative enzyme reactivity and therefore cell viability was calculated from equation 4.2. 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =  
𝑂𝐷1− 𝑂𝐷2
𝑂𝐷3− 𝑂𝐷2
 𝑥 
100
1
 . . . . . (Equation 4.2) 
where OD1, OD2 and OD3 are the optical densities of wells with cells and Ca2+ fortified media, 
blank wells containing normal media with no cells, and wells with cells in normal media (control) 
respectively.  
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4.2.2.6.3.3 Transepithelial electrical resistance (TEER) 
The ohmic resistance (resistance to current flow via the paracellular pathway) of cells grown on 
transwell inserts was measured every 2-3 days (30 mins after media change) during the cell culture, 
as well as before and after each permeability experiment, using an EVOM™ volt ohmmeter (World 
Precision Instruments, US) with chopstick electrodes. The electrodes were placed erect, such that 
the longer arm just touched the fluid in the basolateral chamber, while the shorter arm barely 
touched the apical membrane. The transepithelial electric resistance which reveals the integrity of 
the cellular layers was calculated using equation 4.3. TEER values were reported as mean ± 
standard deviation of triple readings from replicate transwells (n=9).  
𝑇𝐸𝐸𝑅 = (𝑅(𝑖𝑛𝑠𝑒𝑟𝑡 𝑤𝑖𝑡ℎ 𝑐𝑒𝑙𝑙𝑠) −  𝑅𝑖𝑛𝑠𝑒𝑟𝑡 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑒𝑙𝑙𝑠) ∗ 𝐴    (Equation 4.3) 
where R is the measured resistance and A is the cross-sectional area of the transwell inserts. 
4.2.2.6.3.4 Permeability studies using transport markers 
4.2.2.6.3.4.1 Transport studies 
The permeability of TR146 cell layers grown in increasing extracellular Ca2+ concentrations on 12 
well polyester transwell inserts (Appletonwoods, UK) to the transport of paracellular markers 
(FITC labelled dextran 4kDa, propranolol and atenolol) and insulin was determined over 4 hours 
as described by Nielsen and Rassing (1999) at 36ºC and 140 rpm in an orbital plate shaker. Cells 
on transwell inserts were rinsed twice with HBSS (37ºC) by adding and withdrawing 0.5 mL and 
1.5 mL respectively to/ from the apical and basolateral chambers respectively. After incubation for 
30mins, TEER readings were taken in triplicate per insert. The basolateral chamber was then 
replaced with fresh HBSS and the apical chamber with 0.5 mL test solution (0.5mM FITC labelled 
dextran 4 kDa, 100 mM atenolol or propranolol, or 1 mg/mL insulin solution prepared in HBSS). 
Immediately, 100 µL of test solution was withdrawn from the apical and basolateral chambers at 
time 0. Basolateral sampling of 700 µL was done every 30 mins for 4 hours with immediate 
replacement with pre-warmed HBSS. At the end of the experiment, 100 µL of apical solution was 
taken. Cells grown in normal (unfortified media) were used as control (Portero et al 2002, Xue et 
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al 2012, Sander et al 2013). After 4 hours, cells were rinsed twice with 0.5 mL HBSS and 
equilibrated for 30 minutes after which TEER values were recorded. All FITC-dextran samples 
were transferred to 96 well plates, protected from light using aluminium foil and immediately read 
using a fluorescent plate reader at pre-determined excitation and emission wavelengths of 490 nm 
and 535 nm respectively. All other samples were made up to 700µL (where necessary) using HBSS, 
and analysed by HPLC (section 4.2.2.6.3.4.2). The resultant data was used to calculate the apparent 
coefficient of permeability through the insert with cells (Papp), the cell-free apparent permeability 
coefficient (Pinsert), the cell apparent permeability coefficient (Pcell), and the recovery %. 
𝑃𝑎𝑝𝑝 =
𝑑𝑄
𝑑𝑡
 𝑥
1
𝐴∗𝐶𝑜
         (Equation 4.4) 
𝑃𝑖𝑛𝑠𝑒𝑟𝑡 =  
𝑑𝑄
𝑑𝑡
 𝑥 
1
𝐴∗ 𝐶𝑜
        (Equation 4.5) 
1
𝑃𝑎𝑝𝑝
=
1
𝑃𝑐𝑒𝑙𝑙
 +  
1
𝑃𝑖𝑛𝑠𝑒𝑟𝑡
        (Equation 4.6) 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 % =
𝑋𝑎𝑝𝑖𝑐𝑎𝑙+ 𝑋𝑏𝑎𝑠𝑜𝑙𝑎𝑡𝑒𝑟𝑎𝑙 
𝑋𝑜
 𝑥 
100
1
     (Equation 4.7) 
where dQ/dt is the rate of drug transport at steady state in µg/s, A is the cross sectional area of cells 
in cm2, CO is the initial apical solution concentration in µg/mL, Xapical is the quantity of insulin 
remaining in the apical chamber after 4 hours, Xbasolateral is the cumulative amount of insulin 
sampled from the basolateral chamber after 4 hours and Xo is the initial quantity of insulin in the 
apical chamber at the start of the experiment (Portero et al 2007, Xue et al 2012, Sander et al 2013).  
Drug stability after permeation was monitored by HPLC, where possible, for changes in retention 
time and/ or appearance of multiple peaks on the HPLC chromatogram.  
4.2.2.6.3.4.2 High performance liquid chromatography (HPLC) 
A Waters HPLC system (Alliance) with gradient pump and UV/ fluorescent detector employing a 
reversed phase RP-C18 analytical column (Phenomenex® 110A, 150 x 4.6mm, 5µm), was utilised 
to quantify the test markers used for transport experiments, as well as monitor stability after 
permeation through TR146 cell layers. HPLC conditions validated by ICH guidelines for the 
various test substances are highlighted in Table 4.3. 
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Table 4.3 HPLC conditions for test substances 
S.N. Marker Mobile Phase composition Other conditions 
1 Propranolol 
HCl 
0.1% TFA in water and 
acetonitrile, 67:33  
Injection volume 10µL, UV 
detection at 235nm wavelength. 
 
2 Atenolol  0.1% TFA in water and 
acetonitrile, 67:33  
Injection volume 10µL, 
fluorescent detection at emission 
and excitation wavelengths of 350 
and 397 nm respectively 
 
3 Insulin A: 0.1% TFA in water and 
B:acetonitrile. Gradient elution 
from 74:26 to 67:33 
compositions of A:B over 3 mins, 
and then maintained at 67:33 for 
4 mins. 
  
Injection volume 10µL, UV 
detection at 214nm wavelength. 
4.2.2.7 Statistical analysis 
All data generated in replicates were presented as mean ± standard deviation (SD).  The data was 
then analysed for statistical significance using one-way analysis of variance (ANOVA) and Tukey-
Kramar multiple comparison  post-test from Graphpad Prism® version 6.02 (San Diego, CA, 
USA). The level of significance was quoted as p<0.05 (confidence levels of 95%). 
4.3 Results and discussion 
4.3.1 Cell proliferation of TR146 cells using light microscopy 
Proliferation pattern of TR146 cells on T75 flasks over five days is depicted in Figure 4.1. The 
cells showed a progression from about 90% confluence on arrival with cells exhibiting distinct 
intercellular boundaries, to cells which had lost their morphology, become non-adherent and 
assumed a ‘liposome-like’ shape upon trypsinisation during sub-culture/ passaging. Trypsin is a 
proteolytic enzyme that hydrolyses cell membrane proteins required for cell-cell and cell-substrate 
attachment (Yamada et al 1990). Onward, the cells adhered to the solid support, assumed epithelial 
morphology and had begun replicating and forming small, then larger colonies by 48 hours post-
passage. This process of cell attachment is facilitated by divalent cations (usually Ca2+) and proteins 
including cell surface glycoproteins, serum derived glycoproteins and conditioning factors secreted 
by cells (Butler 2003). These factors form an adherent layer between the cells and the substratum.   
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Figure 4.1 Light microscopy (10x magnification) showing proliferation pattern of TR146 cells grown in normal 
media on 75cm3 T-flasks from receipt, sub-culture, until confluence and onward stratification. 
By 5 days post-passage, monolayer formation was completed and onward stratification initiated, 
as observed by the indistinct intercellular junctions due to overlapping of stratifying cells. As 
expected, cells exhibited the stratified squamous epithelial characteristics expected of their buccal 
origin (Jacobsen et al 1995).  
4.3.2 Effect of extracellular Ca2+ concentration on cell proliferation, viability, 
stratification and permeability 
4.3.2.1 Light microscopy 
Initial qualitative Ca2+ toxicity assay was carried out by seeding TR146 cells on 48 well plates in 
media fortified with increasing Ca2+ concentrations (Figure 4.2). Cells were observed to grow faster 
and appear healthier at concentrations between 1.2 mM and 2.1 mM concentrations.  Increasing 
concentrations to 8.4 mM showed slower growth rates and less healthy cells, while concentrations 
of 16.8 mM and above resulted in cell lysis.  
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Figure 4.2 Representative light microscopic images (10x magnification) of TR146 cells cultured on 48-well plates 
for two days in media fortified with increasing calcium chloride concentrations, with normal (uncalcified) media 
used as control (n=3). Cell lysis was observed to occur at concentrations >8.4mM. 
Calcium ion is a mediator for many cell processes including cell adhesion/ attachment; however at 
high concentrations, it has been implicated in cell death due to initiation of oxidative stress 
(Zhivotovsky and Orrenius 2011). A large concentration gradient exists between the intracellular 
and extracellular fluids of healthy cells. This gradient is between 1-3 mM extracellularly and 0.1-
0.2 µM in the cytoplasm. An increase of cytoplasmic calcium levels up to 0.5 µM due to leaky 
membranes caused by lipid peroxidation via oxidative stress results in a cascade of events that 
destabilises enzyme functions, alters ion and pH balance, as well as interferes with functions of 
critical organelles like mitochondria (Bers 2008). Thus, to maintain calcium homeostasis, 
mitochondria remove calcium from the cytoplasm by a process called calcium cycling. Intra-
mitochondrial calcium then stimulates release of enzymes of the TCA cycle, resulting in energy 
production. When cell membranes are damaged (after subculture with trypsin-EDTA or other 
chelators), influx of calcium into the cytoplasm increases, leading to an imbalance in cellular 
homeostasis. At extremely high ECF Ca2+ concentrations, cytoplasmic calcium cannot be returned 
to the nanomolar range, placing a burden on calcium cycling via the mitochondria, ultimately 
Chapter Four 
144 
 
resulting in halting of ATP production, permanent opening of the mitochondrial membrane pores, 
and triggering of apoptosis-inducing factors that cause cell death (Bers 2008). This would explain 
the cell death observed at higher extracellular Ca2+ concentrations. Maeno et al (2005) reported 
toxicity to osteoblast cells when exposed to >10mM Ca2+ concentrations: 2-4 mM Ca2+ was found 
to induce cell proliferation, while 6-8mM was reported to enhance differentiation and 
mineralisation. Cao et al (2012) also reported cell death when cells were exposed to media 
containing 100mM calcium ion concentrations.  
A similar trend was seen in cells grown on microscope coverslips (Figure 4.3), with maximal cell 
proliferation effects observed at 1.5 mM and a slow proliferation observed at 2.1 mM 
concentration. Figure 4.4 shows a higher magnification of cells cultured on 25cm2 T-flasks in 
increasing Ca2+ concentrations. Cell density was higher as Ca2+ concentration increased to 1.5 and 
1.8mM above the control. By day 4, evidence of stratification was observed across all 
concentrations. Thus, the range of 1.2mM to 1.8mM Ca2+ concentration was chosen for further 
optimisation. 
 
Figure 4.3 Representative light microscopic images (10x magnification) of TR146 cells cultured on collagen-coated 
microscope coverslips for two days in media fortified with increasing calcium chloride concentrations, with 
normal (uncalcified) media used as control (n=2). Maximal cell growth was observed at 1.5mM concentrations. 
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Figure 4.4 Representative light microscopic images (40x magnification) of TR146 cells cultured on 25cm2 T-flasks 
in media fortified with increasing calcium chloride concentrations, with normal (uncalcified) media as control 
(n=3). Cell proliferation increased at concentrations between 1.5-1.8 mM, with stratification observed by day 4. 
4.3.2.2 Confocal Laser Scanning Microscopy (CLSM) 
To further investigate the role of extracellular calcium, TR146 cells were grown using the 
optimised Ca2+ concentration range (1.2 – 1.8 mM) on microscope coverslips and 6 well 
polycarbonate or 12 well polyester transwell inserts. Cells were fixed with 4% PFA and stained 
with DAPI (4’,6-diamidino-2-phenylindole) which is a fluorescent dye that binds strongly to 
double stranded DNA (A-T rich regions) in the nuclei of cells (Manzini et al 1983). Figure 4.5 
shows the horizontal plane of DAPI-stained nuclei of cells grown on collagen-coated microscope 
coverslips. It can be observed that cell density was seen to increase with increasing Ca2+ 
concentration. Also evidence of stratification, inferred from the grouping of nuclei together 
(highlighted with arrows) was seen with 1.5 mM and 1.8 mM concentrations, when compared to 
1.2 mM and control. Calcium has been reported to show paradoxical effects on cell growth. Low 
concentrations of extracellular calcium have been reported to influence cell proliferation while high 
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concentrations (1.0mM and above) have been reported to favour stratification and terminal 
differentiation (Boyce and Ham 1983, Freshney and Freshney 2004).  
 
Figure 4.5 Representative confocal microscopic images of TR146 cells grown on collagen coated microscope 
coverslips in increasing Ca2+ fortified media, stained with DAPI (horizontal plane). Arrows indicate areas of 
stratification; depicted by grouping of nuclei together. 
 
Furthermore, Lechner et al (1982) reported that the effect of calcium was dependent on cell density 
of clonal cells; where at low cell densities, variations in extracellular Ca2+ concentrations between 
0.1 and 1.0 mM had no significant effect on cell proliferation, but when cell density increased to 
greater than 10,000cells/cm2 there was increased cell differentiation at Ca2+ concentrations greater 
than 0.4mM (Freshney and Freshney 2004). Hennings et al (1980) reported fast cell growth, 
continuous keratinisation, absence of stratification and no desmosome formation with mouse 
epidermal cells exposed to low concentrations (0.5 – 1.0mM) of calcium; while at concentrations 
from 1.2mM and above, desmosome formation and stratification was observed. Evidence from 
light microscopy (results not presented) revealed that once a colony of cells of reasonable size had 
been established, stratification could be initiated; even though the solid support was not completely 
covered by a monolayer of cells. This can be noticed in Figure 4.5.  A similar trend was noted from 
cells grown on transwell permeable supports (Figure 4.6). Cell density on permeable supports was 
much higher than on coverslips as expected, because cells are maintained in a polarised, more 
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natural state on permeable supports (Cereijido et al 1978). An increase in cell density was also 
noted with increasing Ca2+ concentration.    
 
Figure 4.6 Representative confocal microscopic images of TR146 cells grown for 8 days on polycarbonate 
transwell inserts in increasing Ca2+ media, stained with DAPI (horizontal plane). 1.5-1.8 Mm Ca2+ enhanced cell 
proliferation. 
Transverse sections of the cells grown on coverslips (Figure 4.7) and permeable supports (Figure 
4.8) were able to demonstrate the stratifying nature of the cells, as seen by DAPI-stained nuclei 
stacked on top of each other. It could be inferred that higher stratification occurred as the 
concentration of Ca2+ increased from the control to 1.8mM. During proliferation of stratifying 
epithelia, the basal cells divide and push up on cell layers above, causing the topmost layers to 
flatten (Shojaei 1998). It was, therefore, hypothesised that transverse images revealing clear DAPI 
stained nuclei were less stratified than those with indistinct nuclear boundaries. Evidence of this 
can be seen in cells grown on transwell inserts (Figure 4.8), which is a better model than the 
coverslips for depicting proliferation/ stratification. 
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Figure 4.7 Representative confocal microscopic images of TR146 cells grown on collagen coated microscope 
coverslips in increasing Ca2+ fortified media, stained with DAPI (transverse plane). Distinct DAPI-stained nuclei 
could be seen by day 5, but unclear boundaries were observed as cells begin to flatten out by day 8. 
 
 
Figure 4.8 Representative confocal microscopic images of TR146 cells grown for 8 days on polycarbonate 
transwell inserts in increasing Ca2+ concentration, stained with DAPI (transverse plane). Indistinct cell 
boundaries at higher Caa2+ may account for higher stratification. 
4.3.2.3 MTT assay  
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay, which is 
dependent on the reduction of MTT by NAD(P)H-dependent oxidoreductase enzymes in rapidly 
metabolising or dividing cells to the purple formazan, was adapted as an indirect method to measure 
cell proliferation. After subculture, cells were seeded unto 96 well plates in media fortified with 
increasing Ca2+ concentrations. This was slightly different from the normal MTT assay where the 
test substance is added to already adhered and growing cells. This was done to determine the effect 
of Ca2+ concentration on the adhesion, proliferation and viability of the cells over 7 days. From 
Figure 4.9 which shows MTT results for cells grown in continuous Ca2+ exposure, on day 1, there 
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was a decrease in proliferation of cells in increasing calcium ion concentrations compared to the 
control; however, by day 2, all concentrations except 2.8 mM showed higher or equal proliferation 
as the control. This trend can be explained based on the fact that membrane damage caused by 
trypsinisation requires maintenance of calcium homeostasis to further promote proliferation.    
 
Figure 4.9 Results of MTT proliferation assay of TR146 cells grown in media continuously fortified with 
increasing calcium chloride concentrations, with respect to cells grown in normal (uncalcified) media used as 
control (n=24). Cells in 2.8 mM Ca2+ concentration showed significantly lower proliferation/ viability than the 
control. 
 
 
 
However, after membrane restoration and cell adhesion had been achieved by day 2, there was an 
increase seen in cell viability or proliferation, even above that of the control. On the other hand, 
increased mitochondrial activity due to increased need for calcium cycling could have also 
prompted this rise in formazan absorbance values; and obscured the results. So this test may not 
have been as representative as expected. For MTT assay of cells grown in media intermittently 
fortified (every other 24 hours) with increasing Ca2+ alternating with normal control culture media 
(Figure 4.10), higher cell viability was observed on days where calcium ion was added (days 2, 5 
and 7); as compared to days when fortified media was replaced by normal media (days 1, 3 and 5). 
For both continuous and intermittent exposures tested, cells in 2.8 mM Ca2+ concentration showed 
significantly lower proliferation and viability than the control. 
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Figure 4.10 Results of MTT proliferation assay of TR146 cells grown in media intermittently fortified (every 24 
hours) with increasing calcium chloride concentrations, with normal (uncalcified) media used as control (n=24). 
Cells in 2.8 mM Ca2+ concentration showed significantly lower proliferation/ viability than the control. 
 
 
4.3.2.4 Haemocytometry 
Results of cell count by haemocytometry are shown in Figure 4.11. Results showed that by days 1 
and 4, cells in 1.5mM Ca2+ media were significantly more than the other concentrations and the 
control. This result ties in with the light microscopy results seen in Figure 4.3 & Figure 4.4 above. 
However, by day 7, there was no significant difference in the number of cells between all 
concentrations tested and the control.   
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Figure 4.11 Cell count by haemocytometry results for proliferation of cells grown on 25cm2 T-flasks in media 
fortified with increasing calcium ion concentrations, with normal (uncalcified) media as control (n=12) 
4.3.2.5 Transepthelial electrical resistance (TEER)  
TEER is a sensitive index used to measure the integrity of intercellular junctions. It is based on 
Ohm’s law and measures the resistance to current flow when a potential difference is applied 
between the formed cell layer and the culture medium (Benson et al 2013).  TEER values in normal 
media (Figure 4.12) were seen to rise steadily to about 105 Ωcm2 on day 5, which corresponds to 
the formation of a monolayer (Figure 4.4), after a slight fall in TEER values on day 7, values rose 
to 127 Ωcm2 by day 9. A further fall in TEER values was recorded on day 14, with an increase on 
day 16 to 150 Ωcm2. Thereafter, TEER values rose steadily to about 190 Ωcm2 by day 26 and 
remained relatively constant until day 29.  
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Figure 4.12 TEER measurements for TR146 cells grown on 24 mm transwell inserts in normal media. Results are 
the mean of single measurements of 6 different transwell inserts (n=6). Proliferation pattern of cells in lower Ca2+ 
concentrations differed from that at higher concentrations of 1.5-1.8 mM, giving indications of the point when a 
complete monolayer was formed and stratification commenced. 
 
TEER values are expected to increase with age of culture and reach a plateau; with a significant 
fall in TEER associated with destruction of the cell layer and possible cell death (Gardner et al 
1997, Prytherch et al 2011). However, the latter increase in the observed TEER values indicates 
the formation of tighter layers (Prytherch et al 2011). Such fluctuations have been previously 
reported in literature (Gardner et al 1997, Prytherch et al 2011). It has been hypothesised that 
subsequent increase in TEER values may coincide with completion of stratifying layer formation 
and expression of desmosomal proteins yielding tighter intercellular junctions. Immunohistlogical 
and further microscopic assays will be necessary to validate this hypothesis. In calcium fortified 
media (Figure 4.12) at 1.2 mM Ca2+ concentration, cells showed identical proliferation patterns to 
that of the control media, while fluctuations in TEER values were absent at 1.5 mM and 1.8mM 
Ca2+ concentrations. The addition of calcium to culture media is expected to enhance cell-to cell 
adhesion and therefore increase TEER values. However, there was no significant difference in 
TEER values of cells grown at all Ca2+ concentrations tested compared with the control; except at 
on days 7 and 14 when the fall in TEER values was observed for control and 1.2 mM cells. 
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4.3.2.6 Permeability of paracellular and transcellular markers 
In order to verify that the proliferation and stratification enhancement observed from microscopic 
examination of TR146 cells grown in Ca2+ fortified media impacted on the permeation barrier 
provided by these cells, known paracellular transport markers (FITC dextran 4kDa, atenolol and 
propranolol HCl) and human insulin were employed for permeation studies. FITC-labelled dextran 
4kDa (FD4) has been reported to permeate cell layers via the paracellular route without the need 
for permeation enhancers, and therefore served as a convenient marker (Nielsen et al 1999). 
Amount of FD4 that permeated the TR146 cell layers from apical to basolateral direction was 
quantified using fluorescent spectrophotometry, and method validation results are highlighted in 
the appendix. Table 4.4 displays the permeability parameters for all drugs through the TR146 cell 
layers. FD4 transport was seen to display a bell shaped curve, with cells grown in 1.2 mM & 1.5 
mM Ca2+ concentrations exhibiting significantly lower permeation than the control. This result 
implies that tighter paracellular junctions were formed at these concentrations of extracellular Ca2+ 
and ties in with results observed from microscopic examinations and haemacytometry. However, 
the highest permeation of FD4 was observed at 1.8 mM Ca2+ concentration, and optimal Ca2+ 
concentrations were chosen at 1.2 - 1.5 mM.  Furthermore, to confirm that FD4 was transported 
paracellularly, after permeation experiments, cell layers were washed and stained with DAPI, then 
viewed by confocal microscopy and representative results are shown in Figure 4.13. It can be 
observed that FD4 was localised to the cell membrane and was totally absent from the nucleus, as 
depicted by DAPI staining.  
 
Figure 4.13 Representative confocal microscopic images of FITC-dextran 4kDa localisation (A) in the intercellular 
spaces of TR146 cells, showing paracellular transport (white arrows). DAPI stained nuclei (blue stain) (B) confirm 
the absence of the paracellular marker in the cell nucleus. 
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Table 4.4 Four hour permeability parameters of transport markers through TR146 cells grown in media fortified with increasing Ca2+ concentrations, normal media 
used as control (n=3). (*) represents the level of significant difference from the control (p<0.05) 
Marker Sample % permeated Papp (x10-6) Pcell (x10-6) % Recovery 
FITC dextran 4kDa 
0.5 mM 
Cont  19.10 ± 7.95 5.49 ± 1.72 9.17 ± 3.98 98.23 ± 3.77 
1.2  mM 8.76 ± 1.89** 3.70 ± 2.31 5.71 ± 5.16 98.33 ± 16.68 
1.5 mM 14.22 ± 1.68* 3.59 ± 0.54 4.74 ± 0.96 103.18 ± 4.32 
1.8 mM 23.06 ± 6.02** 6.20 ± 1.77 11.14 ± 5.72 115.48 ± 4.28 
Propranolol HCl 
0.1mM  
Cont  36.25 ± 2.14 10.89 ± 0.43 22.32 ± 1.76 95.97 ± 4.24 
1.2  mM 36.38 ± 1.63 10.77 ± 0.93 22.01 ± 4.00 99.77 ± 4.10 
1.5 mM 43.20 ± 2.06** 13.00 ± 0.12 33.32 ± 0.79 109.42 ± 6.32 
1.8 mM 40.66 ± 4.24** 12.53 ± 1.10 30.97 ± 6.67 101.11 ±8.89 
Propranolol HCl 
0.01mM 
  
  
Cont  69.99 ± 9.52 13.51 ± 2.04 18.59 ± 3.69 85.21 ± 11.33 
1.2  mM 84.05 ± 3.48*** 17.45 ± 2.02 26.89 ± 4.89 93.68 ± 4.87 
1.5 mM 77.52 ± 5.07* 14.47 ± 1.53 20.37 ± 2.95 90.42 ± 1.77 
1.8 mM 78.77 ± 1.77* 15.80 ± 0.92 23.06 ± 1.94 92.83 ± 0.90 
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Atenolol  
0.1mM 
  
  
Cont  43.62 ± 8.39 3.27 ± 0.59 4.87 ± 1.22 110.52 ± 7.90 
1.2  mM 52.58 ± 8.21* 3.87 ± 0.61 6.33 ± 1.64 115.70 ± 8.96 
1.5 mM 43.53 ± 4.49 3.49 ± 0.42 5.34 ± 0.96 94.49 ± 4.82 
1.8 mM 53.18 ± 3.42* 4.03 ± 0.32 6.70 ± 0.87 111.08 ± 2.87 
Insulin 
1mg/mL 
Cont  1.33 ± 0.26 0.84 ± 0.17 0.84 ± 0.17 74.74 ±  0.58 
1.2  mM 2.01 ± 0.14 1.06 ± 0.23 0.11 ± 0.23 102.26 ± 7.75 
1.5 mM 2.17 ± 0.38 1.22 ± 0.37 1.22 ± 0.37 104.21 ± 1.98 
1.8 mM 2.16 ± 0.10 1.12 ± 0.37 1.12 ± 0.37 103.44 ± 1.23 
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Propranolol is a highly lipophilic beta receptor blocker that quickly partitions into the lipid bilayer 
of cell membranes and is transported through the transcellular route (Dressman and Reppas 2010). 
Use of the hydrochloride salt reduces its lipophilicity, but the drug retained its high permeability 
with up to 85% drug permeation observed in 1.2mM cells after 4 hours (Table 4.4). There was a 
significantly lower permeability of propranolol observed in the control and 1.5mM Ca cells, than 
in the 1.2 and 1.8mM. Penetration of the highly hydrophilic beta-blocker, atenolol was much lower 
than that of propranolol as expected, with maximum permeation of <55% in all cells tested. The 
high hydrophilicity of atenolol restricts its transport to the paracellular route, and this is a better 
model to study paracellular transport than propranolol HCL. However, a similar trend to that seen 
with propranolol HCl permeation was observed. Control and 1.5mM cells had almost identical 
permeation profiles, and by 2.5hrs were significantly lower than 1.2 and 1.8mM cells; 1.2mM cells 
showed the highest permeation of atenolol. As the presence of calcium in the extracellular fluid is 
expected to enhance intercellular attachment and stratification by alignment and formation of 
desmosomes, it was expected that a greater barrier to permeability than the control would be seen 
with increasing Ca2+ concentrations; however this was not the case for these small molecules.  
Results for permeation of recombinant human insulin are also highlighted in Table 4.4. It was 
observed that the control showed the highest barrier to insulin permeation than cells in all Ca2+ 
fortified media. However, confocal microscopic results of permeation of FITC labelled insulin 
through TR146 control cells (Figure 4.14) revealed that insulin permeated the cell layers via the 
transcellular route, and not the paracellular route. A similar finding was reported by Thompson et 
al (2011) who investigated the transport of FITC-insulin across Caco-2 cell lines (model for the 
small intestine) and reported localisation of FITC-insulin in the cell cytoplasm after 30 minutes 
exposure at 3µg/ mL. These results for insulin suggest that although paracellular integrity of TR146 
cells may be enhanced in the presence of 1.5 mM Ca2+ added to the specialised culture media for 
these cells, this effect may not translate to the transcellular pathway, and effect on biochemical 
composition, protein expression and lipid barrier need to be further investigated for these modified 
cell lines. 
Chapter Four 
157 
 
 
Figure 4.14 Representative confocal microscopic images of FITC-insulin (A) localisation and DAPI nuclear stain 
(B) on control TR146 cells. DAPI staining confirms localisation of FITC insulin in the nucleus (white arrows) 
 
4.4 Conclusion 
Ca2+ has been shown to regulate the proliferation and/ or stratification of cells in vitro, depending 
on the concentration employed. Results from microscopic examination revealed that addition of 
1.5 mM Ca2+ to the specialised media for TR146 cells yielded enhanced proliferation and 
stratification of cells in vitro. Investigation of the effectiveness of this enhancement on the 
permeation barrier to paracellular transport of large and small molecules revealed a concentration 
dependent increase in the penetration barrier to large molecules like FITC-labelled dextran 4kDa 
which was transported via the paracellular route. For small molecules transported via the 
paracellular route (atenolol and propranolol HCl), and a large peptide transported via the 
transcellular route (insulin), no positive effect on enhancing the permeation barrier was observed, 
with 1.5 mM Ca2+ showing similar permeation barrier to the control; lower than other 
concentrations tested. Ca2+ enhancement of the barrier to paracellular transport was expected since 
calcium is a major component of desmosomal proteins that attach cells together. Thus, 1.5mM 
extracellular Ca2+ concentration was the optimal concentration that was able to enhance cell 
proliferation, cell stratification and enhance the permeation barrier of large paracellularly 
transported molecules. However, the effect of extracellular Ca2+ concentration on the biochemical 
composition, protein expression and lipid barrier; as well as on desmosome formation and 
alignment, need to be further investigated for these modified cell lines 
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Protein quantification and 
characterisation
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5.1 Introduction 
5.1.1 Protein structure and aggregation 
Proteins are macromolecules made up of polypeptides which comprise of amino acids linked by 
peptidic/ amide (-CONH-) bonds. Protein structure is determined by amino acid composition and 
sequence of the polypeptide chain, and this structure determines the function (or loss of function) 
of a particular protein (Walsh 2007). The primary protein structure refers to the precise amino acid 
sequence and location of disulphide linkages. The secondary structure describes the conformation 
of the polypeptide backbone in space, without taking into cognisance the amino acid sequence. 
These can be ‘twisting’ (α –helix) or ‘zig-zag/ parallel’ (β-Sheets). The tertiary structure of the 
protein relates to the three-dimensional positioning of all the constituent atoms of the peptide in 
space, to one another; and tertiary protein structure may be analysed by x-ray diffraction, nuclear 
magnetic resonance and electron microscopy (Walsh 2007). The quaternary protein structure is 
obtained when two or more protein molecules associate together to form dimers. Overall, protein 
structure is stabilised by hydrophobic interactions, electrostatic attractions as well as covalent 
linkages. Because most polypeptides consists of mainly non-polar amino acid residues, these 
residues align themselves in a manner that minimises interactions with the polar surrounding 
aqueous environment, thus causing the proteins to fold. Therefore, hydrophobic interactions 
contribute the most to stabilising the native structure and functionality of the protein (Walsh 2007). 
Electrostatic attractions include hydrogen bonding, Van der Waals attractions and ionic 
interactions, while covalent bonds are generated by the disulphide linkages present in the 
polypeptides. Protein functionality is closely related to its stability and conformation/ structure, 
therefore it is important to monitor changes (if any) in protein conformation during processing, 
manufacture and usage (Walsh 2007). 
5.1.2  Insulin 
The biologically active and circulating form of human insulin (Figure 5.1) is a polypeptide 
comprising 2 amino acid chains linked by two di-sulfide linkages afforded by cysteine. It contains 
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51 amino acids; 21 amino acids make up the A chain and 30 make up the B chain; with molecular 
weight of 5800 Da. A di-sulphide linkage exists within the A chain (Sarmento et al 2006). Insulin 
is administered subcutaneously for the management of insulin-dependent diabetes in patients 
whose pancreas do not produce insulin, or those whose cells have low insulin sensitivity. It is also 
the most important hormone in the regulation of glucose homeostasis in the body (Xu et al 2006).  
 
Figure 5.1 Primary structure of insulin showing A and B polypeptide chains, with inter- and intra-molecular di-
sulphide bridges (Snyder et al 2012) 
Insulin was isolated in 1921 by Frederick Banting and Charles Best in John Macleod’s laboratory 
in Canada. The protein has since been administered by the parenteral route due to stability and 
bioavailability challenges associated with oral administration. However, attendant complications 
related to insulin parenteral therapy have driven the on-going search for non-invasive methods of 
insulin delivery. 
5.1.3 Circular dichroism (CD) 
Circular dichroism (CD) is a spectrophotometric method that analyses changes in protein 
secondary structural conformation in the liquid state, using circularly polarised light (Whitmore 
and Wallace 2004). Plane polarised light comprises two circularly polarised components of equal 
magnitude - one rotating clockwise (right-handed) and the other anti-clockwise (left-handed). If 
these components are not absorbed upon passage through a sample, or if they are equally absorbed, 
the resulting radiation would occur in the same plane (Figure 5.2). If however, the two components 
are absorbed to different magnitudes, the resulting radiation will be skewed in the direction of the 
larger component and would be said to exhibit “elliptical polarisation” (Kelly et al 2005).  
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Figure 5.2 The circular dichroism effect. I: Equal absorption of left and right circularly polarised components of 
plane polarised light resulting in plane polarised radiation. II: Absorption of components to different magnitude 
resulting in skewed/ elliptical polarisation (Kelly et al 2005) 
Thus, CD measures the difference in radiation of these two components, or the elliptical 
polarisation, and can only be applied to materials/ compounds with differential absorption of 
circularly polarised light. Spectropolarimeters measure the difference in absorbance (ΔA) of left 
(AL) and right (AR) circularly polarised components, (ΔA = AL – AR). This change is defined in 
terms of ellipticity, ө.  
The advancement in production of therapeutic proteins by recombinant technologies has advanced 
science; but this has also exposed some challenges. Some of these include short serum half-life, 
immune responses and/ or reduced bioavailability of the protein. These occur mainly because 
production, purification and storage processes could affect the stereochemical structure of the 
protein causing unfolding and/ or aggregation (Bertucci et al 2011). Thus, it is important to carry 
out techniques that monitor these changes whenever they are likely to occur.  
Different information may be extracted from CD studies and they include: composition of the 
secondary structure of the protein, tertiary structure fingerprint, co-factor binding sites integrity, 
conformational changes in proteins, overall structural features and protein folding (Kelly et al 
2005). For the purpose of this work, discussions will be limited to secondary structure and 
conformational changes. Figure 5.3 shows the CD spectra of different protein secondary structures 
in the far UV region. Databases comprising information on the structure of various proteins whose 
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structures have been ascertained by methods such as x-ray crystallography etc. have been 
developed.  When the data from a CD spectrum is inputted into the database, the contribution of 
each protein molecule is used to elucidate the overall secondary structure of the protein (Whitmore 
and Wallace 2008). 
 
Figure 5.3 Circular dichroism spectra showing representative secondary structures of some proteins and peptides 
(Greenfield (2007), data supplied by W. C. Johnson) 
Generally for insulin, α-helix shows a maximum at about 193 nm, and two minima at 208 and 222 
nm; anti-parallel β-sheets show one maxima at 195 nm, and a minimum at about 216 nm; while 
disordered proteins are characterised by low ellipticity above 210 nm and negative bands near 195 
nm (Chen et al 1974, Bouchard et al 2000, Greenfield 2007).  
5.1.4 High performance liquid chromatography (HPLC) 
HPLC is an analytical technique used for the separation, isolation and quantification of components 
of a sample (Aguilar 2004). HPLC is often employed for the quantitative analysis of 
pharmaceutical products because chemical methods (such as iodometry or colorimetry) and some 
spectrophotometric methods commonly employed have limited specificity, with chemical methods 
showing lower precision; while gas chromatography cannot be effectively utilised because of the 
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thermolabile nature of many pharmaceuticals (Nachtmann 1979, Roškar and Lušin 2012). HPLC 
also allows for rapid analysis of different drugs and their metabolites (Chan et al 1986). As a 
process, HPLC involves the introduction of a small volume of liquid sample into a column packed 
with minute particles (the stationary phase), and a solvent system (the mobile phase) is used to 
force the sample through the column under high pressure with the aid of a pump. The components 
of the liquid sample are then separated from each other by the stationary phase based on physical 
and/ or chemical interactions of the sample with the stationary phase and/ or the mobile phase 
(Aguilar 2004). The separated components are transferred at the end of the column through a 
detector, which measures their signal and produces the results as a liquid chromatogram. The most 
common detectors used being UV, fluorescence and refractive index detectors. 
There are two phases of HPLC; normal phase HPLC utilises a highly polar stationary phase and a 
non-polar mobile phase, while reverse phase HPLC (more commonly used) employs a non-polar 
stationary phase and a less polar solvent system as the mobile phase. Two elution techniques are 
also employed and they include the isocratic elution, in which the composition of the mobile phase 
remains constant throughout the chromatographic run, and gradient elution where there is a change 
in mobile phase composition with time, leading to increasing elution, strength throughout the run. 
Gradient HPLC is preferred because it can effectively separate samples containing mixtures of 
solutes with various retention capacities (Aguilar 2004). However, isocratic HPLC can be used for 
analysis of simple solutions conveniently and is less expensive. 
HPLC has found increasing applications in the isolation and purification of peptides and proteins 
in recent years. Proteins like insulin have been quantified using biological assays in the past. These 
assays, though specific, were limited by their ineffectiveness at detecting very low doses, and could 
not identify contaminant or decomposition products; hence, the increased use of HPLC (Grego and 
Hearn 1981). However, the chemical nature and size of proteins makes their HPLC difficult 
because various factors such as temperature and pH need to be optimised (Rajan et al 2006, Moussa 
et al 2010). The official monographs (British Pharmacopoeia, United States Pharmacopoeia, 
European Pharmacopoeia) contain methods for the detection and assay of insulin by HPLC, but 
Chapter Five 
164 
 
these methods require extended runtimes, or the use of elevated temperatures (Rajan et al 2006, 
Sarmento et al 2007). Various researchers have also employed HPLC for quantification of insulin 
in literature (Table 5.1) using buffered (Oliva et al 2000, Rajan et al 2006, Moussa et al 2010, 
Makhlof et al 2011, Yilmaz et al 2012) and unbuffered mobile phases (Sarmento et al 2006, Amidi 
et al 2008). However, these methods require either the use of elevated temperatures, specialised 
detectors or resulted in long run times. More importantly, difficulty in reproducing methods 
obtained from published literature in different laboratories using different equipment is a constant 
challenge. The onus, therefore, is on the researcher to develop and validate a suitable reproducible 
method for quantification of these proteins. The said method should ideally be carried out at room 
temperature, with as few variables as possible. 
The aim of this work, therefore, was to describe our implementation of a literature derived method 
and step-by-step progression within our laboratory to establish a simple, rapid and effective method 
for quantification of insulin by HPLC, which would be validated by ICH guidelines (ICH 1996) 
and can be reproduced in any laboratory using simple UV detectors at room temperature. 
Furthermore, because changes in protein structure/ conformation that might occur during 
processing affect protein stability and functionality, the effect of compaction pressure on insulin 
secondary structures was also investigated. 
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Table 5.1 Some HPLC methods for insulin quantification in literature 
Column Mobile phase Detector/ wavelength Reference 
 
RP-Intersil C18 
column (250mm 
x4.6mm) 
Acetonitrile / 0.1M NaH2PO4/0.05 M Na2SO4 (30:35:35, v/v, pH 2.5). UV/visible detector 
214nm 
(Makhlof et al 2011)  
RP C18 column Gradient elution with Acetonitrile/ 0.1% trifluoroacetic acid (TFA) UV detector  
214 nm 
 
(Sarmento et al 2006) 
C18 column 
(300x7.8mm i.d; 
5μm particles with 
poresize 300Å) 
 
0.2M sodium suphate buffer (pH 2.3) and acetonitrile (74:26). UV detector 
 214nm 
(Oliva et al 2000) 
C18 column 
(150x4.6mm; 5 μm 
particles) 
Solutions A and B (60:40v/v). 
 A: 1mmol Na2S04 and 0.2% triethylamine in water, pH adjusted to 
3.2 by phosphoric acid. B:acetonitrile 
 
UV turnable absorption 
detector 
214 nm 
(Rajan et al 2006) 
C-18 (30x4.6, 3μm) 
 
Solutions A and B (48:52v/v) 45-50degC. 
A: 56.8 Na2S0 in WFI, adjust pH to 2.3 with o-phosphoric acid and 
filter. B: 28.5g Na2S0 in 400mL WFI, adjust pH to 2.3 with o-
phosphoric acid; make up to 1L with WFI; and up to 2L with 
acetonitrile. Flow rate 1mL/min 
 
UV detector 
214 nm 
(Moussa et al 2010) 
C18 (5µm, 4.6 x 
250mm) 
0.2M sodium sulphate/ acetonitrile (pH adjusted to 2.4 with 
phosphoric acid), 25:75v/v, flow rate 1.2mL/min 
 
Diode array detection 
206 nm 
(Yilmaz et al 2012) 
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5.2 Materials and methods 
5.2.1 Materials 
Human recombinant insulin powder, phosphate buffered saline (PBS) tablets, triethylamine and 
anhydrous sodium sulphate were purchased from Sigma-Aldrich, UK; while o-phosphoric acid and 
hydrochloric acid were purchased from Fisher Scientific, UK. All water used was double distilled. 
5.2.2 Methods 
5.2.2.1 High performance liquid chromatography (HPLC) assay 
Gradient RP-HPLC was employed for quantitative analysis of insulin in solution and was adapted 
from Rajan et al (2006). A Dionex 1100 autosampler (AS50) system, with gradient pump (GP50), 
UV detector (UVD 170U) set at 230 nm was used, employing a reversed phase RP-C18 analytical 
column (Phenomenex 110A, 150x4.6 mm, 5 µm). The mobile phase consisted of solution A: 
1mmol sodium sulphate and 0.2% v/v triethylamine in water, pH adjusted to 3.2 with o-phosphoric 
acid; and solution B: acetonitrile; both filtered under vacuum and sonicated (Rajan et al 2006). A 
gentle gradient was run from 75:25 v/v to 60:40 v/v compositions of A:B over 5 mins, and then 
maintained at 60:40 v/v for 2 minutes. Pump flow rate was 1.5 mL/min, with sample injection 
volume of 20 µL. The maximum wavelength of absorption of insulin had been pre-determined 
using a Unicam UV-visible spectrophotometer. Finally a rectilinear (Beer-Lamberts) calibration 
curve was established for insulin within a concentration range of 10-1000 µg/mL dissolved in 
0.01N HCl. 
5.2.2.2 HPLC assay validation 
The HPLC method was validated according to ICH guidelines in terms of specificity, accuracy, 
precision, linearity, limits of detection/ quantification and stability of insulin solutions (Sarmento 
et al 2006, Moussa et al 2010). 
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5.2.2.2.1 Specificity (identification and assay) 
20 μL of 200 mg/mL insulin and 0.01N HCl solutions respectively were separately injected into 
the HPLC system, retention time and resulting chromatograms were recorded. Insulin percentage 
recovery (the calculated concentration of insulin relative to the actual concentration used) was 
calculated using the regression equation obtained from linearity experiments below. 
5.2.2.2.2 Linearity 
A Beer-Lamberts calibration curve was developed by plotting mean peak area against insulin 
concentration. Linearity was estimated by computing the regression line of the calibration curve 
for insulin concentration from 10-1000 μg/mL; the correlation coefficient (R2) was calculated.  
5.2.2.2.3 Accuracy 
20 μL aliquots of standard solutions were injected into the HPLC system and the protocol described 
for linearity above followed. The areas under the curve for insulin were recorded and the percentage 
recovery was calculated using the regression equation.  
5.2.2.2.4 Precision 
Operator precision was determined by developing the insulin calibration curve in triplicates. The 
area under the curve was calculated by the HPLC software and relative standard deviation (RSD) 
was calculated using the equation below:  
𝑅𝑆𝐷 =  
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑚𝑒𝑎𝑛
 . . . . . . (Equation 5.1) 
Calibration curves were repeated on different days (n=6 or 9) using freshly prepared mobile phase 
and the RSD calculated.  
5.2.2.2.5 Limit of detection (LOD) & limit of quantification (LOQ) 
The LOD and LOQ were determined by the signal-to-noise ratio method (Xu et al 2002, Moslemi 
et al 2003). 20 μL of 0.01 N HCl blank was injected into the HPLC system twenty times and the 
mean peak area recorded. The standard deviation of the recorded peak areas was multiplied by 3 
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and 10 to calculate the LOD and LOQ respectively. This was repeated twice for two different 
samples of the blank, in order to validate the obtained results (Moussa et al 2010).  
5.2.2.2.6 Inter-laboratory method validation 
The validated method was further validated by an independent operator in a different laboratory 
using a different HPLC system on different days to establish method reproducibility. 
5.2.2.3 Stability of insulin solutions 
1000 μg/mL insulin solution was freshly prepared in triplicates and immediately analysed on the 
HPLC system. The solutions were stored in the fridge (2 - 8 °C) and quantified after three days (72 
hrs). The peak areas and RSD were recorded. 
5.2.2.4 Circular dichroism (CD) 
The far UV circular dichroism spectrum of insulin from 290 - 190nm was recorded on a Jasco J-
715 spectropolarimeter (Tokyo, Japan). The sample concentration was 1mg/mL insulin in PBS, pH 
7.4. The cell path length was 0.01 cm, 2 nm bandwidth, 200 nm/min scan rate, data acquisition 
interval 0.5 nm and 8 accumulations. To determine the effect (if any) of tablet compaction pressure 
on insulin conformation, CD data was also collected for neat insulin tablets compressed at 10 and 
30 kN compaction pressure respectively, dissolved in sufficient PBS to yield a concentration of 1 
mg/mL. Mean residue ellipticities, [θ]λ were calculated from the equation: 
[θ]λ =  θλM0Cl  . . . . . . . (Equation 5.2) 
where θλ is the observed ellipticity at wavelength λ, M0 is the residue molecular weight for the 
protein calculated as 116 for insulin, C is the protein concentration in g/mL and l is the optical path 
length in cm (Goldman and Carpenter 1974). The composition ratio of the protein secondary 
structure was computed using CDSSTR algorithm of the online CD analysis software, Dichroweb 
(Whitmore and Wallace 2004). Statistical analysis of reliability/ validity of CD analysis were 
carried out using normalised root mean square deviation (NRMSD) and comparison plots of 
calculated and experimental spectra generated.  
Chapter Five 
169 
 
5.2.2.5 Fourier transform infra-red (FTIR) spectroscopy   
To identify processing effects on the functional groups present in insulin pre- and post-
compression, FTIR spectroscopy was carried out on insulin powder and neat tablets compacted at 
10 and 30 kN using a Nicolet IS5 FTIR spectrometer equipped with an iD5 attenuated total 
reflectance (ATR) diamond from Thermo Fisher Scientific (Massachusetts, USA). A small mass 
of dry powder was lightly sprinkled (or tablet gently placed) on the lens and after measurements 
the accompanying software identified the available peaks.  
5.3  Results and discussion 
5.3.1  HPLC method development for quantification of insulin 
The HPLC method development began with a method adapted from Rajan et al (2006), employing 
an isocratic elution using a mobile phase comprising 40 volumes of solution A (1mmol sodium 
sulphate and 0.2% triethylamine (TEA) in water, pH adjusted to 3.2 with o-phosphoric acid), and 
60 volumes of solution B (acetonitrile); UV detection at 214 nm. This method was employed 
instead of the USP or BP methods, because unlike these official methods that were run at elevated 
temperatures, the chosen method could be run at room temperature and had less than half the 
retention time expected from the BP and USP methods. Thus, it minimised the possible variables 
in the HPLC system. Using this system, insulin eluted almost immediately at about 1 min (Figure 
5.4).  
 
Figure 5.4 Representative chromatogram of 0.5mg/mL insulin in 0.01N HCl at 214nm. Insulin peak was poorly 
resolved and eluted off the column in about 1 min 
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The resulting peak was poorly resolved with an accompanying hump. Running a blank solution 
(containing 0.01N HCl) on the HPLC system showed solvent front coming off the column at about 
the same retention time as the drug (Figure 5.5). Thus, the hump on the insulin chromatogram 
resulted from the overlapping of the drug peak with that of the solvent front (Xu et al 2006). RP-
HPLC exploits the interactions between the hydrophobic regions of insulin and that of the 
stationary phase (Moslemi et al 2003). Fast elution of insulin off the column implied very low 
affinity of insulin for the non-polar column. Generally in reversed phase HPLC, the interaction of 
hydrophobic analyte with the n-alkyl chain of the column would lead to longer retention of the 
analyte on the column. But the presence of steric hindrances in large molecules like insulin may 
restrict access of insulin molecules to the pores of the stationary phase where these interactions 
take place (Gerber et al 2004).  Also, the presence of polar groups (-NH2, COO–) in the insulin 
moiety would increase the affinity of insulin for the highly aqueous mobile phase, and result in fast 
elution of insulin. These factors could account for the observed immediate elution of insulin off 
the column (Aguilar 2004).  
 
Figure 5.5  Chromatogram showing elution of the solvent front (blue line) at about the same time as insulin (black 
line), resulting in poor resolution of the insulin peak. 
  
According to the BP 2013, “insulin is practically insoluble in water” (despite the presence of –OH 
and –NH bonds in the comprising amino acids); however, some authors have reported insulin as 
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highly water soluble (Xu et al 2006). It was expected that hydrophobic insulin would interact with 
the non-polar column (reverse-phase HPLC) and would, therefore, have a longer retention time on 
the column (Aguilar 2004). As this was not the case as discussed above, reducing the non-polar 
organic modifier in the mobile phase would reduce the interaction of insulin with the mobile phase 
(increased mobile phase polarity), thereby increasing insulin’s interaction with the non-polar 
column; ultimately resulting in an increase in insulin retention time (Lindsay and Kealey 1987). 
Thus, various mobile phase compositions (from 50:50 to 75:25) were employed in an attempt to 
increase insulin’s retention time, and thereby separate the drug peak from that of the solvent front. 
A mobile phase composition of solution A:B 70:30 resulted in  an increase in insulin retention time 
from 1 to 2 minutes. However, this minimal shift was not sufficient to completely separate the 
insulin peak from that of the solvent front. This minimal shift in insulin retention time despite a 
10% change in mobile phase composition could be attributed to the large size of insulin molecules, 
as large molecules may not easily enter the pores of the column to increase column retention 
(Gerber et al 2004) .   
A further reduction in the amount of the organic modifier used would be expected to further 
increase the retention time of insulin for reasons discussed above. However, the final composition 
of the mobile phase would be highly aqueous and would not effect a complete separation of other 
impurities or degradation products when utilising this method for quantification of insulin from 
samples. Moreso, highly polar aqueous phases may result in poor retention and separation due to 
the collapse of the octadecyl alkyl side chains in the stationary column (Olsen 2001). Xu et al 
(2006) reported an increase in insulin retention time with increasing acetonitrile content of the 
mobile phase. 
At this point, it became necessary to run a blind HPLC to determine the exact mobile phase 
composition where insulin elutes off the column. Thus, a gradient HPLC was run from 80 – 20% 
for solution A and 20 – 80% for solution B. From Figure 5.6, it was observed that insulin eluted at 
about 6 minutes which was equivalent to mobile phase composition of 60:40 for solution A:B. 
Thus, insulin was eluted off the column immediately the mobile phase composition turned to 60:40, 
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and using an isocratic system would always produce a poorly resolved peak because of interference 
from the solvent front. Also the resultant peak caused an upward shift in the baseline, probably due 
to the changing gradient.  
In order to obtain a better resolved insulin peak, we further investigated the role of the mobile phase 
additives in the HPLC quantification. Triethylamine (TEA) was used in the mobile phase to 
facilitate end-capping of the free silanol groups on the reversed phase column, resulting in the 
prevention of band tailing in HPLC (Dolan and Snyder 1989, Li et al 2000). However, TEA is 
easily degraded and has been implicated to interfere with UV absorption because it has a high UV-
cut off above 190 nm. This means that TEA can be picked up by the detector and would interfere 
with the resolution of obtained peaks. Because the column had been described as endcapped by the 
manufacturers, it would be irrelevant to retain TEA in the mobile phase if it was interfering with 
the results. 
 
Figure 5.6 HPLC chromatogram showing insulin elution at 6 minute upon gradient elution from solution A:B 
80:20 to 20:80. An upward shift in the baseline may be due to the changing gradient. 
Thus, TEA was removed from solution A and a gradient HPLC repeated with solution A (1mmol 
sodium sulphate in water, pH adjusted to 3.2 with o-phosphoric acid) 80 – 20% and solution B 
(acetonitrile) 20 – 80%. The resulting chromatogram produced no peak for insulin even after 30 
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minutes, signifying the importance of TEA for insulin elution. Thus, although a column may be 
claimed to be end capped by the manufacturers, this process might not completely mop up the free 
silanol groups. This, as well as column use and age, would necessitate the addition of a moiety like 
TEA to compete with the analyte for the free silanol groups on the column. 
Following the unsuccessful reproduction of the HPLC method adapted from the journal article, a 
return to first principles was necessary, and a UV scan was run for 0.5 mg/mL insulin in 0.01N 
HCl. The spectrum displayed two maximum wavelength peaks - a major peak at 230 nm and a 
smaller peak at 275 nm. Thus, a HPLC gradient (80:20 to 20:80) was run at 214, 230 and 275 nm 
respectively. From Figure 5.7, it can be seen that at 214 nm, there was an upward shift in the 
baseline, at 275 nm, the insulin peak was highly reduced; while at 230 nm, a well resolved peak 
with a relatively stable baseline was achieved. Thus, 230 nm was chosen as the wavelength for 
recombinant insulin detection. 
 
Figure 5.7 Chromatograms showing insulin elution at various wavelengths: 214 nm (black), 230 nm (blue), and 
275 nm (pink). 
Because insulin eluted off the column immediately when the mobile phase composition was 60:40, 
and this early elution resulted in a poorly resolved peak due to the concurrent appearance of the 
solvent front, isocratic HPLC could not be applied to this system.  A gradient (80:20 to 20:80 v/v) 
HPLC for insulin was run at 230 nm and resulted in a well resolved peak with a relatively stable 
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baseline, and no interference from the solvent front, and elution after about 4 minutes was obtained 
(Figure 5.8). After it had been established that insulin eluted off the column at 60:40 mobile phase 
composition, it was not necessary to continue the steep 80:20 to 20:80 gradient, it seemed necessary 
to employ a gentle gradient. To determine the optimum gradient for separation, the following 
gradients were run:  
Option 1 Option 2 
0-5 mins: 75:25 - 50:50 
5-7 mins: 50:50 - 50:50 
7-10 mins: 50:50 - 75:25 
0-5 mins: 70:30 - 45:55 
5-7 mins: 50:50 - 50:50 
7-10 mins: 50:50 - 75:25 
 
The resulting chromatogram for option 1 showed a well resolved peak, completely separated from 
the solvent front, with a slight shifting of the baseline. Modification of the gradient to option 2 
resulted in a poorly resolved peak, which eluted off the column very fast and showed solvent front 
interference. Thus, the first protocol was maintained. 
 
 
Figure 5.8 Chromatogram showing gradient elution of insulin from mobile phase composition A:B of 80:20 to 
20:80 at 230 nm UV detection wavelength 
Finally, to achieve a sharper peak, the flow rate was increased to 2 mL/min. A sharper insulin peak 
was achieved but it eluted off the column at 2 minutes. Gerber et al (2004) reported that increased 
flow rate could reduce retention times, increase baseline noise and produce narrower peaks. 
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Therefore, flowrate was maintained at an average of 1.5 mL/min. The chromatogram for the final 
method is shown in Figure 5.9 below: 
 
Figure 5.9 Representative chromatogram showing the developed method for insulin elution employing a gentle 
gradient at 230 nm detection wavelength and 1.5 mL/min flow rate 
5.3.2 HPLC assay validation 
5.3.2.1 Specificity 
To investigate the specificity of the HPLC method, 20 µL each of insulin in 0.01N HCl and the 
blank (0.01N HCl) were separately injected into the HPLC and chromatograms developed. Figure 
5.10 shows the chromatograms of insulin and the blank run in triplicate. From this chromatogram, 
the insulin peak was well resolved with retention time of 3.84 ± 0.08, there was no interference 
from the solvent front which eluted at 1.12 ± 0.04 mins (Table 5.2). It would be necessary to test 
all excipients of the formulated tablets to ensure specificity of the method for insulin in the presence 
of contaminants.  
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Figure 5.10 Representative chromatograms showing selectivity and instrument precision of HPLC method. 
Triplicate measurements of 500 µg/ mL insulin solution produced identical peaks that were well resolved from 
that of the blank. 
According to Gupta et al (2012), an assay shows specificity when the signal measured from the 
test compound show no interference with signals from other excipients at the test wavelength. As 
an evaluation of accuracy, insulin concentrations ranging from 50 – 500 µg/mL were used to 
calculate the percentage recovery of insulin using the described method. The mean absolute 
recovery value for insulin was 100.89 ± 1.40% (Table 5.4 below). These results connote that the 
developed method can quantify insulin effectively. However, the effect of dosage form excipients 
on the recovery of insulin using this method will need to be investigated (Xu et al 2006). 
5.3.2.2 Linearity  
A Beer-Lamberts calibration curve (Figure 5.11) was established for insulin over a concentration 
range of 10-1000 µg/mL by plotting the peak area from the chromatograms against the 
concentration. The regression analysis gave the equation of the line as y = 0.0543x - 1.0026, with 
R2 = 0.9993. Parameters of the regression coefficient are presented in Table 5.3.  The high 
correlation coefficient connotes a linear relationship between peak area and insulin concentration 
within the proposed range (Epshtein 2004, Sarmento et al 2006).  
Table 5.2 Specificity of insulin HPLC method 
S.N. Sample Retention time (min) % RSD 
1 Insulin 3.84 ± 0.08 2.08 
2 Blank (0.01N HCl) 1.12 ± 0.04 3.66 
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Therefore, the concentration of insulin in any sample can be calculated from this curve using this 
method. 
 
Figure 5.11 Beer-Lamberts calibration curve for insulin. 
5.3.2.3 Repeatability (instrument and operator precision) 
Instrument precision (accuracy) was determined by injecting the same concentration of insulin 
solution into the HPLC three times and calculating the %RSD. Figure 5.10 shows the overlapping 
of the three insulin chromatograms (lines 1-3), indicating precision of the instrument. From Table 
5.2, the RSD for insulin and the blank were relatively low at 2.01 and 3.66%, respectively. Similar 
results were obtained during validation of a HPLC method for insulin reported by Moussa et al 
(2010).  Operator precision was determined by establishing the calibration curve in triplicates. 
%RSD values calculated ranged from 7.7 – 9.76% (Table 5.4). 
Table 5.3 Factors of the regression equation linking insulin concentration to the analytical response (area under 
the peak) 
 Parameter Value 
 Linearity range, µg/mL 10-1000 
 
 LOD, µg /mL 0.63 
 
 LOQ, µg /mL 2.00 
 
 Slope of regression equation 0.05 
 
 Intercept -1.00 
 
 Correlation coefficient 0.99 
 
 Standard error 0.81 
 
y = 0.0543x - 1.0026
R² = 0.99
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Table 5.4 Table highlighting intra-day accuracy and precision parameters of the HPLC method due to high 
%recovery and low RSD (n=3) 
 Insulin conc. 
actual (µg/mL) 
Peak Area 
(mAU) 
RSD 
 
Insulin conc. 
calculated (µg/mL) 
 
Recovery (%) 
 50 1.78 ± 0.14 0.07 51.31 ± 2.55 100.56 ± 2.42 
 
 100 4.49 ± 0.43 0.10 101.11 ± 7.85 101.38 ± 4.89 
 
 200 9.27 ± 0.06 0.06 197.60 ± 10.14 98.80 ± 4.71 
 
 500 26.52 ± 2.59 0.10 506.90 ± 47.67 101.11 ± 3.99 
 
 1000 53.60 ± 3.72 0.07 1005.57 ± 68.56 102.63 ± 3.30 
 
 
Mean % recovery  =  100.89 ± 1.40% 
RSD % Recovery  =  0.01 
LOD = 0.63 µg /mL 
LOQ = 2.00 µg /mL 
 
Correlation coefficient  =  0.99 
 
 
  
These values were within the limits for precision as reported by Epshtein (2004). Inter-day 
precision was determined by establishing calibration curves on different days – results are shown 
in Table 5.5. The overall %RSD values ranged from 3.3 – 9.3%.  These values for %RSD are within 
the limits for precision. Ephstein (2004) reported that for precision in analysis of pharmaceuticals, 
%RSD should range between 0-15%. 
Table 5.5 Inter-day precision and accuracy parameters for HPLC method (n=6) 
Insulin conc. 
actual (µg/mL) 
Amount 
measured on day 
1 (µg/mL) 
 
RSD 
 
Amount 
measured on day 
2  (µg/mL) 
RSD 
  
Overall 
RSD 
  
50  51.31 ± 2.55  0.05  56.03 ± 4.37  0.08  0.08 
 
200  197.60 ± 10.14  0.05  202.43 ± 3.71  0.02 
 
0.04 
400  380.55 ± 22.20  0.06  397.27 ± 15.18  0.04  
 
0.05 
500  506.90 ± 47.67  0.09 457.48 ± 30.44  0.07  
 
0.09 
1000  1005.57 ± 68.56  0.06  1012.82 ± 55.61  0.05  
 
0.06 
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5.3.2.4 Limit of detection & limit of quantification 
The LOD and LOQ were calculated using the signal-to-noise ratio, as well as from the standard 
deviation of the response and the slope and were found to be 0.63 and 2.00 µg/mL respectively 
(Table 5.4). Thus, the lowest amount of insulin that can be detected and quantified respectively, 
within the limits of accuracy and precision, using this method are 0.63 and 2.0 μg/mL (Moslemi et 
al 2003, Sarmento et al 2006). 
5.3.2.5 Inter-laboratory method validation 
The HPLC method was validated according to ICH guidelines by an independent operator in a 
different laboratory and a different HPLC system on three different days, to assess the method’s 
reproducibility. Retention time was 3.70 ± 0.03 mins, with a peak well resolved from the solvent 
front (Figure 5.12). Regression analysis yielded equation of the line as y = 0.0851x - 1.2928 and 
R2 = 0.9998. Intra-day and inter-day results are presented in Table 5.6 and Table 5.7, respectively. 
From here, it can be seen that the method was reproducible with %RSD of 1-3%. well within the 
expected limits. Thus, this method could be reproduced in any laboratory and employed for the 
quantification of insulin from samples. 
 
Figure 5.12 Representative chromatogram of insulin elution during inter-laboratory validation of HPLC method 
at Liverpool John Moores University, UK. A well separated insulin peak with no interference from the mobile 
phase was seen. 
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Table 5.6 Intra-day HPLC validation parameters for insulin method carried out in a different laboratory, with a 
different operator and different HPLC system on the same day, to assess method reproducibility (n=3) 
 Insulin conc. 
actual (µg/mL) 
Insulin conc. 
calculated (µg/mL) 
 
RSD Recovery (%) RSD 
 62.5 55.60 ± 1.10 0.02 88.95 ± 1.76 0.02 
 
 125.0 120.01 ± 1.30 0.01 96.01 ± 1.04 0.01 
 
 250.0 254.47 ± 6.07 0.02 101.83 ± 2.43 0.02 
 
 500.0 513.29 ± 13.14 0.03 102.66 ± 2.63 0.03 
 
 1000.0 1003.48 ± 23.84 0.03 100.35 ± 2.38 0.02 
 
 
Mean % recovery      =    97.96 ± 5.65 
RSD % Recovery      =    0.02 
LOD = 0.53 µg /mL 
LOQ = 1.78 µg /mL 
 
 
Correlation coefficient  =  0.99 
 
 
5.3.3 Stability of insulin solutions  
Results of stability of 1000 μg/mL insulin solutions stored in the fridge for 72 hours are shown in 
Table 5.8. The percent recovery was calculated using the regression equation of the calibration 
curve. ANOVA for the peak areas and amount of insulin measured on both days showed no 
significant difference (p > 0.05). The overall %RSD of 7.94 – 8.07% shows that insulin solutions 
can be stored in the fridge for up to three days without deterioration.  
Table 5.7 Inter-day precision and accuracy parameters carried out in a different laboratory with a different 
operator and HPLC system on three different days, to assess method reproducibility (n=9) 
Insulin 
conc. 
actual 
(µg/mL) 
Amount 
measured on day 
1 (µg/mL) 
Amount 
measured on 
day 2  (µg/mL) 
Amount 
measured on day 
3  (µg/mL) 
Overall amount 
measured 
(µg/mL) 
Overall 
RSD 
62.5 55.60 ± 1.10 57.51 ± 2.98 59.43 ± 3.00 57.51 ± 1.91 0.03 
 
125.0 120.01 ± 1.30 123.40 ± 2.79 125.28 ± 6.81 122.90 ± 2.67 0.02 
 
250.0 254.47 ± 6.07 259.08 ± 3.28 257.82 ± 10.57 257.16 ± 2.33 0.01 
 
500.0 513.29 ± 13.14 521.10 ± 4.14 516.62 ± 22.13 517.00 ± 3.92 0.01 
 
1000.0 1003.48 ± 23.84 985.23 ± 10.22 985.94 ± 4.07 991.54± 10.34 0.01 
 
Mean % recovery = 96.06 ± 8.29% 
RSD % recovery = 0.09 
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 This is in line with results obtained by Moussa et al (2010), who reported that insulin solutions 
remained stable in the fridge for up to 5 days. 
Table 5.8 Stability of 1000 μg/mL insulin solutions after storage at 2 - 8 °C for 72 hours (n=3). Results show that 
insulin solutions are stable for 3 days when stored in the fridge. 
 Day 0 Day 3 Overall RSD 
Peak Area 
(mAU) 
62.32 
67.80 
54.15 
62.32 
61.37 
56.14 
0.08 
Amount measured 
(µg) 
1054.78 
1145.52 
919.45 
1052.54 
1036.66 
949.26 
0.07 
Mean % recovery = 102.64 ± 1.85% 
RSD %recovery = 0.08 
 
 
5.3.4 Effect of compaction pressure on the secondary structure of insulin 
5.3.4.1 Circular dichroism (CD) 
5.3.4.1.1  CD data verification 
The normalised root mean square deviation (NRMSD) for the CD analysis of the samples is 
highlighted in Table 5.9. NRMSD values illustrate the ‘goodness of fit’ or validity of the data and 
compares “how well the theoretical CD spectrum calculated from the derived secondary structure 
composition matches the experimental data over the whole wavelength range of interest” 
(Whitmore and Wallace 2004, Kelly et al 2005). This value ranged from 0.01- 0.012 for all samples 
tested. Basically, values over 0.25 reflect experimental errors. A value of zero implies a perfect fit. 
Thus, the CD results obtained were a very good fit. A representative plot comparing the calculated 
and experimental spectra for the samples are displayed in Figure 5.13 (others appear in the 
appendix). For all samples, the experimental and reconstructed data points were superimposed on 
the graph and the difference between them almost a completely straight line. The superimposition 
of both spectra, and absence of difference, confirms the validity of the data analysis (Whitmore 
and Wallace 2004).  
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Table 5.9 Parameters of CD analysis of insulin powder and insulin tablets compacted at 10 and 30 kN respectively 
(n=3). Normalised root mean square deviation (NRMSD) values close to zero depict the validity of the data 
generated. 
Parameter Neat insulin Insulin tablet  
at 10 kN 
Insulin tablet  
at 30 kN 
NRMSD 
 
0.01 0.01 0.01 
Helix per 100 residues 
 
5.48 5.69 5.69 
Strand segments per 100 residues 
 
2.54 2.52 2.77 
Mean helix length per segment 
 
8.25 8.66 8.33 
Mean strand length per segment 
 
4.21 4.10 4.08 
 
5.3.4.1.2 CD data interpretation 
Figure 5.14 shows the CD spectrum of insulin before, and after compaction at 10 and 30 kN, 
respectively. On analysis, the neat insulin spectrum exhibited two distinct negative minima at 
wavelengths of 208 and 222 nm, characteristic of α-helical structure (Goldman and Carpenter 1974, 
Oak and Singh 2012b). Proteins consisting of only the α-helical secondary structure would be 
expected to exhibit an ellipticity (ө) maximum, about double the ө minimum.  Because the 
maximum for the neat insulin appeared at <20mdeg, one would expect the presence of some other 
secondary structures in the protein. This was confirmed by results of analysis using the Dichroweb 
software (Table 5.10). As expected, the neat insulin was found to contain about 45% α-helix, 11% 
β-strands, 13% turns and 31% unordered secondary structures. This is in line with x-ray 
crystallisation results for insulin reported by Blundell et al (1971) and Bouchard et al (2000). 
Absorption in the far UV region (below 240 nm) has been attributed to the peptide bond, although 
in specific cases, the aromatic amino acid side chains of polypeptides may absorb in this region  
(Kelly et al 2005). 
The CD spectra of insulin tablets at 10 and 30 kN compaction pressures were superimposed on that 
of the neat insulin (Figure 5.14). ANOVA results of the secondary structure quantifications in 
Table 5.10 showed no significant difference (p > 0.05) between the neat and the tableted insulin. 
The contributions to the secondary structure were almost equal, and there was no shift in the 
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minimum wavelengths; thus, compaction pressures of 10 and 30 kN were not observed to affect 
insulin secondary structure. 
 
Figure 5.13 Plot of calculated and experimental CD spectra for neat insulin. The difference between the 
calculated/ reconstructed data and actual experimental data appears as a straight line, depicting the validity of 
the results generated. 
 
Figure 5.14 Circular dichroism spectrum of insulin powder (neat insulin) and pure insulin tableted at 10 and 30 
kN compaction pressures. Each sample was dissolved in sufficient quantities of PBS to prepare a 1 mg/mL solution 
 
Although no scientific papers could be found that compared the CD analysis of insulin before and 
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the protein would mean that the experimental variable had no significant effect on the secondary 
structure of the protein (Oak and Singh 2012a). Furthermore, it will be necessary to determine the 
effect on protein structure, of tablets containing excipients before and after transmucosal delivery. 
Table 5.10 Summary of CD data for insulin before and after compaction at 10 and 30 kN respectively (n=3). One-
way ANOVA results (P>0.99) showed no significant difference in quantitation of secondary structures in all 
samples 
Sample Helix 1 Helix 2 Strand 1 Strand 2 Turns Unordered Total 
Neat 
insulin 
 
0.23 0.22 0.06 0.05 0.13 0.31 1.00 
Insulin tab 
at 10 kN 
 
0.26 0.23 0.05 0.05 0.13 0.28 1.00 
Insulin tab 
at 30 kN 
 
0.25 0.23 0.06 0.06 0.14 0.27 1.01 
 
5.3.4.2 Fourier-transform infra-red (FTIR) 
FTIR spectra for insulin powder (Figure 5.15) was characterised by the presence of absorption 
bands for amide I (1644 cm-1) and amide II (1514 cm-1) which are due to -C=O stretching 
characteristic of protein structures. Similar results were obtained by Sarmento et al (2006). The 
amide I band around 1644 cm-1 has been observed in small α-helical peptides in water (Bredenbeck 
et al 2005). This observation was in line with the high α-helical structure of insulin obtained from 
CD data. Second derivative FTIR analysis of the amide I region has been reported to separate and 
identify other secondary structures such as beta-sheets and random coil (Bouchard et al 2000, 
Nielsen et al 2001). Analysis of the FTIR data from the tableted drug (Figure 5.15) showed 
identical spectra to the insulin powder in the amide I and amide II regions. This result was expected, 
and correlates nicely with results from CD studies indicating that compaction pressure did not 
significantly affect the secondary structure of the insulin powder. 
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Figure 5.15 FTIR spectra of insulin before and after compaction at 10 and 30 kN, showing the amide I and amide 
II absorption bands. Identical spectral patterns were obtained pre- and post-compaction, highlighting that 
compaction did not affect the secondary structure of insulin. 
 
5.4 Conclusion 
Considering the complex nature of proteins, the aim of this work was two-fold. Firstly, to describe 
the steps involved in our optimisation and validation of a simple, rapid and efficient method for 
insulin quantification by HPLC that could be reproduced in any laboratory at room temperature. 
And secondly, to characterise our protein using circular dichroism (CD) and FTIR and then 
investigate the effect that compression into tablets had on its secondary structure, which could 
affect protein activity in vivo. Insulin was effectively eluted at 3.8 mins with no interference from 
the solvent front. The method was validated in our laboratories and independent operator 
laboratories with similar results that complied with the ICH guidelines for HPLC method 
validation. Thus, the developed method is rapid with short runtime, at room temperature with 
simple UV detectors, and low detection and quantification limits, which can be employed for the 
HPLC quantification of insulin from any sample with high reproducibility from other laboratories. 
CD evaluation of insulin secondary structure revealed majorly an α-helical structure, with the 
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presence of some β sheets, turns and unordered secondary structures. FTIR spectroscopy also 
identified amide I and II bands, which are characteristic of proteins, with the amide I band 
specifically found in small α-helical peptides. CD and FTIR results showed that insulin secondary 
structure was not affected by compaction at elevated pressures. Thus, the developed HPLC method 
can be employed for the HPLC quantification of insulin from any sample, and compaction 
pressures up to 30 kN may be used for insulin without affecting its structural integrity. However, 
the effect of formulation additives on insulin HPLC specificity and on insulin integrity upon 
transmucosal permeation would need to be studied. 
 
 
 
 
Chapter Six 
187 
 
 
 
Chapter 6 
Pre-formulation and systematic 
evaluation of amino acid assisted 
permeability of insulin across buccal 
cell layers in vitro 
 
 
 
 
 
 
 
 
 
 
 
 
Publications relating to chapter 6 
 
Iyire, A.; Alayedi, M; Mohammed A.R. (2016) Pre-formulation and systematic evaluation of 
amino acid assisted permeation of insulin via buccal cell layers. Nature Scientific Reports 
(accepted) 
Chapter Six 
188 
 
6.1 Introduction 
The primary driving factor for investigating non-invasive routes for insulin delivery are built on 
obtaining stringent blood glucose control (that mimics the situation found in non-diabetics) in 
diabetic patients, by reducing/removing the need for multiple daily injections of insulin that puts a 
major strain on patient compliance (Owens et al 2003). On the other hand, mucosal delivery of 
biologicals has been reported to be less effective than parenteral delivery for various reasons, 
including limited mucosal permeation, as well as absorption site metabolism (Veuillez et al 2001). 
However, high vascularisation and presence of fewer proteolytic enzymes in the buccal mucosa 
than the gastrointestinal tract (GIT) mucosa promotes buccal delivery as a potential site for protein 
and peptide delivery. Limitations of buccal delivery of proteins include: large molecular weight 
and hydrophilicity, leading to low diffusivity; instability, fast metabolism, adsorption, aggregation, 
biocompatibility and possible immunogenicity (Veuillez et al 2001). Thus, factors affecting 
peptide drug absorption including structure (molecular weight/ size, conformation, 
stereospecificity, immunogenicity and electrostatic charge); physicochemical properties 
(solubility, hydrophilicity/ partition coefficient, aggregation, self-aggregation and hydrogen 
bonding); buccal mucosal properties (structure and biochemistry); biological environment 
(enzyme sensitivity and intracellular metabolism) and available transport mechanisms have to 
be considered during buccal insulin formulation development (Veuillez et al 2001). 
Strategies such as chemical modification by derivatisation, or prodrug approaches may enhance 
peptide stability and lipophilicity, and may prevent degradation by proteolytic enzymes at the 
mucosal surface (Veuillez et al 2001). Other strategies that result in the formation of non-covalent 
complexes between the protein and hydrophilic moieties have been reported to impart a slight 
reversible unfolding to the peptide molecule, leading to enhanced protein flexibility and 
lipophilicity (Milstein et al 1998, Owens et al 2003). This increases passive transcellular diffusion 
and enhances protein permeability, and is the principle behind the use of ion pairs to enhance drug 
permeation. An ion pair is formed when a pair of oppositely charged (counter) ions are held 
together without the formation of a covalent bond, by Coulombic forces forming a neutral molecule 
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with higher lipophilicity, that can partition into the cell membrane easier than the parent 
compounds (Samiei et al 2013). Most ion pairing agents, such as inorganic surfactants and co-
solvents, require high volumes, resulting in high toxicity/ allergenicity and have limited 
applications in pharmaceutical preparations; thus, the use of biocompatible agents as ion pairs with 
drug molecules would eliminate this challenge (Miller 2009, Hemenway et al 2010, Samiei et al 
2013). Recently, the use of amino acids as ion pairs to enhance solubility/ permeability of small 
molecules has been investigated as a biodegradable, low toxicity/ irritant and high stability 
alternative (Hemenway et al 2010). Moreover, the availability of amino acid transport systems 
across cells may enhance facilitated transport of drug – amino acid complexes (after ion pair 
formation), leading to enhanced permeation (Elshaer et al 2011). Various studies have investigated 
the use of amino acids as ion pairs to improve solubility/ permeability of small molecules (Chen et 
al 1999, Ivaturi and Kim 2009, Samiei et al 2013, Elshaer et al 2014, Samiei et al 2014). However, 
the use of amino acids as ion pairs to enhance solubility/ permeability has not been reported for 
proteins and macromolecules. Usually, with small molecules, molar ratios of the counter ion are 
used in excess (Miller 2009), but molar ratios cannot be employed for macromolecules like insulin 
because these would require minute quantities of amino acids with negligible effects observed. 
Also, the large size, amphiphilic nature, and presence of multiple ionisable sites on proteins further 
complicate the expected results in vitro. 
In order to establish the role of ion pairs in the formulation of biologicals, the proposed work is 
built on insulin as a model compound. Insulin has been classified as a BCS class III molecule with 
high solubility (depending on solution pH) and low permeability, mostly due to its large molecular 
weight, low lipophilicity and quick degradation in the presence of proteases (Ohshima and Makino 
2014). The insulin monomer (Figure 6.1) consists of six basic groups (two N-terminal amino 
groups, two histidines, one lysine and one arginine) and six acidic groups (two C-terminal 
carboxylates and four glutamates) (Matsuura et al 1993). Therefore, at pH values around its 
isoelectric point of 5.35, charges on the monomer balance out providing a neutral molecule, 
rendering insulin practically insoluble in water (Hames and Hooper 2005, Samiei et al 2013).   
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Figure 6.1 Primary structure (amino acid sequence) of insulin monomer highlighting basic (black arrows) and 
acidic (blue arrows) groups which provide ionisable sites to the molecule (adapted from http://www.interactive-
biology.com/wp-content/uploads/2012/05/Human-Insulin-Protein-Structure-917x1024.pg 
 Structures of the ionisable sites on the insulin monomer provided by basic and acidic amino acids 
are presented in Figure 6.2. At acidic pH, the acidic groups on insulin become protonated, and the 
resulting charge on the molecule is provided by the basic groups (NH3+), thus insulin has a positive 
charge in acidic media. However, in basic media, the acidic groups lose their protons and the charge 
on the monomer is provided by the acidic groups (COO-), thus insulin has a negative charge in 
basic media (Hames and Hooper 2005).  
The current work was based on two hypotheses. Firstly, that ionised insulin molecules could form 
ion pairs with opposite charges provided by basic and acidic amino acids to form an insulin-amino 
acid neutral complex, with lower hydrophilicity and therefore enhanced lipophilicity, which could 
then permeate the buccal membrane via transcellular passive diffusion. Secondly, that 
complexation of insulin with amino acids could possibly trigger alternate transport mechanism of 
insulin-amino acid complex across buccal membranes, potentially via amino acid nutrient 
transporters available on the cell membranes (Figure 6.3).  
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Figure 6.2 Structures of basic and acidic amino acids that provide ionisable sites on the insulin monomer; adapted 
from Hames and Hooper (2005). 
 
 
 
Figure 6.3 Schematic representation of active transport of insulin-amino acid ion pair complex. Where (A) 
represents amino acids transport via their nutrient carriers, (B) represents amino-acid facilitated insulin 
transport through amino acid carriers. Adapted from https://www.premedhq.com/passive-active-
transport 
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Thus, the aim of this work was, therefore, to investigate the ion pairing effect of basic and acidic 
amino acids on the solubility, distribution coefficient, permeability, mechanism and transport route 
of insulin across TR146 buccal cell layers, in order to highlight safe and effective permeation 
enhancers for buccal insulin delivery.  
6.2 Materials and methods 
6.2.1 Materials 
The TR146 cell line was purchased from Public Health England, UK. Human recombinant insulin, 
L-arginine (non-animal source, cell culture tested), L-lysine (≥ 97%), L-histidine (≥ Reagent 
Plus™ 99%), L-glutamic acid (minimum 99% TLC), L-aspartic acid (99%), sodium deoxycholate, 
MTT (methylthiazolydiphenyl-tetrazolium bromide; ≥97%; enzymatic), dimethyl sulfoxide 
(DMSO) and trifluoroacetic acid were purchased from Sigma-Aldrich, UK. Hank’s balanced salt 
solution (HBSS), fetal bovine serum (FBS), Hams F-12 nutrient mix and trypsin-EDTA were 
obtained from Gibco® Lab., UK. Gentamicin and penicillin/ streptomycin were obtained from Bio 
Sera, UK. Acetoniltrile and absolute ethanol were purchased from Fisher scientific, UK. 6 well 
plates, 6 well polycarbonate transwell inserts and 12 well polyester transwell inserts were 
purchased from Appletonwoods, UK. All the chemicals and reagents were used as obtained. All 
water used was double-distilled and autoclaved. 
6.2.2 Methods 
6.2.2.1 High performance liquid chromatography (HPLC) assay 
 
Quantitative analysis of insulin in solution was achieved by gradient RP-HPLC adapted from 
Sarmento et al (2006). A Waters HPLC system (Alliance) with gradient pump and UV/ fluorescent 
detector was used, employing a reversed phase RP-C18 analytical column (Phenomenex® 110A, 
150 x 4.6mm, 5µm). The mobile phase consisted of solution A: 0.1% v/v TFA in water and solution 
B: absolute acetonitrile, both filtered under vacuum and sonicated prior to use. A gentle gradient 
was run from 74:26 to 67:33 compositions of A:B over 3 mins, and then maintained at 67:33 for 4 
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mins. Pump flow rate was 1mL/min, with sample injection volume of 10µL and UV detector 
wavelength of 214nm. Column and samples were maintained at room temperature. A rectilinear 
(Beer-Lambert’s) calibration curve was established for insulin within a concentration range of 1 – 
1000 µg/mL (0.027 – 27 IU/mL) dissolved in 0.01N HCl and linearity calculated. Instrument 
precision was evaluated by injecting the same concentration of insulin solution (1000µg/mL) into 
the HPLC three times and calculating the percent relative standard deviation (%RSD) using 
equation 6.1. Intra-day and inter-day operator precision were evaluated by establishing the 
calibration curve in triplicates on the same day, and on three different days respectively, and %RSD 
calculated. Method accuracy was evaluated by calculating the %RSD of percentage recovery 
(equation 6.2) inter- and intra-day; while limits of detection and quantification (LOD & LOQ) were 
calculated from the regression line using equations 6.3 & 6.4 respectively (1CH 2005, Sarmento et 
al 2006): 
%𝑅𝑆𝐷 =
𝑚𝑒𝑎𝑛
𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
 𝑥
100
1
  . . . . . (Equation 6.1) 
% 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
𝑎𝑐𝑡𝑢𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑒𝑑
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑
 𝑥
100
1
  . . . (Equation 6.2) 
𝐿𝑂𝐷 =
3.3𝜎
𝑠
  . . . . . . . . (Equation 6.3)  
𝐿𝑂𝑄 =
10𝜎
𝑠
 . . . . . . . . (Equation 6.4)  
where σ is the standard deviation of the response and s is the slope of the regression line.  
6.2.2.2 Insulin solubility in water & HBSS 
To investigate the effect of model basic (L-arginine) and acidic (L-glutamine) amino acids on the 
solubility of insulin in water, solubility studies were carried out at 25 ºC by adding excess amounts 
of insulin in 5mL of deionised water containing 4, 27 or 50µg/mL concentrations of each amino 
acid respectively. pH of the solutions was measured using a pHenomenal® pH meter (VWR, USA). 
The solutions were then allowed to stir on a multi IKA magnetic stirrer overnight (Nicolescu et al 
2010, Elshaer et al 2011). After standing for 2 hours, the supernatant was filtered through 0.45µm 
filters, and insulin content quantified by the validated HPLC method described above. Similar 
experiments were carried out using 10, 50, 100, 200, & 400 µg/mL concentrations of basic 
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(arginine, lysine & histidine) and acidic (glutamic acid & aspartic acid) amino acids, and sodium 
deoxycholate, using HBSS in place of deionised water; because in vitro permeability studies would 
be carried out in HBSS. Solutions without amino acids were used as control.    
6.2.2.3 Insulin distribution coefficient in 1-octanol/ water  
To determine the effect of amino acids on the partition behaviour of insulin between polar and non-
polar phases, 1 mg insulin was added to 5 mL octanol-saturated deionised water and 5 mL 
deionised water saturated 1-octanol in the presence of arginine or glutamic acid (4, 27 & 50 µg/ 
mL) respectively and stirred overnight similar to water solubility experiments described above. 
The solutions were then separated by allowing to stand in a separating funnel for 4 hours, after 
which the aqueous fraction was filtered using a 0.45 µm nylon filter and insulin content quantified 
by HPLC. Solutions without amino acids were used as control.    
6.2.2.4 TR146 cell culture procedures 
TR146 cells were maintained in 75cm3 T-flasks in Ham’s F-12 cell culture media fortified with 
10% FBS, 2 mM glutamine, 100 IU penicillin/ streptomycin, 10 µg gentamicin; and incubated at 
37 ºC, 5% CO2 and 95% air. Media change occurred every 2-3 days and at 90% confluence, cells 
were passaged using 5mL trypsin-EDTA solution in HBSS, and seeded unto 12 well transwell 
inserts at a density of 24,000 cells/cm2 and grown for 28-29 days. Transepithelial electrical 
resistance was used to monitor cellular layer integrity 30 minutes after each media change (Elshaer 
et al 2014). Passage numbers 30-39 were used for these experiments. 
6.2.2.5  Trans-epithelium electric resistance (TEER) 
The ohmic resistance (resistance to current flow via the paracellular pathway) of cells grown on 
transwell inserts was measured every 2-3 days (30 mins after media change) during the cell culture, 
as well as before and after each permeability experiment, using an EVOM™ volt ohmmeter with 
chopstick electrodes. The electrodes were placed erect, such that the longer arm just touched the 
fluid in the basolateral chamber, while the shorter arm barely touched the apical membrane. The 
transepithelial electric resistance which reveals the integrity of the cellular layers was calculated 
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using equation 4.5. TEER values were reported as mean ± standard deviation of triple readings 
from replicate transwells (n=9). 
𝑇𝐸𝐸𝑅 = (𝑅(𝑖𝑛𝑠𝑒𝑟𝑡 𝑤𝑖𝑡ℎ 𝑐𝑒𝑙𝑙𝑠) −  𝑅𝑖𝑛𝑠𝑒𝑟𝑡 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑐𝑒𝑙𝑙𝑠) ∗ 𝐴  . . (Equation 6.5) 
where R is the measured resistance and A is the cross-sectional area of the cells. 
6.2.2.6 Cytotoxicity testing via MTT assay 
The methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay was used to assess the cytotoxicity 
of the enhancers on TR146 cells in their exponential growth phase. Cells were seeded unto 96 well 
plates at a density of 24,000 cells/cm2 and incubated for 24 hours. The media was removed and 
200µL of increasing concentrations (25, 50, 100, 200, 400 & 800 µg/) of each enhancer in HBSS 
was added to each well in replicates of 12 per concentration. Cells were incubated for 4 hours (the 
duration of permeability experiments) after which 20 µL MTT solution (5 mg/mL in HBSS) was 
added to each well and incubated for a further 4 hours. Finally, wells were emptied and solutions 
replaced with 100 µL dimethyl sulfoxide (DMSO) and left to shake at 140 rpm and 37 ºC for 30 
minutes. The absorbance was read at 490nm using a Multiskan® spectrum plate reader (Thermo 
Scientific, US). The relative enzyme reactivity and therefore cell viability was calculated from 
equation 6.6.  
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =  
𝑂𝐷1− 𝑂𝐷2
𝑂𝐷3− 𝑂𝐷2
 𝑥 
100
1
  . . . . (Equation 6.6) 
where OD1, OD2 and OD3 are the optical densities of wells with cells and enhancer solution, blank 
wells without cells or enhancer solution, and wells with cells but no enhancer solution respectively.  
6.2.2.7 In vitro transbuccal permeation studies  
TR146 cells cultured on transwell inserts for 28-29 days with passage numbers 30-39 were used 
for permeability studies. Permeability studies were conducted as described by Nielsen and Rassing 
(1999) at 36ºC and 140 rpm in an orbital plate shaker. Test solutions containing 1000µg/mL (27 
IU/mL) insulin dissolved in HBSS in the presence of increasing concentrations (10, 50, 100, 200, 
400 and 600 μg/ mL) of basic and acidic amino acids as well as sodium deoxycholate were prepared 
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and stirred until a clear solution was observed, and pH of solutions measured. Cells on transwell 
inserts were rinsed twice with HBSS (37ºC) by adding 0.5 mL and 1.5 mL to the apical and 
basolateral chambers, respectively. After incubation for 30mins, TEER readings were taken in 
triplicate per insert. The basolateral chamber was then replaced with fresh HBSS and the apical 
chamber with 0.5mL test solution. Immediately, 100 µL of test solution was withdrawn from the 
apical and basolateral chambers at time 0. Basolateral sampling of 700 µL was done every 30 mins 
for 4 hours with immediate replacement with pre-warmed HBSS. At the end of the experiment, 
100 µL of apical solution was taken. Test solutions without permeation enhancers were used as 
control (Portero et al 2002, Xue et al 2012, Sander et al 2013). After 4 hours, cells were rinsed 
twice with 0.5mL HBSS and equilibrated for 30minutes after which TEER values were recorded. 
All samples were made up to 700 µL where necessary, using HBSS, and analysed for insulin 
content by HPLC, and resultant data used to calculate the apparent coefficient of permeability 
through the insert with cells (Papp), the cell-free apparent permeability coefficient (Pinsert), the cell 
apparent permeability coefficient (Pcell), the percent enhancement ratio (%ER) and the recovery %. 
𝑃𝑎𝑝𝑝 =
𝑑𝑄
𝑑𝑡
 𝑥
1
𝐴∗𝐶𝑜
   . . . . . . . (Equation 6.7) 
𝑃𝑖𝑛𝑠𝑒𝑟𝑡 =  
𝑑𝑄
𝑑𝑡
 𝑥 
1
𝐴∗ 𝐶𝑜
  . . . . . . . (Equation 6.8)  
1
𝑃𝑎𝑝𝑝
=
1
𝑃𝑐𝑒𝑙𝑙
 +  
1
𝑃𝑖𝑛𝑠
  . . . . . . . (Equation 6.9) 
%𝐸𝑅 =  
𝑃𝑐𝑒𝑙𝑙 (𝑒𝑛ℎ𝑎𝑛𝑐𝑒𝑟)
𝑃𝑐𝑒𝑙𝑙 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 𝑥 
100
1
  . . . . . .           (Equation 6.10) 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 % =
𝑋𝑎𝑝𝑖𝑐𝑎𝑙+ 𝑋𝑏𝑎𝑠𝑜𝑙𝑎𝑡𝑒𝑟𝑎𝑙 
𝑋𝑜
 𝑥 
100
1
  . . . .           (Equation 6.11) 
Where dQ/dt is the rate of insulin transport at steady state in µg/s, A is the cross sectional area of 
cells in cm2, CO is the initial apical solution concentration in µg/mL, Xapical is the quantity of insulin 
remaining in the apical chamber after 4 hours, Xbasolateral is the cumulative amount of insulin 
sampled from the basolateral chamber after 4 hours and Xo is the initial quantity of insulin in the 
apical chamber at the start of the experiment (Portero et al 2007, Xue et al 2012, Sander et al 2013). 
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Insulin stability after permeation was monitored by HPLC for changes in retention time and/ or 
presence of multiple peaks on the HPLC chromatogram.  
6.2.2.8 Route of insulin transport 
To investigate the transport route of insulin in the presence of the enhancers, solutions containing 
FITC-labelled insulin (0.6 mg/mL in HBSS) along with concentrations of enhancers that 
effectively enhanced insulin permeability, were incubated with TR146 cells grown on transwell 
inserts for 28 days on an orbital plate shaker equilibrated at 36ºC and 140 rpm for 4 hours; as with 
the transport experiments (Luo et al 2006). The transwell inserts with cells were washed three times 
with warm HBSS before and after the experiment. TEER values in HBSS were also measured 
before and after the experiment. After washing, transwell inserts were fixed with 4% 
paraformaldehyde (PFA) in PBS for 10 minutes, and cells were rinsed four times with PBS. Inserts 
were placed on microscope slides and the membrane carefully cut out using a scalpel. Two drops 
of DAPI (4’6’-diamidino-2-phenylindole) in Vectashield™ (Vector Laboratories) were used to 
mount the specimen, which was immediately covered with a microscope cover slip and allowed to 
air dry for 10 minutes. Samples were then viewed using a Leica® laser confocal scanning 
microscope (Wetzlar, Germany) at 10x (dry) and 40x (oil) magnifications.  
6.2.2.9 Mechanism of insulin transport 
To investigate the presence of passive transport, permeability studies described above were carried 
out using a single concentration of glutamic acid (200 µg/mL) with increasing concentrations of 
insulin (250, 500, 1000 & 1500 µg/mL = 6.75, 13.5, 27 & 40.5 IU/mL) and all permeability indices 
calculated. While to investigate the presence of active amino acid-facilitated transport of insulin, 
permeability studies were repeated at suboptimal temperatures (9ºC) with 1000 µg/mL (27 IU/mL) 
insulin in the presence of increasing concentrations of glutamic acid (100, 200, 400 µg/mL). 
Transwells were maintained at 9ºC for 1 hour prior to commencing studies to ensure a cessation of 
enzymatic activity, and the resulting insulin transported analysed by HPLC.  
Chapter Six 
198 
 
6.2.2.10 Statistical analysis 
All data generated in replicates were presented as mean ± standard deviation (SD), where n≥3.  The 
data was then analysed for statistical significance using one-way analysis of variance (ANOVA) 
and Tukey-Kramar multiple comparison  post-test from Graphpad Prism® version 6.07 (Graphpad 
Software, San Diego, CA, USA). The level of significance was quoted as p<0.05 (probability 
values of 95%). 
6.3 Results & discussion 
6.3.1 Insulin solubility in water 
There is a lack of consensus on solubility of insulin in water as various authors have either reported 
it as soluble/ hydrophilic (Xu et al 2006) or insoluble/ hydrophobic (BP 2012). However, the 
solubility of insulin is determined by the pH of the solution, and its closeness to the isoelectric 
point of insulin (Lens 1946). Kramer et al (2012) described protein solubility as “a thermodynamic 
parameter deﬁned as the concentration of protein in a saturated solution that is in equilibrium with 
a solid phase, either crystalline or amorphous, under a given set of conditions”. This solubility 
depends primarily on intrinsic factors such as the characteristics of its constituent amino acids, as 
well as extrinsic factors such as temperature, pH, ionic strength and solvent additives (Kramer et 
al 2012). The solubility of insulin in water was tested in the presence and absence of arginine and 
glutamic acid, as models for basic and acidic amino acids, respectively (Figure 6.4). In the absence 
of amino acids, insulin remained only slightly soluble in deionised water (<3µg/mL at pH 6.64) 
(Trevino et al 2008). Similar results were obtained by Lens (1946) who measured insulin solubility 
at pH 6.0. Landreh (2012) also reported low insulin solubility at pH 5 – 6. The insulin monomer 
comprises six acidic groups (two C-terminal carboxylates and four glutamate residues) and six 
basic groups (two N-terminal amino groups, two histidine, one lysine and one arginine) (Matsuura 
et al 1993) (Figure 6.1). At the pH of deionised water, the charges on the acidic and basic groups 
balance out to give a neutral molecule with no net charge, thus being unionised, solubility of the 
protein is hindered (Hames and Hooper 2005, Samiei et al 2013).  
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Figure 6.4 Solubility in water at 25  ͦC and resulting pH of solutions of insulin in the presence/ absence of basic 
and acidic amino acids (n=3). Horizontal line depicts the isoelectric point of insulin (1 mg insulin = 27 IU). 
From Figure 6.2, it can be seen that arginine with a highly basic side chain (pKa = 12.48) was able 
to increase the pH of the resulting solution to about 9 - over 3 units above the isoelectric point (pI) 
of insulin (Figure 6.4) (Hames and Hooper 2005). The pI is the pH at which insulin has no net 
charge across its amino acid groups. The system’s basicity was increased to up to pH 9 due to the 
contribution of the –NH2 group from arginine. Thus, insulin solubility increased significantly with 
increasing concentrations of arginine.  This can be explained using the Henderson-Hasselbalch 
equation (Leninger et al 1993, Wang et al 2002): 
pH = pKa + log 
[A−]
[HA]
  . . . . . . (Equation 6.12) or 
pH = pKa + log (
[proton acceptor ] 
[proton donor ]
)  . . . . (Equation 6.13)  
where pH is the negative logarithm of hydrogen ion concentration [H+], pKa is the negative 
logarithm of the acid dissociation constant, Ka, and represents the pH at which the acid is halfway 
dissociated i.e. [HA] = [A-]; [A-] is the molar concentration of the acid’s conjugate base, and [HA] 
is the molar concentration of the undissociated weak acid (Hames and Hooper 2005). Therefore, 
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the solubility of a weak acid would increase with increasing pH, while that of a weak base would 
increase with decreasing pH (Hörter and Dressman 2001). So, for a protein like insulin that is 
amphoteric in nature, and has the ability to act either as a weak acid or a weak base, solubility of 
the protein would be expected to increase when pH is at least 2 units below or above its isoelectric 
point. Thus, the trend seen where increasing concentrations of arginine increased pH, and therefore 
increased insulin solubility, was expected. At low pH, all acidic groups of insulin become 
protonated and the resultant charge on the molecule is supplied by the basic groups; while at high 
pH, all basic groups lose their protons and the resultant charge on the molecule is supplied by the 
acidic groups (Matsuura et al 1993). Thus, insulin remains insoluble at its pI of 5.0-5.35, but 
solubility increases with change of pH (Matsuura et al 1993). In this system, insulin acts as a weak 
acid to release its proton from the –COOH group to arginine to form –NH3+, leaving insulin with a 
negative charge from COO-.  This dissociation of insulin enhanced its solubility since only ionised 
molecules are soluble (Samiei et al 2013). However, because from Figure 6.4, this relationship was 
not found to be linear, probably due to the presence of various ionisable amino acid groups on the 
insulin molecule; it could be said that insulin was not fully dissociated in the arginine solution 
(Elshaer et al 2011). However, it should be noted that the ionisation of insulin would be expected 
to be more complicated than that seen with small molecules due to the presence of multiple 
ionisable groups on its various component amino acids. 
With glutamic acid, there was no significant change in insulin solubility. In the presence of 
glutamic acid, all acidic groups on the insulin molecule would have been expected to be protonated, 
leaving a resultant positive charge supplied by its basic groups. However, this was not observed to 
occur for various reasons. At 4µg/mL glutamic acid, solution pH was 5.26, very close to the 
isoelectric point of insulin, thus insulin would not be dissociated and solubility would not change. 
At higher concentrations of glutamic acid, solution pH was 4.2 – 4.3. Although insulin should have 
been dissociated at this pH, the solution pH was very close to the pKa of glutamic acid 4.07 (Table 
6.1). The dissociation of glutamic acid would have been limited, leading to its inability to freely 
donate protons to insulin, resulting in no change in insulin solubility (Kramer et al 2012). 
Therefore, it is possible that insulin dissociation was not enhanced and its solubility remained 
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unaffected. These findings are in line with previous reports which have suggested that weak acids 
exhibit highest buffering capacity within one pH unit of their pKa (Hames and Hooper 2005).  
6.3.2 Insulin solubility in HBSS 
Insulin solubility in HBSS was determined because it was expected that at pH 7.4, more than 2 
units above the isoelectric point of insulin, the protein would be soluble, overcoming precipitation 
(Trevino et al 2008). HBSS also enabled the circumvention of the potential toxicity related to 
solubilising insulin in 0.01N HCl prior to permeation experiments, as reported by other authors 
(Yin et al 2009, Xue et al 2012). For HBSS solubility studies, a range of amino acids were utilised, 
their physicochemical properties are presented in Table 6.1. The effect of amino acids on insulin 
solubility was compared to that of sodium deoxycholate, a hydrophobic bile salt that has been 
widely studied as a permeation enhancer.  
Table 6.1 Properties of amino acids used in this study, highlighting the pKa of their ionisable side chains (Silen 
and Forte 1975, Hames and Hooper 2005). 
 
 Enhancer Molecular 
weight (g/mol) 
Side chain                            pKa 
NH3+    COOH    Side chain 
pI 
 L-arginine 174.20 Basic 1.82 8.99 12.48 10.76 
 
 L-lysine 146.19 Basic 2.16 9.06 10.54 9.74 
 
 L-histidine 155.16 Basic/ neutral 1.80 9.33 6.04 7.59 
 
 L-glutamic 
acid 
147.13 Acidic 2.10 9.47 4.07 3.22 
 L-aspartic 
acid 
 Acidic 1.99 9.90 3.90 2.77 
 
 Sodium 
deoxycholate 
414.60 - - - - 6.58 
 
This is a surfactant that enhances permeability of biological membranes by dissolution of 
membrane lipids, thereby interfering with membrane fluidity and integrity (Gandhi and Robinson 
1992, Yamamoto et al 1992, Uchiyama et al 1999, Türker et al 2004).  
Compared with deionised water, insulin was highly soluble in HBSS even in the absence of amino 
acids and the bile salt. This can be related to the fact that the pH of HBSS is buffered at 7.4 which 
is much higher than the pI of insulin and would maintain insulin in its ionised form, thereby 
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enhancing solubility (Franks et al 2000). Lens (1946) reported complete solubility of insulin in 
phosphate buffer at pH 7.4, but a solubility of <3 µg/mL in phosphate buffer pH 6.0, with higher 
solubility of about 5 µg/mL observed at pH 4.95. Figure 6.5 and Figure 6.6 compare the effect of 
the presence and/ or absence of increasing basic and acidic amino acids and the bile acid salt on 
insulin solubility and solution pH. Na deoxycholate did not have any significant effect on insulin 
solubility except at a concentration of 100 µg/mL of the bile salt (Figure 6.5).  
 
 
Figure 6.5 Comparing the effect of basic amino acids and the bile salt, Na deoxycholate, on the solubility of insulin 
in HBSS at 25  ͦC (n=3). Only lysine was able to alter solution pH and insulin solubility significantly (1 mg insulin 
= 27 IU). 
 
As a detergent, Na deoxycholate acts as an amphiphile and possesses both polar and non-polar 
properties and is able to enhance the emulsification of insoluble substances by reducing interfacial 
surface tension (Rotunda et al 2004).  This significant reduction in insulin solubility can be 
explained as Na deoxycholate has been shown to confer a concentration - dependent 
hydrophobicity on proteins like insulin, thereby enhancing their lipophilicity, which would reduce 
aqueous solubility (Sun et al 2011). 
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At other concentrations tested, no significant change in insulin solubility was observed, although 
the graph showed a reversed/ inverted bell shaped curve. This was expected as (being a salt of a 
weak acid with pKa 6.58, which was close to that of HBSS) even at the highest concentrations of 
the salt used, there was no change in pH of the resulting solution. Therefore, apart from 
hydrophobic interactions, no counter-ion effects were expected or observed with Na deoxycholate.  
Surprisingly, in the presence of arginine, there was no significant change in the solubility of insulin 
in HBSS even at high concentrations (200-400µg/mL). Data from pH profile in Figure 6.5 also 
showed that the buffering capacity of HBSS was maintained in the presence of arginine until 200 
and 400µg/mL, after which pH increased from 7.4 to about 9 units. Theoretically, an increase in 
insulin solubility was expected at this pH, following the Henderson-Hasselbalch equation, however 
this was not evident. A possible reason for this observation could be based on the isoelectric point 
of arginine (10.76), which is less than two units away from the solution pH, thereby preventing 
complete ionisation of arginine, to cause the dissociation of insulin. On the other hand, lysine 
showed similar pH results as that seen for arginine; however, a significant increase in insulin 
solubility was observed at higher lysine concentrations (200-400 µg/mL) that resulted in an 
increase in pH from 7.4 to about 9. This difference between solubility enhancement characteristics 
of arginine and lysine, despite similar effects on pH, can be explained based on the pKa of these 
amino acids. Because of the high basicity of the arginine side chain, and the presence of other ions 
contributed by the buffer to the system, ion pairing between arginine and any non-protein ion would 
be hardly reversible due to high basicity of arginine. Therefore, in the presence of arginine, despite 
the high pH, insulin might still remain in its non-ionised form and thus have low solubility. 
However, in the presence of lysine with lower basicity of the side chain, the amino acid would be 
more available to interact with insulin ions, thereby maintaining its ionised state and enhancing 
insulin solubility. Elshaer et al (2011) also reported a higher indomethacine solubility in lysine than 
in arginine solution, despite the higher pKa of the arginine amino acid. This disparity was attributed 
to the self-association that exists between lysine and the drug, but is absent in the presence of 
arginine, due to the presence of two proton acceptor and 1 proton donor groups in lysine, but low 
proton acceptor groups in arginine; resulting in low self-association of arginine. For histidine, 
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although a slight increase in insulin solubility was observed with the addition of the amino acid, 
insulin solubility (and solution pH) remained constant irrespective of the concentration of histidine 
used. Histidine has a side chain pKa of 6.04 and was not able to alter the pH of the system, as 
expected from the Henderson-Hasselbalch equation. Histidine has slight basic or neutral properties 
at neutral pH. The low basicity of the histidine side chain means it can gain or lose electrons easily, 
thereby keeping insulin in both an ionised or non-ionised state. This property of histidine may be 
of no benefit to insulin solubility, but its usefulness might be enhanced during insulin permeation. 
Elshaer (2011) reported the inability of histidine to dissociate the acidic drug indomethacin due to 
its weak basicity, thus ion pairs and salt formation could not be established. Golovanov et al (2004) 
reported that the presence of arginine or glutamic acid alone was unable to significantly improve 
the solubility of proteins tested; however, a significant increase in solubility and stability was 
observed when equimolar ratios of both amino acids were added to the system. Xue et al (2012) 
also suggested that combinations of permeation enhancers may improve efficacy and further lower 
the concentrations of each enhancer to be used; resulting in lower toxicity.   
In the presence of the acidic amino acids (Figure 6.6), insulin solubility in HBSS was slightly 
increased by glutamic acid, with no observed change in solubility in the presence of aspartic acid 
from 10-200 µg/mL amino acid concentration. This was not surprising since at these concentrations 
of both acidic amino acids, no change in pH was observed, due to the buffering capacity of HBSS 
(Franks et al 2000). However, a drastic reduction in insulin solubility was observed at 400 µg/mL 
amino acid concentrations, with a simultaneous drop in system pH from about 7 to 5.95 and 6.25 
for aspartic and glutamic acids, respectively. This reduction in solubility was expected due to the 
closeness of the system pH to the isoelectric point of insulin, leading to precipitation of the protein 
from solution. Physical observation showed the formation of a cloudy solution. Wintersteiner and 
Abramson (1933) reported low solubility of insulin at pH values around its pI. At these pH values 
(4.6 – 6.5), the solubility of insulin was low and fairly constant (Wintersteiner and Abramson 
1933). 
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Figure 6.6 Comparing the effect of acidic amino acids and Na deoxycholate on the solubility of insulin in HBSS at 
25  ͦ C, (n=3) (1 mg insulin = 27 IU). 
 
 
Therefore, it can be concluded that the amino groups of the basic amino acids and the carboxyl 
groups of the acidic amino acids have the capacity for ionisation, and affect insulin solubility due 
to the ease of formation of ion pairs and soluble complexes in the presence of counter ions furnished 
by ionisable sites on the insulin moiety (Elshaer et al 2011). This effect was dependent on the 
resultant system pH, pKa of the amino acids and the differences between these values and the 
isoelectric points of both insulin and the amino acids/ bile acid salts (Hames and Hooper 2005). 
6.3.3 Insulin octanol/ water distribution 
Because octanol has been reported to possess similar lipophilicity as the cell membrane, the 
octanol/ water distribution coefficient (log D) has been employed as a simplistic investigative tool 
to predict the behaviour of compounds at the cell membrane surface (Elshaer et al 2014). The 
partition behaviour of insulin from the organic phase (deionised water saturated 1-octanol) to the 
aqueous phase (1-octanol saturated deionised water) was determined, to calculate the log D of 
insulin, and thereafter determine the ability of basic/ acidic amino acids to modify insulin partition 
characteristics, as a prediction of in vivo behaviour (Camenisch et al 1998, Elshaer et al 2014). 
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Figure 6.7 represents the partition behaviour of insulin at equilibrium between aqueous and 
lipophilic phases in the absence and presence of representative amino acids.  
 
Figure 6.7 Effect of basic and acidic amino acids on octanol/ water distribution of insulin (n=3), as a means of 
predicting in vivo characteristics (1 mg insulin = 27 IU). 
 
 
An increase in insulin hydrophilicity was observed with increasing amino acid concentrations, 
irrespective of either their basic or acidic nature. However, for the basic amino acid arginine, this 
increase in hydrophilicity was observed to plateau after 27µg/mL, an observation that was not seen 
with the acidic amino acid, glutamic acid. Arginine was able to reduce the apparent distribution 
coefficient (log D) of insulin from 1.4 to about 0.7 at 27µg/mL arginine. Similarly, glutamic acid 
was able to reduce the log D of insulin to about 0.7 at 27µg/mL glutamic acid, with a further 
reduction to 0.3 at 50µg/mL glutamic acid. Matsuura et al (1993) reported an increase in the 
apparent distribution coefficient of insulin in 1-octanol in the presence of increasing stoichiometric 
quantities of sodium dodecyl sulphate resulting in a significant loss in aqueous solubility due to 
the formation of an insulin-SDS complex with higher lipophilicity than insulin. Thus, it is believed 
that in this system, the presence of the amino acids impacts on pH, which keeps insulin in the 
ionised state, and this ionised state of insulin, enhances its solubility in and partitioning into the 
aqueous phase (Matsuura et al 1993, Samiei et al 2013). The trend that insulin could not be 
partitioned from the octanol phase into the aqueous phase beyond 27µg/mL arginine, but was still 
observed to occur beyond this concentration for glutamic acid, may be explained using the higher 
free energy required for arginine (12.3 kJ/mol) than glutamic acid (8.2 kJ/mol) to partition into the 
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octanol phase; since the charged side chains need to be protonated (or deprotonated, respectively) 
before partitioning can occur. (Engelman et al. 1986). Furthermore, it has been reported that at 
high concentrations of positively charged arginine, promotion of refolding of recombinant proteins 
is observed; and at higher concentrations, arginine may increase protein destabilisation (Golovanov 
et al 2004). 
6.3.4 Insulin permeability across TR146 cell layers 
Ion pairs can be formed in the presence of oppositely charged ions in solution. Polypeptides such 
as insulin with multiple potentially ionisable regions depending on the amino acid sequence and 
system pH, have the potential of forming ion pairs with reactive amino acid side chains, to increase 
lipophilicity and thus may enhance permeability (Quintanar-Guerrero et al 1997). Quintanar-
Guerrero et al (1997) concluded that ion-pairing should be investigated as a potential route for 
enhancing lipophilicity of compounds to facilitate their absorption across lipophilic membrane 
barriers. TR146 cells were grown on transwell inserts for 28 – 29 days before use for permeability 
experiments. Integrity of the stratified layers was monitored using TEER as shown in Figure 6.8. 
TEER results showed the formation of a stable stratified layer between days 28 to 29 which were 
used for experiments, as reported by other authors (Xue et al 2012).  
The permeation of insulin across TR146 cell layers was tested in the absence/ presence of 
increasing concentrations of the five amino acids and Na deoxycholate. HPLC was used to monitor 
insulin stability after permeation and there was no significant change in insulin retention time, nor 
was the appearance of multiple peaks observed. For all the experiments, insulin concentration was 
held constant at 1000 µg/mL (Xue et al 2012). Generally, irrespective of the formulations tested, 
the amount of insulin permeated increased with time. The maximum amount of insulin that 
permeated the cells in the absence of enhancers (control) was 4.07 ± 0.82% after 4 hours.  
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Figure 6.8 Transepithelial electrical resistance results for TR146 cells grown on transwell inserts for 30 days (n=9). 
Cell layer integrity was found to be maintained over the time period used for the permeability studies.  
 
6.3.4.1 Basic amino acids 
6.3.4.1.1 Arginine 
For arginine (Arg), the highest percentage permeated was seen with 50µg/mL, at 1.85 ± 0.09% 
after 30 minutes with a steady increase to 9.86 ± 0.62% after 4 hours (Figure 6.9). The coefficient 
of apparent permeability of insulin through the actual cell layers, without the interference of the 
membrane Pcell, was calculated using equation 6.9. As expected, 50 µg/mL Arg solution exhibited 
the highest Pcell values at 5.65 ± 0.56 x 10-6 cm/s (Table 6.2) and highest enhancement percentage 
of 184.89 ± 44.83% (Figure 6.10). However, these values were not significant compared to the 
control. 
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Figure 6.9 Percentage of insulin permeated in the presence of various concentrations of arginine (Arg) (n=3). No 
significant enhancement in insulin permeability (p>0.05) was observed in the presence of arginine.  
 
 
 
 
Table 6.2 Effect of penetration enhancers on permeability of insulin through TR146 cell layers (n=3) 
Formulation Concentration 
(µg/mL) 
Papp ± SD (x10-6) 
(cm/sec) 
Pcell ± SD (x10-6) 
(cm/sec) 
Recovery ± SD 
(%) 
Control - 2.98 ± 0.40 3.12 ± 0.41 83.94 ± 28.87 
 
Arg 10 3.01 ± 0.38 3.16 ± 0.40 103.03 ± 5.24 
 
 50 5.18 ± 0.40 5.65 ± 0.56 101.72 ± 2.18 
 
 100 2.11 ± 0.39 2.19 ± 0.42 97.56 ± 2.82 
 
 200 2.53 ± 1.48 2.64 ± 1.59 91.75 ± 2.70 
 
 400 3.46 ± 1.40 3.66 ± 1.51 86.63 ± 4.85 
 
 600 3.19 ± 1.75 3.40 ± 1.95 83.55 ± 3.04 
 
     
Lys 10 7.08 ± 1.82* 7.95 ± 2.12* 81.47 ± 2.13 
 
 50 3.76 ± 1.66 4.02 ± 1.85 82.28 ± 3.03 
 
 100 9.51 ± 0.56*** 11.19 ± 0.76*** 83.48 ± 0.45 
 
 200 8.92 ± 4.94*** 10.56 ± 6.59*** 107.14 ± 7.29 
 
 400 3.31 ± 0.65 3.49 ± 0.71 89.83 ± 4.29 
 
 600 0.81 ± 0.80 1.25 ± 0.71 85.96 ± 3.22 
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His 10 10.7 ± 2.93*** 12.9 ± 3.91*** 98.76 ± 3.94 
 
 50 3.21 ± 1.19 3.38 ± 1.30 82.22 ± 19.89 
 
 100 2.89 ± 2.30 3.09 ± 2.48 90.57 ± 10.48 
 
 200 4.58 ± 2.96 4.99 ± 4.07 84.05 ± 2.33 
 
 400 3.87 ± 0.62 4.13 ± 0.89 86.16 ± 8.40 
 
 600 2.84 ± 1.12 2.98 ± 1.71 88.18 ± 4.83 
 
     
Glu 10 6.12± 1.83* 6.77E-06 ± 2.16* 87.83 ± 2.31 
 
 50 5.83 ± 2.53 6.45 ± 2.99 85.43 ± 1.02 
 
 100 7.29 ± 2.77 8.27 ± 3.44* 87.49 ± 0.52 
 
 200 9.05 ± 2.02*** 10.61 ± 3.63** 102.32 ± 3.63 
 
 400 5.02 ± 2.64 5.58 ± 3.34 91.28 ± 2.79 
 
 600 0.11 ± 0.01 0.11 ± 0.05 78.39 ± 1.15 
     
Asp 10 7.71 ± 0.92** 8.78 ± 1.19* 95.27 ± 2.60 
 
 50 5.58 ± 2.16 6.13 ± 2.49 89.97 ± 5.76 
 
 100 3.32 ± 0.85 3.51 ± 0.94 96.92 ± 6.27 
 
 200 8.52± 2.61*** 9.86 ± 3.32** 85.77 ± 12.40 
 
 400 3.88 ± 0.68 4.14 ± 0.79 77.55 ± 20.39 
 
 600 2.95 ± 0.41 3.09 ± 0.45 63.59 ± 5.53 
     
SDC 10 4.94 ± 0.54 5.12 ± 0.68 109.40 ± 12.72 
 
 50 5.72 ± 0.60 5.96 ± 0.87 104.41 ± 9.39 
 
 100 5.66 ± 0.60 5.90 ± 0.89 108.25 ± 5.63 
 
 200 11.16 ± 0.17*** 13.55 ± 0.65*** 89.98 ± 2.86 
 
 400 11.00 ± 0.72*** 13.26 ± 0.59*** 92.55 ± 2.03 
 
 600 11.13 ± 0.68*** 13.46 ± 0.55*** 95.41 ± 1.35 
 
Pinsert (no cells) = 65.192 x 10-6 cm/s 
Solubility data for arginine in HBSS presented in Figure 6.5, showed that arginine did not 
significantly alter the solubility (and therefore the dissociation) of insulin compared to the control. 
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Thus, it was not surprising that arginine could not significantly alter the permeation of insulin, 
although a slight increase was observed at 50µg/ mL compared with the control.  
 
Figure 6.10  Comparing the percent enhancement of insulin permeability through TR146 cell layers in the 
presence of various concentrations of arginine and solution pH (n=3). 
 
This was expatiated in Figure 6.11 that compares the solubility of insulin in the presence of the 
amino acids to the permeation observed at these concentrations. Arginine has a basic side chain 
with pKa 12.48 and at lower arginine concentrations of 10 – 100 µg/mL (pH 7.4 – 7.8), both insulin 
and arginine would be expected to be ionised and able to form stable unionised ion pairs that would 
enhance insulin permeability (Elshaer et al 2014). Significant increase in permeability at these 
lower concentrations of arginine was not observed, possibly due to the presence of limited 
concentration of ionised arginine molecules to pair with the ionised insulin moieties. However, as 
arginine concentration increased, solution pH increased steadily to a maximum of 9.36 at 
600µg/mL arginine. Since this pH is close to the isoelectric point of arginine (10.71), it is possible 
that although insulin molecules were ionised, less ionisation of the arginine molecule occurred, 
with the presence of less counter ions available to form neutral insulin-arginine moieties, and the 
final result of insignificant difference in insulin permeation was observed (Samiei et al 2013, 
Samiei et al 2014). It would seem that for the concentrations of arginine tested, the 50µg/mL 
concentration gave the best balance of insulin-arginine unionised molecules to enhance 
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permeability, since only the non-ionised form of a drug would permeate the cell membrane (Ivaturi 
and Kim 2009, Dahan and Miller 2012).  
 
Figure 6.11 Comparing the solubility in HBSS at 25ºC and permeability of insulin through TR146 cells layers, in 
the presence of various concentrations of arginine (n=3) (1 mg insulin = 27 IU). 
Since an aim of this study was to identify effective and safe penetration enhancers for insulin 
through buccal cells, transepithelial electrical resistance (TEER) of the cell layers and the MTT 
assay were conducted to assess the toxicity of amino acids to the cells, to determine if any observed 
permeation enhancement was due to destruction of cell layers or increase in cellular toxicity. The 
TEER results for arginine represented in Table 6.3 exhibited no significant reduction in TEER 
values across all concentrations of arginine used. Thus, cell layer integrity can be said to have been 
maintained throughout the 4 hours of the permeability experiment (Nielsen and Rassing 2002, Xue 
et al 2012, Elshaer et al 2014). Elshaer (2014) reported similar findings where high concentrations 
of arginine did not significantly affect the TEER measurements before and after permeability 
studies using Caco-2 cells. This was an expected result since MTT results (Figure 6.12) revealed a 
reduction in cell viability from arginine concentrations 500µg/mL and above. Thus, although 
arginine was safe, it did not significantly enhance the permeation of insulin through TR146 cells 
(Van Meerloo et al 2011). These MTT results for arginine were in conflict with findings reported 
by Xue et al (2012), where 10 - 50µg/mL arginine solutions were found to be toxic to TR146 cells 
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using the MTT assay. This conflict could be explained on the basis that in the current study, TR146 
cells were exposed to amino acids for 4 hours - duration of a permeability study, adapted from  
Jacobsen et al (1996); while in the earlier study, exposure times ranged from 24 – 48 hours. 
However, because the TR146 cells used for permeability studies formed multiple layers of 
stratified squamous epithelial cells, while MTT assays were carried out on single cells in active 
exponential growth phase, low toxicity is to be expected from the permeability studies (Xue et al 
2012).  
 
 
 
Table 6.3 Transepithelial electrical resistance (TEER) measurements for enhancers before and after permeability 
experiments through TR146 cell layers (n=9). 
 
Formulation Concentration 
(µg/mL) 
TEER 
measurements 
before ± SD (Ω/cm2) 
TEER 
measurements 
after ± SD 
(Ω/cm2) 
Recovery 
(%) 
Control - 254.99 ± 75.45 254.12 ± 83.06 99.66 
 
Arg 10 255.73 ± 60.48 266.56 ± 83.77 104.23 
 
50 223.25 ± 25.88 281.49 ± 60.83 126.09 
 
100 215.16 ± 46.03 238.68 ± 48.21 110.93 
 
200 265.19 ± 98.54 275.40 ± 53.04 103.85 
 
400 255.11 ± 72.29 281.74 ± 80.82 110.44 
 
600 324.43 ± 112.63 260.09 ± 90.12 80.17 
     
Lys 10 275.27 ± 58.57 299.91 ± 97.82 108.95 
 
50 317.21 ± 54.83 294.44 ± 53.03 107.18 
 
100 447.00 ± 69.32 274.4 ± 41.58**** 61.39 
 
200 337.37 ± 86.83 299.91 ± 54.94 88.90 
 
400 296.55 ± 70.94 283.86 ± 65.75 95.72 
 
600 279.63 ± 38.03 304.27 ± 69.22 108.81 
     
Chapter Six 
214 
 
His 10 284.60 ± 69.65 338.99 ± 71.12 119.11 
 
50 283.61 ± 102.74 271.04 ± 70.50 95.57 
 
100 366.86 ± 85.50 298.54 ± 62.06 81.38 
 
200 394.24 ± 69.75 283.86 ± 48.88** 72.00 
 
400 348.82 ± 52.10 273.53 ± 78.09 78.42 
 
600 308.25 ± 50.88 362.76 ± 58.50 117.68 
     
Glu 10 370.60 ± 97.80 336 ± 147.11 90.66 
 
50 381.42 ± 96.48 320.57 ± 59.24 84.05 
 
100 459.2 ± 102.68 286.72 ± 43.37 62.44 
 
200 343.96 ± 86.82 252.37 ± 52.52 73.37 
 
400 350.93 ± 102.59 283.11 ± 38.77 80.67 
 
600 303.77 ± 87.62 337 ± 72.72 110.94 
     
Asp 10 295.06 ± 25.06 295.56 ± 98.81 100.17 
 
50 275.27 ± 27.47 292.44 ± 64.82 106.24 
 
100 289.71 ± 80.61 258.84 ± 46.01 89.35 
 
200 349.44 ± 104.69 243.66 ± 50.88 69.73 
 
400 379.80 ± 114.17 251.25 ± 85.45 66.15 
 
600 558.51 ± 67.52 283.61 ± 
108.87*** 
50.78 
     
SDC 10 211.33 ± 38.58 222.22 ± 40.91 105.15 
 
50 234.56 ± 48.87 195 ± 37.08 83.14 
 
100 179.67 ± 48.87 199.89 ± 44.80 111.26 
 
200 252.78 ± 45.86 188.89 ± 39.91* 74.73 
 
400 244.56 ± 87.71 172 ± 61.47* 70.33 
 
600 224.22 ± 25.82 155.33 ± 57.05** 67.05 
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Figure 6.12 Effect of penetration enhancers on the viability of TR146 cells in the presence of increasing 
concentrations of amino acids and Na deoxycholate, utilising the MTT assay (n=12). Na deoxycholate and lysine 
exhibited the highest toxicity to cells, while histidine, glutamic acid and aspartic acid exhibited the highest safety 
potential. 
6.3.4.1.2 Lysine 
Lysine is a basic amino acid with side chain pKa of 10.54 and isoelectric point 9.74 (Table 6.1). 
Similar to arginine, the increase in insulin permeability in the presence of increasing lysine 
concentrations was concentration-dependent; with maximum percentage permeated observed at 
100 µg/mL lysine (Figure 6.13). Results showed that 4.69 ± 0.42% insulin permeated after 30 
minutes, with a significant steady increase after 2 hours to 13.28 ± 1.78% and 27.11 ± 0.88% at the 
end of the experiment (4 hours). At 600 µg/mL lysine, maximum percentage of insulin permeated 
was observed to be lower than the control. Overall, 100, 200 and 10 µg/mL lysine significantly 
increased the Pcell with values of 11.19 ± 0.76 x 10-6, 10.56 ± 6.59 x 10-6 and 7.95 ± 2.12 x 10-6 
cm/s, respectively (Table 6.2). High enhancement percentages were also recorded as 363.01 ± 
64.22%, 328.01 ±175.85% and 251.43 ± 37.94%, respectively, as highlighted in Figure 6.14. From 
solubility results in HBSS in the presence of increasing lysine concentrations (Figure 6.5), insulin 
solubility (and therefore insulin ionisation) was observed to significantly increase from 200 µg/mL 
lysine concentration, with resultant increase in pH from 7 to 9.  
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Figure 6.13 Percentage of insulin permeated in the presence of various concentrations of lysine (n=3). 10, 100 and 
200 µg/mL significantly enhanced insulin permeation above the control. 
 
 
Figure 6.14 Comparing the %enhancement of insulin permeability through TR146 cell layers in the presence of 
various concentrations of lysine and solution pH (n=3). At higher pH permeation was hindered due to partial 
dissociation of lysine, and therefore reduced potential for counter-ion formation with insulin. 
 
At 100µg/mL lysine with pH of 7, both lysine and insulin molecules would be ionised, the potential 
for formation of insulin-lysine neutral molecules would be enhanced with a further increase in 
permeability. As discussed for arginine earlier, at increasing concentrations of lysine above 200 
µg/mL, pH of the solution moved closer to the isoelectric point of lysine (9.74), causing a reduction 
in lysine ionisation, a fall in the concentration of lysine counter ions available for neutral complex 
formation with insulin, and a resultant fall in permeability as shown in Figure 6.15. However at 50 
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µg/mL lysine, a fall in insulin permeability was observed, probably due to the low concentrations 
of lysine counter ions available for complexation with ionised insulin moieties. Surprisingly, 10 
µg/mL lysine significantly enhanced insulin permeability above the control. This observation could 
be related to the high ionisation of lysine and insulin expected at pH 7. Moreso, insulin permeability 
could have been facilitated in the presence of lysine through amino acid membrane transporters, 
which could have been saturated at higher concentrations (Bröer 2008, Elshaer et al 2014). Insulin 
permeability results with lysine as permeation enhancer reinforced the fact that for permeation 
enhancement to occur in dynamic systems, a stringent balance between ionised and non-ionised 
species must be maintained (Samiei et al 2013, Elshaer et al 2014, Samiei et al 2014).  
 
 
Figure 6.15 Comparing the solubility at 25 ºC and permeability of insulin through TR146 cells layers, of insulin 
in the presence of various concentrations of lysine (n=3). Maximum amount of insulin permeated correlated with 
the lower ionisation of insulin molecules, enabling the permeability of non-ionised moieties (1 mg insulin = 27 IU). 
 
TEER results presented in Table 6.3 revealed that 100 µg/mL lysine significantly reduced TEER 
values post permeability assay, thus the enhancement recorded for this concentration could have 
been produced by leakage through disrupted cellular layers (Xue et al 2012). MTT assay results in 
Figure 6.12 further revealed a significant concentration-dependent decrease in TR146 cell viability 
with lysine concentrations ≥100 µg/mL and this could affect cell integrity (Van Meerloo et al 
2011). Furthermore, above 100 µg/mL lysine, pH values increased beyond physiologically 
accepted pH (Figure 6.15); thus, 10 µg/mL lysine was chosen as the optimal concentration of lysine 
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that effectively enhanced permeation of insulin without affecting cell viability or causing 
membrane disruption (Khafagy El et al 2007, Kumria and Goomber 2011, Patel et al 2011). 
6.3.4.1.3 Histidine 
Histidine has a side chain with pKa of 6.04 and isoelectric point of 7.59 (Table 6.1) which may 
render it neutral or basic at neutral pH. From Figure 6.16, 10µg/mL histidine was found to 
significantly enhance insulin permeation above the control with 1.69 ± 0.90% permeated after 1 
hour, and a steady increase to 8.20 ± 3.50% after 3 hours and a further 16.71 ± 7.65 % after 4 hours. 
Maximum Pcell (Table 6.2) and percent enhancement (Figure 6.17) values achieved at 10 µg/mL 
were 12.9 ± 3.91 x 10-6 cm/s and 409.44 ± 95.14%, respectively. All concentrations of histidine 
above 10 µg/mL showed no significant effect on insulin permeation. As highlighted in Figure 6.5, 
increasing histidine concentration above 10 µg/mL had no significant effect on insulin solubility 
in HBSS, with no change in solution pH at all concentrations tested. It was expected that histidine 
and insulin were ionised at this pH, the availability of counter ions facilitated the formation of 
insulin-histidine neutral complexes that could enhance insulin permeability significantly.  Figure 
6.18 compares the solubility and permeability of insulin at different concentrations of histidine. 
From here, it can be seen that no advantage was produced for both insulin solubility and 
permeability when histidine concentration was increased above 10 µg/mL. Thus, similar to results 
obtained from lysine, 10 µg/mL histidine was able to produce the optimal balance between ionised 
and non-ionised insulin molecules in solution, as well as possibly effectively triggering peptide 
transport proteins to enhance the permeation of insulin across TR146 buccal cells; with higher 
concentration saturating the transporters.  
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Figure 6.16 Cumulative percentage of insulin permeated in the presence of various concentrations of histidine 
(n=3). 10 µg/ mL histidine significantly enhanced insulin permeation above the control. 
 
 
 
Figure 6.17 Comparing the percent enhancement of insulin permeability through TR146 cell layers in the 
presence of various concentrations of histidine and solution pH (n=3). Enhanced insulin transport in the presence 
of histidine occurred with no change in solution pH.  
 
This was further supported by TEER results (Table 6.3) where only 100 µg/mL histidine 
significantly disrupted cellular integrity, and results from MTT assay (Figure 6.12) revealed that 
histidine was non-toxic to TR146 cells even at the highest concentration (800 µg/mL) tested. 
Therefore for the basic amino acids, 10, 100 and 200 µg/mL lysine and 10µg/mL histidine were 
effective as permeation enhancers for insulin, but only 10 µg/mL of each amino acid was both 
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effective and non-toxic to TR146 cells (Figure 6.19). 10 µg/mL histidine showed significantly 
higher permeation enhancement than 10µg/mL lysine. 
 
 
Figure 6.18 Comparing the solubility at 25 ºC and permeability of insulin through TR146 cells layers, of insulin 
in the presence of various concentrations of histidine (n=3). Significant enhancement observed at 10 µg/ mL due 
to a balance between ionised and non-ionised states of insulin, and the possible triggering of amino acid 
transporters (1 mg insulin = 27 IU). 
 
 
 
Figure 6.19 Graph highlighting concentrations of basic amino acids that significantly enhanced insulin 
permeability with no toxicity to TR146 cells (n=3). 10µg/ mL of both lysine and histidine were effective and safe 
permeation enhancers. 
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6.3.4.2  Acidic amino acids 
6.3.4.2.1 Glutamic acid 
Glutamic acid has an acidic side chain with pKa 4.07 and isoelectric point 3.22 (Table 6.1). From 
Figure 6.20, 10 and 100 µg/mL glutamic acid concentrations were able to significantly increase 
insulin permeability to 13.97 ± 3.01% and 16.98 ± 9.30% after 4 hours. 200 µg/mL increased 
permeability to 13.66 ± 4.77% after 3 hours. However, at concentrations above 200 µg/mL, no 
significant improvement in insulin permeation was observed; with no permeation occurring at 600 
µg/mL. Maximum Pcell values were achieved for 200 µg/mL at 10.61 ± 3.63 x 10-6 cm/s (Table 
6.2). Maximum enhancement percent for 200, 100 and 10 µg/mL were 307.82 ± 79.23%, 260.36 ± 
88.40% and 215.70 ± 53.10%, respectively (Figure 6.21).  
 
Figure 6.20 Cumulative percentage of insulin permeated in the presence of various concentrations of glutamic 
acid (n=3). 10, 100 and 200 µg/mL glutamic acid showed significantly higher insulin permeation than the control. 
Glu 200 and Control were discontinued after 3 hours following a mishap. 
 
These observations for glutamic acid can be directly related to the solubility profile presented in 
Figure 6.6 and were expected based on the discussions in sections above. No significant difference 
in insulin solubility and solution pH was observed with increasing glutamic acid concentrations up 
to 200 µg/mL, however, at 400 µg/mL, insulin solubility reduced drastically with a solution pH of 
6.09 at 600 µg/mL (Figure 6.21).  
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Figure 6.21 Comparing the percent enhancement of insulin permeability through TR146 cell layers in the 
presence of various concentrations of glutamic acid and solution pH (n=3). No permeation of insulin was observed 
at 600 µg/ mL glutamic acid due to the low solubility of insulin at this pH. 
As these pH values were close to the pI of insulin, less insulin was found in solution with outright 
precipitation of insulin expected at 600 µg/mL. Thus, no insulin was observed to permeate the cells 
at this high glutamic acid concentration (Figure 6.22), because only the soluble form of a drug is 
available to permeate cells and be absorbed into the bloodstream (Dahan and Miller 2012, Samiei 
et al 2013, Samiei et al 2014).  
 
Figure 6.22 Comparing the solubility at 25 ºC and permeability of insulin through TR146 cells layers, in the 
presence of various concentrations of glutamic acid (n=3) (1 mg insulin = 27 IU).  
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TEER results for glutamic acid (Table 6.3) showed no significant reduction in TEER values at all 
concentrations tested, while MTT assay results (Figure 6.12) revealed toxicity of cells only at 800 
µg/mL glutamic acid, which was outside the concentration range tested. Therefore, glutamic acid 
was found to be safe and non-toxic to cells across all tested concentrations. Thus, the enhancement 
in insulin permeability by 10, 100 and 200 µg/mL glutamic acid could be attributed solely to the 
amino acid facilitation of permeation through the formation of neutral ion pairs with insulin, and/ 
or through the use of membrane peptide transporter mechanisms, rather than disruption of cell 
layers or reduced cellular integrity (Elshaer et al 2014, Samiei et al 2014). 
6.3.4.2.2 Aspartic acid 
Aspartic acid has an acidic side chain with pKa of 3.9 and isoelectric point of 2.77 (Table 6.1). For 
aspartic acid, 10 and 200 µg/mL concentrations significantly enhanced the cumulative percentage 
of insulin permeated with respect to the control (Figure 6.23). The percentages of insulin permeated 
were 2.03 ± 0.37% and 2.73 ± 0.96% after 1 hour, and increased steadily to 16.20 ± 2.81 and 17.78 
± 4.79% after 4 hours, respectively. As expected, 200 µg/mL gave maximum Pcell values (Table 
6.2) at 9.86 ± 4.25 x 10-6 cm/s and maximum enhancement percentage (Figure 6.24) of 314.50 ± 
85.46%, while 10 µg/mL produced values of 8.78 ± 1.19 x 10-6 cm/s and 285.56 ± 62.45%, 
respectively. Increasing aspartic acid concentration above 400µg/mL did not enhance insulin 
absorption. Similar to results observed for glutamic acid, increasing aspartic acid concentrations 
up to 200 µg/mL did not significantly change the solubility of insulin or solution pH, as seen in 
Figure 6.6. Moreover, for concentrations above 200 µg/mL, insulin permeability drastically 
declined, with a significant drop in solution pH. However, at all concentrations tested, insulin 
solubility was higher for aspartic acid than for glutamic acid.  
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Figure 6.23 Cumulative percentage of insulin permeated in the presence of various concentrations of aspartic acid 
(n=3). 10 and 200 µg/ mL significantly enhanced insulin permeation above the control. 
 
 
Figure 6.24 Comparing the percent enhancement of insulin permeability through TR146 cell layers in the 
presence of various concentrations of aspartic acid and solution pH (n=3). 
 
This could be attributed to the fact that the pKa of aspartic acid is lower than that of glutamic acid, 
and thus there was a larger difference in pKa between insulin and aspartic acid, than insulin and 
glutamic acid, to enable dissociation and onward ion-pair formation. Elshaer et al (2011) suggested 
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that for candidates to sufficiently ionise to produce counter ions that could form non-ionised 
complexes that enhance permeability, the difference in pKa should be up to 3 units.  
 
Figure 6.25 Comparing the solubility at 25 ºC and permeability of insulin through TR146 cells layers, in the 
presence of various concentrations of aspartic acid (n=3). Low insulin concentration permeated at 400 µg/ mL 
due to low insulin solubility at pH of this solution (1 mg insulin = 27 IU). 
An investigation of TEER results for aspartic acid (Table 6.3) revealed that only 600 µg/mL 
concentration significantly reduced TEER values during the course of the 4 hour experiment. 
Similar to glutamic acid results, MTT assay results in Figure 6.12 showed that aspartic acid was 
non-toxic to cells within the concentration range of the permeation experiments, as only 800 µg/mL 
significantly decreased cell viability. Thus, the permeation enhancement recorded was not due to 
leakage from the disrupted cell membranes or compromised cellular integrity. Therefore, for 
aspartic acid, 10 and 200 µg/mL were observed to effectively and safely enhance permeability due 
to its ability to effectively create an optimal balance between ionised insulin to enhance solubility, 
and the formation of neutral insulin-aspartic acid ion paired molecules with higher lipophilicity; 
and/ or the use of membrane peptide/ amino acid transporters to enhance permeation, as discussed 
in earlier sections (Elshaer et al 2014, Samiei et al 2014). Therefore, for the acidic amino acids, 
10, 100 and 200 µg/mL glutamic acid and 10 and 200 µg/mL aspartic acid were able to effectively 
and safely enhance insulin permeation without any toxicity to TR146 cells, as highlighted in Figure 
6.26.  
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Figure 6.26 Highlighting concentrations of acidic amino acids that significantly enhanced insulin permeability 
with no toxicity to TR146 cells (n=3). 10, 100 & 200 µg/ mL glutamic acid and 10 & 200 µg/ mL aspartic acid 
significantly enhanced insulin permeation without causing toxicity to cells. 
6.3.4.3 Sodium deoxycholate 
Sodium deoxycholate (SDC) is a bile acid salt with pKa 6.58 (Table 6.1), which has been widely 
investigated for its role in enhancing permeation of drugs across cell membranes (Shojaei 1998, 
Junginger et al 1999, Şenel and Hıncal 2001, Nicolazzo et al 2005). In this study, the effectiveness 
and safety of the amino acids as permeation enhancers was compared against that obtained with 
sodium deoxycholate, to verify if amino acids could serve as less toxic and safer alternative 
permeation enhancers for insulin than bile salts. From Figure 6.27, 200, 400 and 600 µg/mL sodium 
deoxycholate were able to significantly enhance insulin permeability at 26.61 ± 0.24%, 23.10 ± 
1.21% and 23.04 ± 1.075%, respectively. These three concentrations were observed to exhibit 
significantly higher Pcell values than the control at about 13.5 cm/s respectively and maximum 
percentage enhancement was 440.82 ± 83.92%, 428.21 ± 45.06% and 434.84 ± 49.26%, 
respectively (Figure 6.28). The high enhancement observed in insulin permeability with sodium 
deoxycholate was an expected finding based on the ability of surfactants to fluidise the lipid 
membranes of the cells and impact on their integrity and barrier forming properties (Şenel and 
Hıncal 2001).  
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Figure 6.27 Cumulative percentage of insulin permeated in the presence of various concentrations of sodium 
deoxycholate (SDC) (n=3). All concentrations ≥ 200 µg/ mL significantly enhanced insulin permeation above the 
control. SDC showed higher permeation enhancement than all the amino acids tested. 
 
Figure 6.28 Comparing the percent enhancement of insulin permeability through TR146 cell layers in the 
presence of various concentrations of sodium deoxycholate and solution pH (n=3) 
This effect was seen with TEER results, where a significant and linear drop in TEER values 
signifying a reduction in cell layer integrity was recorded at concentrations of SDC >100 µg/mL 
(Table 6.3). Cell viability results (Figure 6.12) further confirmed increased toxicity of cells exposed 
to 100 µg/mL SDC and above. Xue et al (2012) reported no significant change in TEER results in 
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the presence of 10 and 50 µg/mL Na deoxycholate, however 10 – 50 µg/mL reduced the viability 
of TR146 cells after 24 – 48 hour exposure using the MTT assay. 
 
 
Figure 6.29 Comparing the solubility at 25 ºC and permeability of insulin through TR146 cells layers, in the 
presence of various concentrations of sodium deoxycholate (n=3). Insulin enhancement observed for SDC found 
to be via disruption of cellular membranes lowering cell integrity (1 mg insulin = 27 IU). 
Because the increase in insulin permeability afforded by SDC showed a linear trend (Figure 6.28), 
while that of the amino acids showed a somewhat “zig-zag trend”, it is possible that for the amino 
acids, a further mechanism (such as triggering of amino acid/ peptide transporters) outside 
disruption of cell membranes, came into play. Surfactants such as SDC enhance drug permeation 
paracellularly by binding to calcium ions or disruption of hemi desmosomes between cells which 
might enhance both paracellular and transcellular transport (Buchert et al 2012, Moghimipour et 
al 2015). Thus, because of the toxicity exhibited by SDC, none of the tested concentrations yielded 
effective and safe permeation enhancement.  
Figure 6.30 compares the concentrations of enhancers that effectively and safely improved insulin 
permeation across TR146 cell layers in vivo. It can be noted that apart from arginine which showed 
no significant improvement in the coefficient of apparent permeability through the cell layers (Pcell), 
at 10 µg/mL all amino acids were safe and effective; SDC was safe but ineffective. At high 
concentrations of 200 µg/mL, the acidic amino acids were both safe and effective while lysine and 
SDC were effective but unsafe; and at 100 µg/mL, only glutamic acid was safe and effective; lysine 
-10
10
30
50
70
90
110
130
150
0
200
400
600
800
1000
1200
1400
1600
1800
0 10 50 100 200 400 A
m
o
u
n
t 
o
f 
In
su
lin
 p
e
rm
e
at
e
d
 (
µ
g)
In
su
lin
 c
o
n
ce
n
tr
at
io
n
 (
µ
g/
m
L)
Sodium deoxycholate concentration (µg/mL)
Solubility of Insulin Amount of Insulin permeated
Chapter Six 
229 
 
was effective but unsafe, while SDC was ineffective and toxic. Thus, we have been able to 
demonstrate that acidic and basic amino acids act as effective penetration enhancers which 
circumvent the toxicity issues related with the use of surfactants such as SDC. 
 
 
Figure 6.30 Graph highlighting concentrations of tested penetration enhancers that significantly enhanced insulin 
permeability with no toxicity to TR146 cells (n=3). Black rectangles signify concentrations that were both effective 
and safe. 
6.3.5 Route of insulin transport 
After identifying safe and effective amino acid permeation enhancers for insulin, the next priority 
was to determine the route of insulin transport (whether paracellular or transcellular) across the 
buccal cell layers. In order to test our first hypothesis that formation of neutral insulin-amino acid 
ion pairs with higher lipophilicity would enhance transcellular insulin transport by passive 
diffusion, FITC-labelled insulin (6 µg/mL) was transported for 4 hours across TR146 cells grown 
on transwell inserts and cells analysed by confocal microscopy. Results revealed localisation of 
FITC-insulin molecules in the cell cytoplasm (not paracellularly), both in the presence and absence 
of amino acids and bile salts.  Figure 6.31 presents the localisation of FITC insulin on TR146 cells 
in the presence of the amino acid concentrations that enhanced insulin permeation, cells without 
amino acids used as control. Figure 6.32 are DAPI-stained images confirming that FITC-insulin 
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localisation occurred close to the nucleus.  These findings were in contrast to investigations for 
FITC-labelled dextran 4kDa as a marker for paracellular transport via TR146 cell layers (data from 
chapter 4). FITC-dextran was seen to traverse the buccal cells via the paracellular route with no 
localisation at all in the nucleus or cytoplasm (Figure 6.33). These results confirmed our hypothesis 
that insulin transport did not occur paracellularly but was through the transcellular facilitated 
transport system.  The paracellular route has been reported to transport small hydrophilic molecules 
(≤300 Da) by passive diffusion. The absence of paracellular transport for insulin could be due to 
its large molecular weight (5,800 Da) and the fact that the intercellular spaces of the buccal cavity 
are highly lipophilic due to the extrusion of the lipid content of the membrane coating granules that 
occur in the upper one-thirds of the buccal epithelium into the intercellular spaces, thereby 
inhibiting buccal paracellular transport (Shojaei 1998, Şenel and Hıncal 2001). The transcellular 
transport observed in the absence of amino acids (control) indicates that insulin transport possibly 
occurred via insulin receptors. Insulin has been reported to adsorb to apical membranes of cells 
and permeate the cell via endocytosic processes (Agarwal and Khan 2001, Muheem et al 2014). 
Similar findings were recorded by Thompson et al (2011) who investigated the transport of FITC-
insulin across Caco-2 cell lines (model for small intestine) and reported localisation of FITC-
insulin in the cell cytoplasm after 30 minutes exposure at 3 µg/mL. This uptake of insulin was 
reported to be mediated by interactions with insulin receptors (Thompson et al 2011). Xu (2002) 
reported that confocal microscopic imaging of FITC-labelled insulin showed that insulin could be 
transported via both the transcellular and paracellular routes in rabbit buccal mucosa.  
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Figure 6.31 Confocal microscopic images x40, showing transport pathway of FITC-labelled insulin through TR146 buccal cell layers in the presence 
of amino acid concentrations that effectively enhanced insulin permeability Insulin observed to traverse transcellularly with localisation in the nucleus. 
Control (A), Arg 50µg/mL (B), Asp10µg/mL (C), Asp 200 µg/mL (D),  Glu 10 µg/mL (E), Glu 100 µg/mL (F), Glu 200 µg/mL (G), Hist 10 µg/mL (H), 
Lys 10 µg/mL (I), Lys 100 µg/mL (J), Lys 200 µg/mL (K), SDC 200 µg/mL (L). 
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Figure 6.32 Representative confocal microscopic images of FITC-insulin, x40 (A) localisation and DAPI nuclear 
stain (B) on TR146 cells for control (1) and in the presence of Glu 10µg/mL (2). DAPI staining confirms 
localisation of FITC insulin in the nucleus (white arrows), with no paracellular transport.  
 
 
 
Figure 6.33 Representative confocal microscopic images of FITC-dextran 4kDa localisation, x40 (A) in the 
intercellular spaces of TR146 cells, showing paracellular transport (white arrows). DAPI stained nuclei (blue 
stain) (B) confirm the absence of the paracellular marker in the nucleus.  
Chapter Six 
233 
 
6.3.6 Mechanism of insulin transport through TR146 cell culture model 
Upon confirming that insulin traversed the buccal cell layers via the transcellular and not the 
paracellular route, we needed to test our second hypothesis that this transport was by active 
transporter facilitated mechanisms. Glutamic acid was chosen as a representative amino acid since 
it showed enhanced permeation and overall safety over the widest range of concentrations tested. 
Sauberlich (1961) reported that of all the 20 amino acids fed in excess of recommended doses to 
weanling rats, L-glutamic acid showed the least toxicity expressed as inhibition of growth, and 
showed the least absorption into the plasma. 
To investigate the presence of active transport, the concentration of insulin was kept constant at 1 
mg/mL (27 IU/mL), while glutamic acid concentration was varied at 0, 100, 200 and 400 µg/mL. 
Transport experiments were carried out in a cold room at 9 ºC. Results depicted in Figure 6.34 
revealed a significant reduction in insulin permeation at 9 ºC compared with 36 ºC. Furthermore, at 
9 ºC the amount of insulin permeated decreased with increasing amino acid concentration.  
 
Figure 6.34 To investigate active insulin transport in the presence of amino acids. Insulin concentration was fixed 
at 1mg/mL while amino acid concentration was varied, and permeation experiments carried out at 9 ºC for 4 
hours (n=3). Note: Results for 200µg/mL at 36 ºC, permeated for only 3 hours. Temperature and concentration 
dependent fall in insulin permeation at suboptimal temperatures confirm the presence of active transport of 
insulin due to enzyme inactivation that occurs at low temperatures, and early saturation of transporters (1 mg 
insulin = 27 IU). 
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These results point to the presence of active transport of insulin-glutamic acid neutral complexes 
formed by ion-pairing, possibly via amino acid/ peptide transporters in the cell membranes (Lehr 
2003). Membrane transporters are membrane bound proteins that selectively facilitate the transport 
of substances across biological membranes (Lin et al 2015). This facilitated transport is depicted 
in Figure 6.3 above. Inactivation of enzymatic activity at suboptimal temperatures results in 
reduced function of these transporters, thereby inhibiting insulin permeation across the cell layer. 
Furthermore, as transporter activity had already been compromised by the low temperature, 
increasing amino acid concentrations above 100 µg/mL caused a further reduction and ultimate 
cessation of insulin transportation probably through early saturation of the transporters (Elshaer et 
al 2014). It is possible that the low transport recorded at 400 µg/mL glutamic acid could be related 
to the low solubility of insulin at this concentration (Figure 6.6), however this concentration 
showed insulin permeation at 36 ºC (Figure 6.34), thereby suggesting that the change was due to 
saturation of the transporter proteins (Artursson et al 2012, Elshaer et al 2014).  
To further establish the presence of active transport in this system, glutamic acid concentration was 
maintained at 200µg/mL while insulin concentration was varied at 250, 500, 1000 and 1500 µg/mL 
(Figure 6.35). It was observed that increasing insulin concentrations above 500µg/mL showed no 
significant increase in permeation. Biochemical reports on the buccal epithelium reveals the 
extrusion of lipid components of the epithelium into the paracellular spaces, thereby increasing its 
lipophilicity and causing an added permeation barrier (Patel et al 2011), Thus, passive paracellular 
diffusion would not be expected for a macro molecule such as insulin (5,800 Da), since this route 
favours the transport of hydrophilic molecules ≤ 300 Da (Lehr 2003). Passive diffusion relies on 
the concentration gradients between the extracellular and intracellular compartments, while active 
transport can occur against a concentration gradient; therefore, no increase in permeation would be 
observed with increasing drug concentration if the molecule was solely transported actively (Lehr 
2003). The rate of transport in passive diffusion is governed by Fick’s law and is, therefore, directly 
dependent on the initial concentration; with active transport, this relationship is only relevant at 
low concentrations, and with increasing concentrations, carrier saturation occurs and no increase 
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in uptake is observed with increasing concentrations (Lehr 2003). Thus, results from Figure 6.35 
point to the presence of passive and active transport mechanisms for insulin. 
 
Figure 6.35 Investigating active and passive transport of insulin-amino acid ion pairs across TR146 buccal cell 
layers (n=3). Glutamic acid concentration was fixed at 200 µg/mL, and insulin concentration varied. Vectoral 
transport was investigated by reversing the transport direction from basolateral-to-apical. Results highlight a 
dependence on initial concentration and direction of transport, pointing to active transport mechanisms (1 mg 
insulin = 27 IU). 
 
We further investigated vectoral transport of insulin across the cell layers. Reversal of transport 
direction from apical-basolateral, to basolateral-apical revealed a concentration dependent increase 
in insulin permeation, with no permeation recorded at 250 and 500 µg/mL insulin. According to 
Biopharmaceutical Classification System (BCS) guidelines, to confirm the presence of passive 
transport in vitro, there should be a lack of dependence on initial concentration and directional 
transport (Lehr 2003). Thus, results from Figure 6.35 further confirm the presence of active 
transcellular transport for insulin, since the concentration of nutrient transporter proteins are higher 
at the apical surface than at the basolateral surface. Artusson et al (2012) agreed that highly potent 
hydrophilic compounds such as peptide antigens, with similar structures as food nutrients could be 
transported across cell layers by a combination of active facilitated transport as well as passive 
transport. However, these results obtained for insulin was the first indication of a possible amino 
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acid mediated transport of insulin via formation of insulin-amino acid neutral complexes by the 
ion pairing mechanism.  
6.4 Conclusion 
The aim of this work was to investigate the effect of basic and acidic amino acids on the 
physicochemical and biological properties of insulin, in order to provide alternative safe and 
effective excipients that enhance buccal insulin delivery. Basic amino acids were able to 
significantly improve insulin solubility in water, while 200 and 400 µg/mL lysine significantly 
increased insulin solubility in HBSS. The presence of amino acids was able to increase the 
hydrophilicity of insulin and lower its log D by 0.7 units. However, despite this reduced 
lipophilicity, amino acids were able to effectively and safely enhance permeation of insulin across 
TR146 cell layers significantly, pointing to the presence of an active carrier transport system. It 
was hypothesised that at buccal cavity pH, both amino acids and insulin were ionised and able to 
form stable ion pairs which penetrated through the cells as one entity. Permeability data showed a 
significant improvement in insulin permeation, especially for 10 µg/mL of lysine (p < 0.05) and 
histidine 10 µg/mL (p < 0.001), 100 µg/mL of glutamic acid (p < 0.05) and 200 µg/mL of glutamic 
acid and aspartic acid (p < 0.001) without affecting cell integrity; in contrast to sodium 
deoxycholate which enhanced insulin permeability but was toxic to the cells.  The results of these 
studies demonstrated a “bell-shaped” impact on insulin permeability upon increasing the 
concentration of amino acid counter ions, and suggest that the concentration of the counter ion 
requires optimisation to provide a stringent control of insulin dissociation to enhance both protein 
solubility and permeation. Interestingly, investigating the mechanism and route of insulin 
permeation using increasing concentrations of insulin at suboptimal temperatures, reversed 
transport direction and confocal microscopy revealed that insulin was transported by both active 
and passive transcellular processes, with active processes afforded by the presence of insulin 
receptors and amino acid nutrient transporters on the cell membrane. Therefore, amino acids were 
established as safer, effective and novel penetration enhancers than the commonly used surfactant 
for insulin using the ion-pairing mechanism. 
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Chapter 7 
Characterisation of insulin buccal 
tablets 
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7.1 Introduction 
Buccal drug delivery has received increasing attention as a potential site for delivery of proteins 
that are inactivated in the GIT due to its high lymphatic drainage, lower drug metabolism and ease 
of patient acceptance (Khafagy et al 2007, Patel et al 2011). A major setback for ODTs is the saliva 
scavenging and accidental swallowing that occurs upon tablet placement into the mouth (Behra et 
al 2012). Thus, an ODT placebo base was formulated (chapter 3) containing various viscosity 
grades of the mucoadhesive polymer polyethylene oxide (Polyox™), that would allow for fast 
disaggregation of the tablet upon placement in the mouth, but continued adhesion of the produced 
slurry to the buccal mucosa until drug release and permeation is completed. Such a tablet would be 
expected to exhibit enough mechanical strength to withstand stress during packaging and transport, 
but also be able to imbibe water into its bulk to facilitate fast disintegration/ disaggregation and 
onward release of the contained drug (Al-Khattawi et al 2014). 
Various kinetic models have been employed to describe the rate of drug release from dissolving 
tablet matrices. Zero order kinetics (equation 7.1) can be used to describe the slow release of a 
poorly soluble drug from non-disintegrating dosage forms, with release rate that is independent of 
initial concentration (Dash et al 2010). This is applicable to coated systems and osmotic systems 
(Dash et al 2010). The first order model (equation 7.2) has been used to describe the dissolution 
soluble drugs from porous polymer matrices, where the rate is dependent on initial concentration. 
Higuchi kinetics (equation 7.3) describes a release that follows a Fickian diffusion from an 
insoluble matrix that is dependent on the square root of time. The Higuchi model has been 
to several modified release dosage forms containing water soluble drugs. While the Hixson-
Crowell cube root law (equation 7.4) describes a dissolution-controlled drug release from 
or tablets that takes into account the change in surface area as the dissolution process proceeds 
(Shoaib et al 2006, Tamilvanan and Sa 2006, Dash et al 2010). The Korsmeyer-peppas model 
(equation 7.5) derived by Korsmeyer et al (1983) is used to determine the overall mechanism of 
drug release from polymer containing systems such as tablets, estimated when ≤60% of the drug 
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has been released (Shoaib et al 2006). The ‘n’ values depict the actual release mechanism, and 
interpretations of this value for a cylindrical system such as a tablet are given in  
Table 7.1 below. 
𝑄𝑡 =  𝑄0 +  𝐾0𝑡 . . . . . . . (Equation 7.1) 
𝑙𝑛𝑄𝑡 = 𝑙𝑛𝑄0 + 𝐾𝑡 . . . . . . . (Equation 7.2) 
√𝑄0
3 −  √𝑄𝑡
3 =  𝐾𝐻𝐶𝑡 . . . . . . . (Equation 7.3) 
𝑄 =  𝐾𝐻√𝑡 . . . . . . . . (Equation 7.4) 
𝑀𝑡
𝑀∞
= 𝐾𝐾𝑃𝑡
𝑛 . . . . . . . . (Equation 7.5) 
Where Q0 is the initial amount of insulin, Qt is the cumulative amount of insulin released at time, 
t; Mt/M   ͚is the fraction of drug released, n is the release exponent that gives an indication of the 
release mechanism involved and K0, K, KHC, KH and KKP are the zero order, first order, Hixson-
Crowell, Higuchi and Korsmeyer-peppas rate constants respectively.  
 
Table 7.1 Table highlighting the overall mechanism of drug release from cylindrically shaped systems such as 
tablets derived from the release exponent of the Korsmeyer-peppas model (Jacques et al 1974, Shoaib et al 2006, 
Dash et al 2010) 
 
Release 
exponent (n) 
Overall release 
mechanism 
Details Rate as a function of 
time  
≤ 0.45 Fickian diffusion Molecular drug 
diffusion via a chemical 
gradient 
 
t-1/2 
0.45 < n < 0.89 Anomalous (non-
Fickian) diffusion 
Diffusion does not obey 
Fick’s law 
 
tn-1 
0.89 Case-II transport Relaxational drug 
release through stress 
and state transition in 
hydrophilic glassy 
polymer that swell in 
water 
 
Zero order release 
>0.89 Super case-II 
transport 
Cannot be described by 
the K-P model 
 
tn-1 
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The aim of this work was to bring together the design parameters generated from the QbD study in 
chapter 3 and results from insulin transport in chapter 6, to formulate buccal tablets incorporating 
insulin and glutamic acid into the placebo tablet base; and thereafter characterise disintegration 
time, mechanical strength and release characteristics, to serve as a basis for the onward assessment 
of in vitro and in vivo effectiveness in buccal insulin delivery. 
7.2 Materials and methods 
7.2.1 Materials 
Sentry Polyox® (polyethylene oxide) WSR N10 (MW 100,000 Da), 1105 (MW 900kDa), N-60K 
(MW 2000 kDa) and Coagulant (MW 5000 kDa) were a gift from Colorcon (Kent, UK). L-HPC 
grade NBD-022 was a gift from Shin-Etsu (Tokyo, Japan). D-Mannitol, magnesium stearate, 
human recombinant insulin powder, L-glutamic acid (minimum 99% TLC) and TFA were 
purchased from Sigma Aldrich Chemicals (Poole, UK). All materials were of pharmaceutical grade 
and used as received. 
7.2.2 Methods 
7.2.2.1 Preparation of insulin buccal tablets 
The critical process parameters (CPP) generated by the MODDE software optimiser for the various 
polyox polymer blend formulations (ODT base) from chapter 3 were used to prepare 50 mg buccal 
tablets containing 1mg insulin and 200 µg glutamic acid each (information from chapter 6). 
Formulation compositions are shown in Table 7.2 below. The ingredients were weighed, 
geometrically mixed, and 50 mg each of the powder blends was singly weighed and compacted at 
30 kN (3 tons) using a semi-automatic bench-top tablet press (Sympatec, UK), equipped with 5 
mm flat faced dies. 
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Table 7.2 Composition of insulin buccal tablets developed from the critical process parameters (CPP) determined 
from results from chapters 3 and 6. 
 
Formulation Quantities  
 
 Mannitol LHPC Polyox Insulin Glutamic 
acid 
Mg stearate 
 
N10 to 50mg 7% 1.32% 1.0 mg 0.2 mg 0.50% 
 
1105 to 50mg 7% 1.32% 1.0 mg 0.2 mg 0.50% 
 
N60K to 50mg 7% 1.36% 1.0 mg 0.2 mg 0.50% 
 
Coag to 50mg 7% 1.36% 1.0 mg 0.2 mg 0.50% 
 
 
7.2.2.2 Tablet disintegration/ disaggregation 
The disintegration/ disaggregation time was determined by placing a tablet in a well of a 12 well 
cell culture plate containing 1.5 mL of HBSS rotated at 30 rpm and 37 ͦ C in an orbital shaker. This 
adapted method was used due to the small size of the tablets, and the limited saliva volume present 
in the buccal cavity for tablet disintegration, compared with the USP apparatus II test employed in 
earlier sections of the work. For these experiments, disintegration/ disaggregation time was taken 
as the time for the tablet to crumble into a slurry still held together by the mucoadhesive polymer.  
7.2.2.3 Tablet friability 
The ability of the tablets to withstand mechanical stress, known as friability was measured using a 
rotating drum friabilator (J. Engelsmann AG, Ludwigshafen, Germany). 6 tablets were utilised at 
25 rpm for 100 revolutions or 4 minutes.  Tablets were carefully dusted before and after the test, 
and friability expressed as the percentage loss in weight. 
𝐹𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡−𝑓𝑖𝑛𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
 𝑥
100
1
  . . . . (Equation 7.6) 
7.2.2.4 Tablet hardness 
The hardness (crushing strength) of the tablets was measured using a 4M hardness tester 
(Schleuniger, Thun-Switzerland). Tensile strength, ơ was calculated from the equation: 
𝑇𝑒𝑛𝑠𝑖𝑙𝑒 𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ (Ơ) =
2 𝑥 𝐻𝑎𝑟𝑑𝑛𝑒𝑠𝑠
𝜋𝑑h
   . . . . . (Equation 7.7) 
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Where d = tablet diameter and h = tablet thickness; measured using a digital Vernier calliper. 
7.2.2.5 Drug release from buccal tablets 
The release of insulin from the buccal tablets was studied using 12 well cell culture plates (similar 
to drug transport studies from chapter 6, but without cells) adapted from Heikkilä et al (2007). 
Each tablet was placed in a well of a 12 well plate containing 1.5 mL HBSS, pH 7.4 and rotated on 
an orbital plate shaker at 140 rpm. The release studies were carried out using a similar method to 
the permeability studies from chapter 6, to provide a basis for comparison when carrying our 
permeability studies of insulin from buccal tablets.  700 µL samples were withdrawn at specific 
intervals and immediately replaced with equal volume of HBSS, to maintain sink conditions where 
drug concentration was <10% saturation solubility of the drug at all times. Samples were assayed 
for insulin content using the validated HPLC method from chapter 6. The amount of insulin 
released per time was calculated from equation 7.8 and percentage drug release calculated from 
equation 7.9 below: 
𝑀𝑡[𝑛] =  
𝑉𝑟∗𝐶[𝑛]+ 𝑉𝑠 ∑ 𝐶[𝑚]
𝑛−1
𝑚=1
1000
 . . . . . (Equation 7.8) 
Where Mt is total drug released at time, t in mg; n is the number of samples taken, Vr is the 
dissolution volume in mL, Vs is the sampling volume, C[n] is the current concentration in the 
dissolution medium in mg/L, ΣC[m] is the summed total of previous concentrations. 
% 𝐷𝑟𝑢𝑔 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 =  
𝐴𝑐𝑡𝑢𝑎𝑙 𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝑎𝑚𝑜𝑢𝑛𝑡
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡
  𝑥 
100
1
 . . (Equation 7.9) 
7.2.2.6 Determination of insulin release mechanism from buccal tablets 
Five kinetic models namely zero order, first order, Hixson-Crowell cube root, Higuchi and 
Korsmeyer-peppas kinetics (equations 7.1, 7.2, 7.3, 7.4 and 7.5, respectively) were applied to the 
collated data, to determine the model that best fit the release pattern of insulin from the 
formulations; based on the highest correlation coefficients (R2) obtained (Shoaib et al 2006, 
Tamilvanan and Sa 2006). From here, five graphs were plotted as follows: cumulative % insulin 
released vs time (zero order kinetics), log cumulative % drug remaining vs time (first order 
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kinetics), cumulative % drug release vs square root of time (Higuchi kinetics), cube root of % 
insulin remaining vs time (Hixson-Crowell cube root kinetics) and log cumulative % insulin 
released vs log time (Korsmeyer-peppas kinetics) (Shoaib et al 2006). 
7.2.2.6 Statistical analysis 
All data generated in replicates were presented as mean ± standard deviation (s.d.), where n=3.  
The data was then analysed for statistical significance using one-way analysis of variance 
(ANOVA) and Tukey-Kramar multiple comparison  post-test from Graphpad Prism® version 6.07 
(Graphpad Software, San Diego, CA, USA). The level of significance was quoted as p<0.05 
(probability values of 95%). 
7.3 Results and discussion 
7.3.1 Insulin buccal tablet characteristics 
Results of tested tablet characteristics are shown in Table 7.3. Porosity of the tablets could not be 
determined due to the small size of the tablets in relation to the size of the pycnometer cell. From 
Table 7.3 it can be seen that tablet disintegration time increased with increasing polymer viscosity 
from Polyox N10 to Polyox coagulant. These results are in line with that obtained for similar 
formulations of 500 mg placebo tablets (without insulin or glutamic acid) discussed in chapter 3 of 
this work. These results also reveal the predictive power of our model and the fact that critical 
process parameters (CPPs) could be extrapolated to smaller sized tablets containing similar 
formulation compositions. All tablets disintegrated in <60 seconds except those containing the 
highest viscosity of polyox. This was an expected result from our model and can be explained, as 
high viscosity polymers form a matrix that impedes the imbibing of water into the tablet and 
therefore hinder disintegration (Royce 1993, Lee et al 1999, Efentakis and Vlachou 2000, Streubel 
et al 2003, Alhusban et al 2011). However, the low concentrations of polyox polymers used in this 
study allowed for fast disintegration/ disaggregation of all the tablets in line with the BP 
specification of <3 mins. 
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Table 7.3 Results of tablet characteristics and drug release parameters for insulin buccal tablets (n=3) 
 
Similar disintegration times were recorded for the 50 mg tablets and the 500 mg placebo tablets 
tested in chapter 3, despite the smaller volume of disintegration medium utilised in the former case. 
This could be due to the presence of water soluble glutamic acid in the formulation of the insulin 
tablets. Water soluble excipients/ carriers have been reported to enhance the disintegration and/ or 
dissolution of poorly water soluble drugs due to their ability to attract water molecules and enhance 
wettability (Vasconcelos et al 2007, Sareen et al 2012) 
As with our model results from chapter 3, tablet hardness did not follow a linear pattern with 
regards polymer viscosity. Only the formulation containing the lowest viscosity polyox (N10) 
showed a significantly lower hardness; there was no significant difference in the hardness of the 
other formulations tested. Hardness for all tablets was less than our minimum limit of 60N, but 
higher than 50 N for all formulations except N10. This value for hardness is not of concern because 
tablet hardness is dependent on tablet dimensions (shape, size and thickness) and the cross sectional 
area of load application (Razavi et al 2015, Gamlen 2016). Therefore, tablet tensile strength, which 
is more representative of mechanical strength, was calculated, as it takes into account the size and 
dimensions of the tested tablet and relates to the crushing strength. The calculated tensile strength 
was above 3 MPa for all formulations and, therefore, within acceptable limits. Amidon et al (2009) 
reported that tablet tensile strengths of >1 MPa are suitable to maintain mechanical strength 
throughout the lifetime of a tablet (Gumaste et al 2013). 
For tablet friability, the lowest viscosity polyox formulation (N10) exhibited the highest friability 
and this was expected due to its low hardness. Polyox 1105 and Polyox coagulant formulations 
Polymer 
viscosity 
grade 
Disintegration 
time (s) 
Friability 
(%) 
Hardness (N) Tensile 
strength (MPa) 
% Drug 
Release 
Polyox  
N10 
25.67  ± 3.51 1.68 37.53  ± 5.15 3.65 ± 0.44 86.89 ± 8.28 
Polyox 
1105 
48.67 ± 3.06 0.96 52.03 ± 3.71 4.60 ± 0.26 102.66 ± 13.43 
Polyox 
N60K 
50.33 ± 1.53 1.29 54.57 ± 1.17 4.49 ± 0.26 106.37 ± 3.22 
Polyox 
Coag 
66.67 ± 2.08 0.85 53.3 ± 1.25 4.35 ± 0.09 87.92 ± 4.90 
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were able to significantly lower the friability of the tablets within the acceptable limits of <1% 
respectively. From our model in chapter 3, 1105 placebo tablets exhibited the lowest friability 
compared to other formulations. The friability of tablets containing polyox is dependent on the 
elastic recovery exhibited by the polymer under compaction, and this in turn affects the tablet’s 
porosity (data from chapter 3). However, tablet porosity was not measured in this study. The 
observed reduction in friability by 1105 and Coagulant was an achievement that was not obtained 
with all the previously tested placebo tablets. It should be noted that for all the critical quality 
attributes (CQAs) tested, a linear relationship was not expected, except for disintegration time due 
to polymer viscosity. This is because the MODDE optimiser selected levels of the critical process 
parameters (CPPs) that would yield optimal CQAs (Table 7.2), and these CPP levels differed for 
the various polyox polymers utilised. 
7.3.2 In vitro insulin release from buccal tablets 
From Figure 7.1 it can be seen that the formulation containing the lowest viscosity grade of polyox 
(N10) had the fastest release rate of insulin, with maximum release occurring within 30 mins; 
closely followed by N1105 and N60K with intermediate viscosities. Conversely, as expected, the 
highest viscosity grade polyox (coagulant) showed a slower release of the drug, with maximum 
drug release after 1 hour. This observation is possibly related to the matrix-forming ability of high 
viscosity polymers (Lee et al 1999). Thus, even at the low polymer concentrations employed 
(<1.5%), polyox polymers were able to modify the release of insulin from the formulations 
depending on their viscosity.  
Fitting the release data into the available kinetic models showed that the release kinetics for all the 
formulations could be described by the Higuchi kinetic model, having the highest correlation 
coefficient (R2) as seen in Table 7.4. This result implies that the release of insulin from the LHPC/ 
polyox containing formulation was determined by a diffusion controlled mechanism (Tamilvanan 
and Sa 2006). 
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Figure 7.1 Results highlighting insulin release from buccal tablets formulated from compositions generated by 
the MODDE software optimiser from chapters 3 and 6 (n=3). High viscosity polyox (coagulant) formulation 
exhibited some modified release of insulin from tablets. 
 
From Table 7.4, Polyox Coag formulation exhibited the highest R2 for the Higuchi model compared 
to the other formulations, and this was in line with visual observations of the formulation which 
disintegrated into a slurry that was held within a sticky matrix, thereby impeding direct contact of 
drug with the dissolution media and thus producing a diffusion controlled release. It had been 
expected that the formulations containing lower viscosity grade polyox would exhibit release 
kinetics described by the Hixson-Crowell cube root law, which describes a dissolution controlled 
release of drug due to direct drug contact with the dissolution medium, as expected for conventional 
tablets (Tamilvanan and Sa 2006). However, our data showed that the presence of polyox 
(irrespective of the polymer grade) was able to impede direct contact of insulin with the dissolution 
media and produce diffusion-controlled release kinetics. The first order kinetics had the next 
highest R2 value to the Higuchi kinetics, for all the formulations and indicated that drug release 
was dependent on initial concentration. The Korsmeyer-peppas equation is used to fit the portion 
of the curve where ≤60% of drug release has occurred (Dash et al 2010). Because >60% of the 
drug had been released by 20mins of the dissolution process, estimation of release mechanism 
using this equation was not carried out due to a limited number of time points. 
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Table 7.4 Release parameters for insulin buccal tablets containing LHPC (7%) and various viscosity grades of 
polyox polymer (n=3) 
 
Formulation Zero order 
kinetics 
First order 
kinetics 
Hixson-Crowell 
kinetics 
Higuchi kinetics 
 R2 K0 
(hr-1) 
R2  K 
(hr-1) 
R2 KHC  
(hr-1/2) 
R2 KH  
(hr-1/3) 
 
N10 0.84 171.55 0.80 2.75 0.68 307.41 0.98 129.38 
 
1105 0.72 89.42 0.95 4.54 0.79 321.60 0.92 105.57 
 
N60K 0.82 131.15 0.96 4.14 0.92 511.91 0.92 125.23 
 
Coag 0.83 80.21 0.98 2.10 0.82 209.49 0.98 91.11 
 
         
 
7.4 Conclusion 
Applying the design parameters obtained from the QbD study in chapter 3 with results obtained 
from insulin permeability studies (from chapter 6) enabled the formulation of buccal tablets 
containing insulin and glutamic acid. Despite difference in the amount of polyox polymers in the 
various formulations, disintegration time of the tablets was still dependent on polymer viscosity, 
rather than polymer concentration, in line with results from our model in chapter 3. A reduction in 
friability to values within the acceptable limits of <1% was achieved for tablets containing polyox 
1105 and polyox coagulant; this was not possible from any of the previous placebo tablet 
formulations and could be related to the smaller tablet size or presence of insulin and/ or glutamic 
acid in the formulation. Drug release from the formulations was shown to be dependent on polymer 
viscosity with a decrease in release rate observed with increase in polymer viscosity. Fitting data 
into the various kinetic models of drug release highlighted insulin release to follow Higuchi 
kinetics for all the formulations (highest R2 value); revealing that drug release was diffusion-
controlled.  
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8.1 General discussion 
Advancements in biotechnology have enabled the large scale production of therapeutic proteins – 
insulin being the first of such biotechnologically engineered molecules to be produced in large 
scale. However, this has only solved one of the problems associated with protein therapy. The 
major challenge of the unavailability of non-invasive routes of administration for these molecules 
still remains. To date, proteins are primarily administered via the parenteral route, raising such 
concerns as psychological trauma, pain at injection site, need for daily injections, risk of infection 
and side effects such as angiopathy from parenteral insulin administration; which culminates in 
poor patient compliance and the risk of therapeutic failure. ODTs have been identified in recent 
years as a highly attractive dosage form that enhances patient compliance, especially for children 
and the elderly. The saliva scavenging and accidental swallowing that occurs after ODT 
administration, however, reduces its potential for epigastric absorption which is one of the 
advantages of this dosage form. Thus, the incorporation of mucoadhesive polymers into ODT 
formulations could prolong drug residence time and enhance drug absorption from the oral cavity. 
The high lymphatic supply, easy accessibility and low peptide degradation characteristics of the 
buccal mucosa has highlighted the buccal route as an emerging site for delivery of GI-sensitive 
proteins. A major setback to buccal delivery is the low drug permeation observed due to the 
stratifying nature of the epithelium, an effect which becomes more pronounced during delivery of 
large molecules such as insulin. This has necessitated the incorporation of permeation enhancers 
within buccal formulations, generating the need for naturally occurring, biodegradable enhancers 
that reduce systemic toxicity and lower the risk of immunogenicity; with the possibility of 
elucidating transport routes and mechanisms for these macromolecules in the presence of various 
enhancers. A further shortcoming during development of buccal dosage forms is the unavailability 
of standardised, highly reproducible, cost-effective pre-clinical methods for assessing buccal drug 
delivery. In vivo methods in humans and animals being cumbersome and non-standardised, in vitro 
methods using animal tissues having low reproducibility, while in vitro cell culture based assays 
are either not representative of in vivo nomenclature, or are expensive for continuous testing. The 
aim of this thesis was, thus, to offer solutions to, and fill existing gaps in the knowledge about 
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buccal delivery of therapeutic proteins using insulin as a model drug. Results of these will be 
highlighted in the following sections. 
To facilitate the development of a placebo ODT base, HPC and LHPC were individually 
characterised and assessed for their role(s) in ODT development in order to identify multi-
functionality within the polymers, which would be applied to develop ODTs with these qualities 
intelligently built into them. The characteristics of LHPC and HPC were found to be controlled by 
the degree of hydroxypropyl substitution of these polymers, which impacted on the appearance of 
crystallinity upon compaction (as seen from XRD results), functional groups available for 
intermolecular interactions (as seen from FTIR results) that further impacted on their water 
solubility. Thus, HPC produced tablets with good binding properties that eroded on contact with 
water, while LHPC produced good binder and disintegrant properties in tablets that broke up into 
smaller pieces (flaking off) in contact with water. A formulation containing 7% LHPC with 
mannitol as filler and magnesium stearate as lubricant gave the optimal balance of good mechanical 
and disintegrating properties with regards ODT acceptance criteria, and was therefore chosen as 
the optimised formulation. 
A QbD study incorporating design of experiments (DoE) was then carried out to identify factors 
that would enhance the incorporation of different viscosity grades of the mucoadhesive multi-
functional polymer, Polyox™ (polyethyleneoxide), into our previously formulated ODT base. This 
study exposed an interesting feature of polyox that allowed an enhancement in disintegration of 
tablets with increasing compaction pressure due to the elastic recovery of polyox at elevated 
compaction pressures that resulted in higher porosity, thereby facilitating drug disintegration.  
Therefore, it was possible to formulate mucoadhesive placebo ODTs containing polyox at high 
compaction pressures that reduced the tablet friability produced by the filler mannitol, without 
compromising the disintegration/ disaggregation time of the tablets. 
The ability of extracellular Ca2+ concentration to alter the stratification and proliferation of the 
TR146 buccal cell line was investigated in an attempt to produce buccal cell cultures with similar 
stratification properties as human buccal mucosa, which would increase the drug permeation 
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barrier of these cells and, therefore, serve as a reproducible, cost effective and reliable method for 
in vitro buccal drug delivery assessment. Addition of 1.5 mM Ca2+ to the specialised culture media 
for TR146 cells yielded enhanced proliferation and stratification of cells as captured using light/ 
confocal microscopy and haemocytometry. This enhancement was further seen to improve the 
penetration barrier of the cells to the paracellular transport marker FIT-C labelled dextran 4kDa. 
This was because calcium is a component of desmosomal proteins that line the intercellular spaces 
between cells.  However, the effect of extracellular Ca2+ on the biochemical properties of these 
cells requires elucidation. 
Characterisation of our model drug was carried out by the development of a simple, rapid method 
for insulin quantification at ambient temperature by UV detection which was validated in our 
laboratory using ICH guidelines, as well as in a separate laboratory employing a different operator, 
a different HPLC system and on different days. The effect of high compaction pressure (from 
formulation of the ODT base) on the secondary structure and bonds available for intermolecular 
interactions of insulin was investigated by circular dichroism (CD) and FTIR respectively. Insulin 
was observed to withstand compaction pressures of 3 tons without significant changes to its 
secondary structure (as assessed by CD) or changes to the appearance and magnitude of functional 
groups as seen from the location and magnitude of FTIR bands; indicating that a compaction 
pressure of 3 tons could be used in the formulation of insulin buccal tablets.  
Furthermore, basic and acidic amino acids were investigated for their effects on the solubility, 
distribution coefficient (log D) and permeability of insulin through TR146 buccal cell layers as 
novel, alternative, safe and effective buccal penetration enhancers for peptides; as well as to 
highlight their effect on the route and mechanism of insulin transport. Basic amino acids were able 
to significantly improve insulin solubility in water, while only lysine significantly increased insulin 
solubility in HBSS. The presence of amino acids was able to increase the hydrophilicity of insulin 
and lower its log D value by 0.7 units. However, despite this reduced lipophilicity, amino acids 
were able to effectively and safely enhance permeation of insulin across TR146 cell layers 
significantly, pointing to the presence of an active carrier transport system. Permeability data 
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showed a significant concentration-dependent improvement in insulin permeation (above 400% 
enhancement) without affecting cell integrity; in contrast to the bile salt sodium deoxycholate, 
which enhanced insulin permeability but was toxic to the cells. Glutamic acid exhibited the highest 
enhancement that was both effective and safe across a wide range of amino acid concentrations 
tested. It was hypothesised that at buccal cavity pH, both amino acids and insulin were ionised and 
able to form stable ion pairs which penetrated through the cells as one entity. Interestingly, 
investigating the mechanism and route of insulin permeation using increasing concentrations of 
insulin at suboptimal temperatures, reversed transport direction and confocal microscopy revealed 
that insulin was transported by active transcellular processes, probably provided by the presence 
of insulin receptors and amino acid nutrient transporters on the cell membrane. This result obtained 
for insulin is the first indication of a possible amino acid mediated transport of insulin via formation 
of insulin-amino acid neutral complexes by the ion pairing mechanism. Amino acids were, 
therefore, established as safer, effective and novel penetration enhancers than the commonly used 
surfactant for insulin using the ion-pairing mechanism. 
Finally, insulin and the amino acid glutamic acid were incorporated into the optimised placebo 
base to produce insulin buccal tablets exhibiting sufficient mechanical characteristics to withstand 
handling during packaging and transport (tensile strength >1 MPa, friability <1%) but with fast 
disintegration/ disaggregation of < 3 mins. Drug release from these tablets was found to follow 
Higuchi kinetics, which describes drug release that is diffusion-controlled. Thus, buccal insulin 
tablets incorporating glutamic acid were successfully fabricated from an ODT placebo base. These 
can then be taken forward to investigate the in vitro and in vivo effect of insulin delivered from 
buccal tablets. 
Future work 
- Elucidation of the effect of extracellular Ca2+ concentration on the biochemical 
composition, protein expression and lipid barrier of TR146 cell lines; and its effect on 
desmosome formation employing techniques such as transmission emission microscopy 
(TEM) and immunohistological assays.  
Chapter Eight 
253 
 
- Investigation of the effect of transmucosal permeation on the secondary structure of 
insulin, employing techniques such as circular dichroism and x-ray crystallography. 
- In vitro and in vivo studies highlighting the release of insulin from the formulated buccal 
tablets and the formulation efficacy in glycaemic control.  
- Stability studies on developed insulin buccal tablets. 
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Figure A-1. Representative graph showing particle size distribution of LHPC powder using laser diffractometry 
(n=3) 
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Table A-1. MODDE worksheet showing experimental run order, factors, observed responses and included/ excluded data sets. All responses are reported as means of triplicate runs. 
(Incl =  included, Excl = excluded) 
 
Exp 
Name 
Run 
Order 
Incl/Excl 
Polymer 
viscosity 
Polymer 
concentration 
Compaction 
pressure 
Disintegration 
time (s) 
Friability 
(%) 
Hardness 
(N) 
Porosity 
N1 14 Incl -1 0.5 1 59 1.75 89.5 0.3034 
N2 6 Incl 1 0.5 1 93.67 1.76 89.2 0.3379 
N3 11 Incl -1 2.5 1 75.67 2.5 52 0.2694 
N4 13 Incl 1 2.5 1 223.33 2.88 52.87 0.2891 
N5 9 Incl -1 0.5 3 38.33 1.11 154.1 0.201 
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N6 7 Incl 1 0.5 3 77.33 1.02 151.3 0.2306 
N7 17 Incl -1 2.5 3 51 1.06 128.3 0.3004 
N8 15 Incl 1 2.5 3 83 1.09 138.27 0.2863 
N9 3 Incl -1 1.5 2 63 1.53 98.47 0.2679 
N10 5 Excl 1 1.5 2 189.67 1.35 123.8 0.2718 
N11 2 Incl 0 0.5 2 53 1.49 97.3 0.2621 
N12 8 Incl 0 2.5 2 142.33 1.52 92.3 0.2686 
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N13 4 Excl 0 1.5 1 122.67 2.92 48.03 0.3036 
N14 12 Excl 0 1.5 3 65.33 1.11 131.67 0.2345 
N15 1 Incl 0 1.5 2 89.67 1.06 124.5 0.2994 
N16 10 Incl 0 1.5 2 66 1.33 104.83 0.2813 
N17 16 Incl 0 1.5 2 77.67 1.32 100.4 0.2696 
Polymer viscosity: Polyox N10 (-1), Polyox 1105 (0), Polyox coagulant (1) 
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Figure A-2. Beer-Lambert’s calibration curve for fluorescent spectroscopic method for assay of FD4, from 
chapter 4 (n=16). 
 
 
 
 
Table A-2. Table highlighting intra-day validation parameters of the fluorescent spectrophotometric method for 
FD4 analysis showing high recovery % and low RSD, including linearity factors of the regression equation linking 
FD4 concentration to the analytical response (area under the peak) (n=8) 
 
 FD4 conc. 
actual 
(µg/mL) 
Peak Area 
(RFU) 
 
 
 
RSD 
 
 
 
FD4 conc. 
calculated 
(µg/mL) 
 
Recovery (%) 
 
 
 
 0.49 5.21 ±  0.44 0.08 0.46 ± 0.04 95.57 ±  8.05 
 3.91 44.55 ±  1.07 0.02 3.99 ±  0.1 102.01 ± 3.7 
 31.25 371.13 ±  15.30 0.04 33.22 ±  1.37 106.3 ±  4.39 
 62.5 748.12 ±  16.07 0.02 66.96 ±  1.43 107.14 ±  2.3 
 250 2896.61 ±  127.73 0.04 259.27 ±  0.04 103.71 ±  4.57 
Mean % recovery = 102.96 ± 4.60% 
RSD % Recovery    = 0.05 
LOD = 0.27 µg /mL 
LOQ = 0.89 µg /mL 
Regression equation 
Correlation coefficient 
Linearity range 
y = 11.172x 
0.99 
0.4 – 500 µg/ mL 
y = 11.312x + 19.02
R² = 0.99
0
1000
2000
3000
4000
5000
6000
7000
0 100 200 300 400 500 600
P
FU
Concentration (µg/mL)
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Table A-3. Inter-day precision and accuracy parameters for fluorescent spectrophotometric method for FITC-
labelled dextran (FD4) analysis (n=24) 
 
FD4 
conc. 
actual 
(µg/mL) 
Amount 
measured on 
day 1 
(µg/mL) 
RSD Amount 
measured 
on day 2  
(µg/mL) 
RSD 
  
Amount 
measured on 
day 3  
(µg/mL) 
RSD 
  
Overall 
RSD 
  
0.49 0.48 ± 0.02 0.05 0.48 ± 0.06 0.11 0.46 ± 0.03 0.06 0.07 
3.91 3.99 ±  0.10 0.02 4.01 ± 0.39 0.10 4.04 ± 0.35 0.09 0.09 
31.25 33.22 ±  1.37 0.04 33.24 ± 2.62 0.05 32.34 ± 1.62 0.07 0.06 
62.5 66.96 ±  1.43 0.05 67.53 ± 1.84 0.03 63.54 ± 4.01 0.06 0.04 
250 259.27 ±  0.04 0.04 272.6  ± 7.79 0.03 260.06 ± 15.68 0.06 0.04 
 
 
 
Figure A-3. Calculated and experimental CD spectra for insulin tablet compacted at 10 kN 
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Figure A-4. Calculated and experimental CD spectra for insulin tablet compacted at 30 kN 
 
 
 
Figure A-5. Beer-Lambert’s calibration curve for insulin method employed for insulin permeation studies in 
chapter 6 (n=3) 
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Figure A-6. Precision parameters of insulin analysis by HPLC method from chapter 6, superimposition of the 
three chromatograms depict instrument precision. 1mg/mL insulin solution was injected three times into the 
HPLC. 
 
 
Table A-4. Table highlighting intra-day validation parameters of the HPLC method for insulin analysis  (chapter 
6) showing high recovery % and low RSD, including linearity factors of the regression equation linking insulin 
concentration to the analytical response (area under the peak) (n=3) 
 
 Insulin conc. 
actual 
(µg/mL) 
Peak Area  
(AU) 
 
 
 
RSD 
 
 
 
Insulin conc. 
calculated 
(µg/mL) 
 
Recovery (%) 
 
 
 
 7.81 42756.3 ±  
1513.3  
0.04 8.61 ± 0.15 110.21 ± 1.94 
 15.63 108581.7 ±  
485500.5 
0.02 15.20 ± 0.55 97.28  ±  3.52 
 31.25 261868.3  ±  
4884.6 
0.02 30.54 ± 0.49 97.74  ±  1.56 
 62.50 575054.3 ±  
17882.2 
0.03 61.89 ± 1.79 99.70  ±  1.96 
Mean % recovery = 101.06 ± 6.14% 
RSD % Recovery    = 0.06 
LOD = 0.46 µg /mL 
LOQ = 1.55 µg /mL 
Regression equation 
Correlation coefficient 
Linearity range 
y = 9991x – 43927 
1 
3.9 - 1000 µg/ mL 
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Table A-5. Inter-day precision and accuracy parameters of the HPLC method for insulin analysis from chapter 
6 (n=24) 
 
 
Insulin 
conc. 
actual 
(µg/mL) 
Amount 
measured on 
day 1 
(µg/mL) 
RSD Amount 
measured 
on day 2  
(µg/mL) 
RSD 
  
Amount 
measured on 
day 3  
(µg/mL) 
RSD 
  
Overall 
RSD 
  
7.81 7.98 ±  0.67 0.05 8.08  ± 0.20 0.03 8.61 ± 0.15 0.02 0.03 
15.63 15.59 ±  0.43 0.02 15.30 ± 0.49 0.03 15.20 ± 0.55 0.04 0.03 
31.25 31.15 ± 1.14 0.04 30.37 ± 0.23 0.01 30.54 ± 0.49 0.02 0.02 
62.50 62.54 ±  1.41 0.05 62.96 ± 1.49 0.02 61.89 ± 1.79 0.03 0.03 
 
 
